An Investigation into Novel helicases from Plasmodium falciparum by Evans, Luke Shaun
I 
 
An Investigation into Novel Helicases from 
Plasmodium falciparum 
 
Luke Shaun Evans 
 
The thesis is submitted in partial fulfilment of the requirements for the 
award of the degree of Doctor of Philosophy of the University of 
Portsmouth 
 
September 2012 
II 
ABSTRACT 
 
With 800 thousand deaths each year resulting from more than 225 million cases of malaria 
worldwide, the increase of drug-resistant parasites and insecticide-resistant Anopheles 
gambiae mosquitoes has given rise to the call for new approaches in combating malaria. 
One proposed strategy focuses on the targeting of Plasmodium helicases due to their 
necessity in all cellular processes, and therefore the survival of the parasite and the 
infection of their host. 
This study describes the novel purification and storage strategies of two Plasmodium 
falciparum helicases; PFEIF4A (formally PFH45) and PFDH60. This resulted in the yield 
of relatively large amounts of protein that can be used in high-throughput screening of 
inhibitors and structural-guided drug design in the future. 
Moreover, further biochemical and biophysical characterisation has been performed to 
investigate the specific substrate requirements of each helicase, and the optimal conditions 
for helicase activity. As well as elucidating information that could provide pathways for 
specific targeting by both established and novel therapeutic molecules, particularly in the 
case of PFEIF4A, exposure to temperature just 3 °C above its 37 °C optimum has been 
shown to have an irreversible and detrimental effect to the proteins activity in vitro. 
Preliminary experiments into the proteins’ structures have been performed, as well as 
experiments exploring the effects of a novel DNA-interactive PBD conjugate and the 
generation and characterisation of aptamers to PFEIF4A. These experiments have 
contributed to future investigations in to novel anti-malarial therapeutics and diagnostic 
platforms. 
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CHAPTER ONE – INTRODUCTION 
 
1.1 Helicases 
Translocases are nucleic acid motor proteins that hydrolyse adenosine triphosphate (ATP) 
upon binding to deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) molecules. They 
transform energy derived from ATP hydrolysis to move directionally along the 
phosphodiester backbone. Helicases are a subclass of translocases, capable of unwinding 
the nucleic acid duplex (DNA, RNA, DNA-RNA hybrids) into its component strands as 
they move along it, a function which separates them from other translocases. As a 
consequence they are vital to all living organisms, playing a role in key cellular processes, 
such as DNA repair and replication (Cobb et al. 2002), transcription (Ciampi 2006), 
translation (Rogers et al. 1999), recombination (Singleton et al. 2004), RNA maturation 
and splicing (Staley et al. 1998), RNA degradation (Py et al. 1996), ribosome biogenesis 
(Venema et al. 1995), nuclear export processes (Kanai et al. 2004), and mitochondrial 
genome replication (Korhonen et al. 2003). 
 
1.2 Biochemical Activities of Helicases 
Helicase activity is a complex process with several biochemical properties that influence 
the many aspects that make up its mechanism. Singleton et al. (2007) describe these 
activities in terms of rate, processivity, directionality, step size, and active or passive 
mechanisms. Rate is defined as the number of base pairs unwound or the number of ATP 
molecules hydrolysed per unit of time. Processivity is the number of base pairs unwound 
per substrate binding event. Directionality is used to describe a processive helicases’ bias 
in its movement along a nucleic acid strand (3’ to 5’ or 5’ to 3’). Step size can describe the 
average distance moved (mechanical step size) or the average number of base pairs 
unwound (kinetic step size) per catalytic cycle. Finally, in addition to the conventional 
sense of an active or passive enzyme; differentiating whether or not an enzyme derives 
energy from the hydrolysis of ATP. Active and passive is used to describe the initial 
mechanism for helicase activity. 
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1.2.1 Rate 
Many studies have focused on helicase rate of translocation, resulting in observations from 
a few to several thousand base pairs per second (bp s
-1
) under comparable conditions. For 
example, monomers of the T7 bacteriophage 2 DNA primase (Kim et al. 2002), and the 
Herpes Simplex Virus type 1 (HSV-1) primase (Falkenberg et al. 1998) have shown rates 
of approximately 130 and 60 bp s
-1
 respectively. 
Alternative studies have shown that rate can be affected and is likely controlled by many 
contributory factors. For instance, the translocation rate of 130 bp s
-1
 by T7 primase is 
based on the monomer interacting with single-stranded DNA (ssDNA). Whereas, 
translocation on double-stranded DNA (dsDNA) is only 10 bp s
-1
 unless coupled with a 
preceding DNA replisome activity, which catalyses the strand displacement (Stano et al. 
2005). Eukaryotic Initiation Factor (EIF) 4A activity is also affected by other proteins. 
Alone eIF4A can only dissociate RNA duplexes of sufficiently low thermodynamic 
stability (Rogers et al. 1999). However, activity is observed to be up-regulated when in the 
presence of eIF4B as part of the eIF4 complex (Rogers et al. 2001; Marsden et al. 2006). 
It makes sense that helicase activity would be affected by other factors as unregulated 
activity is likely to be devastating to the cell, which invests substantial effort in 
maintaining more stable dsDNA over less stable ssDNA. 
 
1.2.2 Directionality 
Due to the anti-parallel nature of duplex DNA it is important that motor proteins have a 
sense of direction. For proteins with an affinity for single strand substrates this is not a 
problem; once the protein is bound the polarity of DNA allows for directionality of 
translocation. dsDNA however is bipolar; two polar ssDNA molecules with the 
phosphodiester backbones anti-parallel to one another gives the molecule an intrinsic 
symmetry. Proteins that translocate along dsDNA appear to determine direction by 
tracking one of the two strands even if the protein is tracking the duplex. 
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Studies of the hexameric helicase of T7 primase illustrate this with a proposed binding 
change mechanism (Singleton et al. 2000) where the sequential association and 
dissociation of nucleotide triphosphates (NTP), nucleotide diphosphates (NDP), and 
inorganic phosphate (Pi) result in a cyclical transfer of the nucleic acid substrate between 
the monomers within the central cavity. 
 
1.2.3 Processivity 
Processivity is a measure of the average number of associated functions or catalytic cycles 
performed per substrate-binding event (number of base pairs unwound per molecule of 
ATP hydrolysed). As the translocases characteristic function is to move along nucleic 
acids, processivity is a major aspect of the mechanism. Therefore, to some degree the same 
is probably true for helicases as they are required to separate large duplex DNA molecules. 
As with rate of translocation it is likely that helicase processivity is greatly dependent on 
their interaction with other proteins. 
 
1.2.4 Step Size 
Aside from the average number of catalytic cycles per substrate-binding event 
(processivity), the number of base pairs unwound per catalytic cycle is also of interest. 
This is referred to as the step size and commonly accompanies each ATP hydrolysis event. 
Determining the step size is difficult due to factors such as base composition, supercoiling, 
and unusual structures such as cruciform and tetraplexes, however a theoretical step size 
can be calculated (Lohman et al. 1996).  
 
1.2.5 Active versus Passive 
In the conventional sense all helicases are active enzymes. That is to say that they use the 
energy derived from the hydrolysis of ATP to drive movement. However, the term active 
or passive has been coined to describe enzymes that either bind at a double stranded region 
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and separate the duplex prior to unwinding (active), or enzymes that bind the ends of 
unravelled single strands, brought about either by an additional enzyme process or by 
thermal “fraying”, before proceeding to unwind the DNA duplex (passive) (Lohman et al. 
1996). 
 
1.3 Classification of Helicases 
Based on primary structure analysis, Gorbalenya and Koonin (1993) designated three 
superfamilies and two families of alleged helicases. The largest two superfamilies, 
superfamily 1 (SF1) and superfamily 2 (SF2) had core domains made up from seven 
conserved motifs; motif I (Walker A), Ia, II (Walker B), III, IV, V, and VI (Figure 1.1). 
However despite providing a fundamental framework for structure-function analysis, 
recent studies have exposed a number of insufficiencies as well as revealing additional 
motifs. Furthermore, it has become clear that the original core motifs are not exclusively 
indicative of helicases but rather of translocases; enzymes that couple ATP hydrolyis with 
directional movement along ribonucleic acids. Although helicases themselves are a 
subgroup of translocases, many proteins may not withstand their classification as helicases 
due to a lack of authentic helicase activity; the physical separation of duplex ribonucleic 
acids. Thus rendering the Gorbalenya and Koonin mode of classification unable to 
differentiate between helicases and translocases (Stanley et al. 2006). 
Despite the possibility for considerable confusion there are some regular structural and 
mechanical themes, such as the translocase core domains; the minimal structural unit 
formed from neighbouring recombination protein (Rec) A-like domains. It is these 
domains that undergo conformational change upon ATP hydrolysis, providing a 
mechanical output from a chemical input (Ye et al. 2004). Two features of the core 
domains are the presence of conserved residues involved in binding and hydrolysis of 
ATP; this is comparable to the Walker A and B motifs found in many ATPases (Walker et 
al. 1982), and an ‘arginine finger’ utilised in coupling NTP binding and hydrolysis to 
protein conformational change by detecting the γ-phosphorylation state of the bound 
nucleotide (Scheffzek et al. 1997; Caruthers et al. 2002). 
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In response to all of the above, a more adequate form of classification has been proposed 
(Singleton et al. 2007). Consequently, helicases have been subdivided into six 
superfamilies; SF1, SF2, SF3, SF4, SF5, and SF6. The seven original motifs of SF1 and 
SF2 have been expanded on to contain the Q Motif (Tanner et al. 2003) and the TPGR 
motif (Pause et al. 1992) also referred to as motif Ib (Cordin et al. 2006), as well as the 
SF1 specific motif IVa (Korolev et al. 1998) and the SF2 specific TRG motif (Mahdi et al. 
2003) (Figure 1.2). In addition, nomenclature based on translocation polarity (A for 3’ to 
5’ and B for 5’ to 3’) and core domain substrate specificity (α for single-stranded nucleic 
acids and β for double-stranded nucleic acids) has also been introduced. 
It should be noted that alternative nomenclature has been proposed by Fairman-Williams 
(2010) to include an alternative motif Ib, a conserved arginine or glycine residue in SF1 or 
SF2 respectively, while the TPGR motif is referred to as motif Ic. Furthermore, motif IVa 
in SF1 has been designated motif IIIa, motif IVa has been designated to the SF2 exclusive 
TRG motif, and additional motifs Va and Vb have been introduced. Acknowledging these 
differences, the nomenclature in this text will follow that described by Gorbalenya and 
Koonin (1993) and reviewed by Hall and Matson (1999), with the additional expanded 
motif nomenclature based on the original identifying studies. 
 
 
 
 
 
Figure 1.1 SF1 and SF2 Motifs Adapted from Hall and Matson (1999). Presented with 
the N-terminus on the left and C-terminus on the right, the coloured boxes represent the 
conserved helicase motifs and are relevant only to the motif’s continuing colour theme 
throughout this text. The letters inside the boxes are those motif’s consensus amino acid 
sequences, and the labels above are the motif’s assigned names. The relative positions of 
motifs and spacing between them are not representative of actual proteins. In all consensus 
sequences + and ○ represent non-specific hydrophobic or hydrophilic residues respectively, 
while × represents residues not constrained to being hydrophobic or hydrophilic. 
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Figure 1.2 The Additional SF1 and SF2 Motifs. Presented with the N-terminus on the left and C-terminus on the right, the smaller boxes represent the 
conserved motifs presented by Gorbalenya and Koonin (1993) and described in Figure 1.1, while the larger boxes represent the motifs included by Singleton et 
al. (2007). The letters inside the larger boxes are those motif’s consensus amino acid sequences, and labelling above the boxes are the motif’s assigned names; 
Q, Ib, IVa, and TRG (Translocation in RecG), by Tanner et al. (2003), Pause et al. (1992), Korolev et al. (1998), and Mahdi et al. (2003) respectively. The GG 
doublet which was first identified by Linder et al. (1989) has been included for the sake of completeness, despite not being largely acknowledged as a motif. 
The presence of a * indicates that motif’s identification in a SF1 species while a * indicates that motif’s identification in a SF2 species. The colours of the 
boxes are relevant only to the motif’s continuing colour theme throughout this text. The relative positions of motifs and spacing between them are not 
representative of actual proteins. In all consensus sequences + and ○ represent non-specific hydrophobic or hydrophilic residues respectively, while × 
represents residues not constrained to being hydrophobic or hydrophilic. Underlined characters are non-specific residues, where any or all may not be present in 
any particular species. 
Additional Superfamily 1 and 2 Motifs 
I Ia II III IV V VI 
TRG* 
 
A××R+×++××S×DGF×+AE×D+×+RG×GE++G×RQSG 
G         T                D    K T 
IVa* 
A×××+×○××A 
Ib 
××+GR××R 
Q 
GF××PT×IQ 
    S 
GG 
GG 
Doublet 
7 
1.3.1 Superfamily 1 (SF1) 
From a structural perspective SF1 helicases are the most comprehensively characterised. 
There has been considerable debate over SF1 oligomeric state, generally however they are 
considered monomeric or dimeric. All members appointed thus far are α enzymes but there 
is no consensus on translocation polarity with both A and B within the family. 
 
1.3.1.1 SF1A 
Two of the best studied members of the SF1A subfamily are the gram-negative bacteria 
helicase Rab escort protein (Rep) (Subramanya et al. 1996) and the gram-positive bacteria 
helicase plasmid copy reduced A (PcrA) protein (Korolev et al. 1997). The crystal 
structures of these proteins have revealed two RecA-like domains; termed the N-core and 
C-core (Subramanya et al. 1996) relating to the N and C-terminal domains respectively. 
These domains also referred to as 1A and 2A, each contain an additional subdomain insert; 
1B and 2B respectively. Within the cleft between the N- and C-core domains there is an 
ATP-binding site lined with many of the SF1 motifs (Figure 1.3). 
Crystallography studies of Rep in complex with ssDNA (Korolev et al. 1997) and PcrA in 
complex with dsDNA, as well as an non-hydrolysable ATP analogue and a sulphate ion 
(Velankar et al. 1999), reveal similar conformational changes. Combined with biochemical 
data such as the kinetic parameters of ATP hydrolysis (Soultanas et al. 1999; Soultanas et 
al. 2000) and a step size of one base pair per ATP (Dillingham et al. 2000), a model for 
duplex unwinding could be proposed. This, although based on studies of Rep and PcrA, 
provided a canonical model for all SF1 helicases (Soultanas et al. 2000; Soultanas et al. 
2001) (Figure 1.4). 
Interaction between the helicase and a single-stranded nucleic acid results in the movement 
of subdomain 2B, exposing a double-stranded nucleic acid interaction surface between 
itself and subdomain 1B. Then ATP binding induces the closure of the cleft between the 
1A and 2A subdomains around the double-stranded nucleic acid, which in turn induces two 
further changes: Firstly, the movement of 1B and 2B which forces the duplex DNA onto a 
negatively charged surface, consequently destabilising the component strands; and 
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secondly, the flipping of the nucleotide bases within the nascent single-stranded region 
between acceptor pockets in the 1A and 2A domain cleft. The movement of these bases, 
which gives rise to translocation along ssDNA, combined with the binding, hydrolysis, and 
release of ATP, resembles Yarranton and Gefters’ (1979) proposed ‘inchworm’ method of 
DNA unwinding. 
 
1.3.1.2 SF1B 
Typical examples of the SF1B helicase subfamily are RecD and DNA-dependant ATPase 
(Dda), although work has been performed on other lesser studied SF1B members such as 
phytochrome interacting factor 1 (Pif1) and RNA recognition motif 3 (Rrm3) (Ivessa et al. 
2002). RecD is a subunit of the RecBCD complex (Exonuclease V) which initiates 
recombinational repair (Kowalczykowski 2000) and provides the only structural insight 
 
Figure 1.3 Crystal Structure of PcrA Bound to dsDNA and ATP (Velankar et al. 1999). 
Rendered using PyMol v0.99 PDB code 3PJR; the assumed biological molecule of PcrA. 
Both renders A and B show the bound dsDNA in magenta (top left) and the ATP ligand 
(bottom centre) in cyan. Render A shows the N and C-core domains (1A and 2A) in the 
bottom right (red) and left (blue) respectively. The corresponding B subdomains are shown 
in the upper half, with subdomain 2B coming out of the plane (yellow), and the subdomain 
1B going into the plane (green). Render B shows the arrangement of the conserved motifs 
(Hall et al. 1999) surrounding the ATP binding cleft; motif I (red), motif Ia (green), motif II 
(blue), motif III (yellow), motif IV (deep purple), motif V (deep teal), and motif VI 
(orange). 
A B 
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into the 1B subfamily. Some biochemical studies have been performed but are in the 
context of the RecBCD complex. Contrastingly, Dda is well biochemically studied but 
lacks structural studies. As a result theories presenting mechanical details have been drawn 
from a combination of these works. 
 
Both RecD and Dda exhibit monomeric activity (Taylor et al. 1995; Nanduri et al. 2002), 
albeit in the case of RecD as part of a heterotrimer containing an SF1A helicase (RecB) 
(Korangy et al. 1993). RecD structure reveals two RecA-like core domains either side of 
an ATP binding site, echoing the SF1A helicases. However, there is also a further N-
terminal domain that interfaces with RecC. This is not a conserved feature within Dda. An 
 
 
 
 
 
 
Figure 1.4 The Translocation Mechanism of SF1 Enzymes (Adapted from Singleton et 
al. (2007)). Based on the intermediate crystal structures of Rep (Korolev et al. 1997) and 
PcrA (Subramanya et al. 1996) with bound ssDNA during alternative ATP hydrolysis 
states. A to C show the three translocation steps of PcrA associated with ATP-binding and 
hydrolysis. The top row shows the stacking between the amino acid residues (yellow) and 
the ssDNA bases (magenta). The middle row is an analogy of each stage; the gripping 
hands depict which domains have tight or loose grips on the bound ssDNA. The bottom 
row shows a cartoon of the structural data in the top row, with the bases (1-6) switching 
between the enzymes nucleotide binding pockets labelled A-D. 
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observable difference that this may bring is that RecD does not interact with duplex DNA 
ahead of the fork within the RecBCD complex. dsDNA interaction however cannot be 
attributed to the Dda N-terminal or any other SF1B members based on a single 
observation. It is more likely that the mechanism of translocation follows the inchworm 
method of the core domains similar to that of the SF1A subfamily. 
 
1.3.1.3 The Active Form of SF1 Helicases 
Deliberation over oligomeric state has led to the conclusion that the most likely form of 
SF1 helicases at the fork is monomeric. This was based on the observation that all 
structural studies present the enzymes to be monomeric under a range of crystallisation 
conditions (Subramanya et al. 1996; Korolev et al. 1997; Velankar et al. 1999), and 
models based on this data involve helicase monomers at the fork (Velankar et al. 1999; 
Soultanas et al. 2000). Dda single-turnover experiments have shown that monomers of the 
enzyme are capable of unwinding dsDNA (Ivessa et al. 2002). In contrast to this wild-type 
Rep helicase requires multiple monomers to unwind the duplex (Ha et al. 2002). However, 
monomers of the truncated form which lacks the 2B domain can actively unwind 
independently suggesting a non-standard regulatory role of the domain in Rep (Brendza et 
al. 2005). 
PcrA and ultraviolet (UV) resistant D (UvrD) monomers have been shown to, if nothing 
more, translocate along ssDNA (Dillingham et al. 2000; Fischer et al. 2004). It should 
however be acknowledged that, although the mechanism of cooperation is not fully 
understood the presence of multiple monomers does enhance the efficiency of helicase 
activity in vitro. Multiple UvrD monomers have been shown to be more effective at 
unwinding dsDNA flanked by longer ssDNA tails (Ali et al. 1999). Likewise, multiple Dda 
monomers can cooperatively unwind DNA substrates (Byrd et al. 2005), as well as 
displace streptavidin from biotinylated DNA more effectively than independent monomers 
(Byrd et al. 2004). 
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1.3.2 Superfamily 2 (SF2) 
SF2 is the largest superfamily of helicases and members have been shown to translocate on 
either single-stranded or intact duplex nucleic acids (α and β respectively). It contains 
several comprehensively studied subfamilies such as the DEAD-box RNA family (Cordin 
et al. 2006), the RecQ-like family (Bennett et al. 2004), and the sucrose non-fermenting 2 
(Snf2)-like family (Flaus et al. 2004; Flaus et al. 2006). Like SF1 helicases their 
oligomeric state is considered to be either monomeric or dimeric. Some SF2 members have 
been shown to operate as NTP-dependant non-processive mechanical switches that alter 
nucleic acid and nucleoprotein conformation (Linder et al. 2006). 
 
1.3.2.1 Translocation on Single-Stranded Nucleic Acid 
Hepatitis C virus (HCV) non-structural protein 3 (NS3) is a SF2α helicase. It has been 
shown to unwind both duplex RNA and DNA (Pang et al. 2002) although it does require a 
3’ single-strand overhang (Tai et al. 1996). Despite observed functionality as a homodimer 
(Levin et al. 2004; Tackett et al. 2005), active unwinding from monomeric NS3 has been 
reported (Dumont et al. 2006). NS3 structural studies have elucidated crystal structures 
unbound and bound to ssDNA (Kim et al. 1998) (Figure 1.5). N- and C-core domains have 
annotated functions in viral polyprotein processing and protein-protein interactions 
respectively (Mackintosh et al. 2006). 
Reminiscent of SF1 helicases, the enzyme core contains two RecA-like domains. However, 
where the aromatic residues within the ssDNA-binding site of SF1 (exampled by PcrA) 
stabilise the elongated conformation of the ssDNA molecule by stacking against the bases, 
in SF2 the ssDNA maintains its shape as if in a B-form duplex, preserving stacking 
between the bases. There is an unconserved domain within NS3 which prevents (by steric 
hindrance) this pseudo B-form ssDNA from base pairing with a second ssDNA molecule. 
If it were possible for DNA base pairing to take place, the B-form duplex would be 
suitable for translocation (β activity) without prior unwinding. On the surfaces of the 
ssDNA-binding site are residues from motifs Ia, Ib, IV, and V that directly contact the 
nucleic acid, principally involving the phosphodiester backbone. In addition, a valine 
residue at position 432 and a tryptophan residue at 501 form two ‘bookends’ that group 
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five bases, while the regions of the RecA-like domains surrounding these bookends form 
two structurally equivalent DNA contact regions. 
 
Mutagenesis (Paolini et al. 2000; Tai et al. 2001; Kim et al. 2003) directed towards these 
residues which lie outside of the fundamental motifs has led to the proposal that they play a 
part in the ratchet translocation mechanism (Kim et al. 1998). In response to ATP 
hydrolysis and product release the core domains open and close altering the distance 
between the bookends. If this is coordinated with the binding and release of the DNA 
substrate it would result in enzyme translocation and possibly DNA unwinding. 
Information on ATP binding induced changes has been determined by studying another 
SF2 RNA helicase; DEAD box polypeptide 4 (DDX4 previously named VASA). 
Structural studies providing DDX4 bound to a non-hydrolysable analogue (Sengoku et al. 
2006) have shown that NTP binding at motif I produces a closed conformation as residues, 
including the arginine finger of motif VI, close around the nucleotide. This mechanism is 
 
Figure 1.5 Crystal Structure of HCV NS3 Bound to ssDNA and a Sulphate Ion (Kim et 
al. 1998). Rendered using PyMol v0.99 PDB code 1A1V; the protease domain is omitted. 
Both renders A and B show the bound ssDNA in magenta and the sulphate ion, marking the 
ATP-binding site, is shown as a stick-model at the top (yellow). Render A shows the N- 
and C-core domains in the top left (red) and right (blue) respectively. Render B shows the 
arrangement of the conserved motifs (Hall et al. 1999) surrounding the ATP binding cleft; 
motif I (red), motif Ia (green), motif II (blue), motif III (yellow), motif IV (deep purple), 
motif V (deep teal), and motif VI (orange). 
A B 
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similar to that of SF1 concluded from PcrA studies. However, there is one potential 
difference; the protein precisely binds to the substrate despite lacking the mechanism of 
un-pairing the duplex DNA by subdomains 1B and 2B. This cannot be regarded as fully 
accurate though, as present crystal derived structures have not contained duplex DNA. The 
lack of a single protein open and closed crystal structure also makes it difficult to assess 
step size. Presumably it would not be more than a few base pairs per hydrolysed ATP, but 
there is no reason why it should be as low as the PcrA step size (1bp/ATP). 
Like SF1 helicases, SF2 also show evidence for potential cooperation between monomers. 
NS3 studies have shown large step sizes, although these observations may be due to the 
cooperative effect of multiple smaller unwinding steps (Levin et al. 2004; Serebrov et al. 
2004; Dumont et al. 2006). 
 
1.3.2.2 Translocation on Double-Stranded Nucleic Acid 
While there are comprehensive examples of a SF2α helicase, SF2β helicases are much less 
represented in the literature (Fairman et al. 2004; Stanley et al. 2006). This is mostly due 
to the difficulty in DNA tracking which produces no products. Triplex displacement assays 
have however been employed in several studies relating to translocase activity (Firman et 
al. 2000; McClelland et al. 2005). 
The only SF2β crystal structure with duplex bound DNA across the terminus domains is 
from Sulfolbus solfataricus alpha thalassemia/mental retardation syndrome X-linked 
(ATRX previously named Rad54) protein (Durr et al. 2005) from the Snf2 family (Flaus et 
al. 2006) (Figure 1.6). This shows the repeated theme of two RecA-like domains, but with 
two inserts of unknown function. However, the C-core domain is rotated 180° from its 
positions in SF1 and SF2α helicases. This difference, although not identical, has been 
observed in other SF2 helicases (Caruthers et al. 2000; Sengoku et al. 2006). The inserts 
may prove to be related to conformational change resulting from ATP or substrate binding, 
not dissimilar to those reported in members of the DExD/H-box RNA helicases responsible 
for local RNA remodelling (Sengoku et al. 2006). 
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The ATRX N-core domain structure in Danio rerio shows a standard open configuration 
which supports the paradigm that the domain must be open for translocation to progress 
(Thoma et al. 2005). The N-core domain of ATRX interacts with both DNA strands 
through contacts between its motif Ia and Snf2 specific motifs, and the minor grooves of 
the phosphodiester backbones. During binding, the DNA remains largely in the B-form. 
Substrate interaction with the C-core domain is minimal, likely due to its orientation. The 
positioning of one of the component single-strands of the duplex relative to the N-core 
reflects that of NS3; it also contains the majority of DNA-protein contacts. These 
observations suggest that ATRX follows an inchworm translocation mechanism, as 
described for PcrA and NS3, capable of twisting the duplex DNA across the core domains 
but does not result in unwinding. 
When observing studies of EcoR124I translocase activity of modified or discontinued 
substrates, changes on the 3’ to 5’ strand showed greater levels of inhibited translocation 
than that of changes on the 5’ to 3’ strand (Stanley et al. 2006). This supports a model 
suggesting a principal motor interaction with the 3’ to 5’ component strand. 
 
Figure 1.6 Crystal Structure of Rad54 Bound to dsDNA (Durr et al. 2005). Rendered 
using PyMol v0.99 PDB code 1Z63; the assumed biological molecule with the intact 
dsDNA ligand. Both renders A and B show the bound dsDNA in magenta. Render A shows 
the N- and C-core domains to the left (red) and right (blue) respectively. Render B shows 
most of conserved motifs (Hall et al. 1999) arranged within the N-core domain; motif I 
(red), motif Ia (green), motif II (blue), motif III (yellow), motif IV (deep purple), motif V 
(deep teal), and motif VI (orange). 
A B 
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1.3.2.3 Polarity of SF2 Helicases 
While the majority of SF2 helicases have type A polarity, type B exceptions have been 
identified. An example of type B are the Xeroderma Pigmentosum D (XPD) family, which 
contribute to the polymeric human transcription factor II complex (TFIIH), and are 
characterised by the presence of an iron-sulphur cluster in the N-terminal domain. Polarity 
for double-stranded substrate translocation depends on enzyme loading so can be difficult 
to define, although polarity experiments utilising modifications to either of the component 
strands of the duplex can give some idea (Stanley et al. 2006). Results from these studies 
support the observation presented earlier, demonstrating a particular importance of one of 
the two strands, imparting a unifying translocation mechanism across the superfamilies 1 
and 2. Cordin et al. (2006) discussed several non-processive DEAD-box helicases with 
bidirectional activity. Rather than being translocases, it may be that these enzymes act as 
remodelling switches (Linder et al. 2006). Given the compelling structural similarities 
across the SF2 helicases, it is likely that the conformational switch mechanisms bear 
resemblance to a single directional step of processive motors. Supporting this is the 
observation that these enzymes do display processivity in response to protein partner 
interactions. 
 
1.3.2.4 Accessory Domains: Targeting SF2 Enzymes 
The RNA helicase eIF4A is an example of a SF2 helicase where the active polypeptide 
chain is located exclusively in the core domains. The majority of SF2 helicases however, 
include accessory domains within either or both of the core domains or N and C-flanking 
regions. The domains seem to impart specificity or complementary catalytic activity. 
Protein partners may act to regulate helicase activity, or to confer accessory functions. This 
is supported by the observation that helicases often contribute to hetero polymeric 
complexes. 
The core domains of several SF2 helicases have been shown to be functionally modified by 
targeting specific nucleic acid structures. RecG, a SF2Aβ helicase, converts replication 
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forks into Holliday junctions. Crystallography of RecG in complex with a replication fork 
analogue (Singleton et al. 2001) has revealed three domains. The first includes a ‘wedge’ 
that directs specificity to the fork junction, while the second and third form the core motor 
domains (Figure 1.7). The wedge guides the template strand toward the core motor in a 
similar direction to that of the SF2α ATRX-dsDNA complex. 
 
Another nucleotide targeting helicase is UvrB, a subunit of the UvrABC Endonuclease 
which locates damaged DNA in the bacterial Nucleotide Excision Repair (NER) pathway. 
A β-hairpin extends from the N-core domain between the component strands of the duplex 
DNA (Linder et al. 2006). The hairpin provides specificity for damaged DNA, and 
functions as a stable clamp at sites of damaged DNA, which then recruits UvrC nuclease to 
excise the damage. Other examples of helicases containing accessory domains that could 
 
Figure 1.7 Crystal Structure of RecG Bound at a Three-Way DNA Junction with ATP 
(Singleton et al. 2001). Rendered using PyMol v0.99 PDB code 1GM5; demonstrates how 
the N-terminal accessory wedge (grey) acts as a specificity factor for the three-way DNA 
junction. Render A shows the DNA duplex (magenta) coordinated towards the N- and C-
core  domains shown in red and blue respectively, in a similar fashion to that of Rad54 
(Figure 1.5). The lagging nascent strand is represented in light pink. The ATP (cyan) 
binding site is shown situated in the cleft between the core domains (bottom). Render B 
shows most of conserved motifs arranged within the N-core domain; motif I (red), motif Ia 
(green), motif II (blue), motif III (yellow), motif IV (deep purple), motif V (deep teal), and 
motif VI (orange). 
A B 
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be involved in targeting substrates include the RecQ-like enzymes which contain multiple 
DNA-binding accessory domains (Bennett et al. 2004). 
Accessory domains have also been shown to target RNA structures, such as the RNA 
helicase DbpA, which contains a modular domain which confers specificity for a particular 
hairpin within the 23S ribosomal RNA (rRNA) of the large prokaryotic ribosomal subunit 
(Diges et al. 2001). 
Other helicase targets include nucleoprotein complexes. Remodelling and disruption of 
various DNA-protein interactions by Snf2 family members have been demonstrated (Flaus 
et al. 2006). As well as containing a nucleic acid-binding core SF2β motor, many Snf2 
members may interact directly with target proteins (Grune et al. 2003). The action of both 
of these interactions simultaneously, id est DNA translocation to or from a bound target 
protein, could result in nucleoprotein remodelling (Flaus et al. 2004; Durr et al. 2005), and 
the generated torque may prove an important role in remodelling mechanisms. 
Unfortunately, information required for a full understanding of the relative core motor and 
protein interaction domain geometries of any Snf2 family members is not available. 
However, alternative enzyme structure studies might contribute to the hypothesis. For 
instance, the bacterial transcription-coupled repair factor Mutation Frequency Decrease 
(Mfd), which displaces stalled RNA polymerase from damaged template DNA, reveals a 
SF2 motor and RNA polymerase interaction module (Deaconescu et al. 2006). Other 
examples are the SF2 DExD/H-box RNA helicases, where studies indicate that they can 
effectively catalyse protein displacement from RNA, thereby participating in the structural 
remodelling of ribonucleoprotein assemblies (Jankowsky et al. 2001) such as the 
spliceosome (Linder et al. 2001). 
The addition of complementary catalytic domains can produce novel enzymatic properties 
in helicases. For example, the juxtaposition of helicase and nuclease domains is common 
in SF2 systems; Werner (WRN), type I restriction endonucleases, and helicase-associated 
endonuclease for fork-structured DNA (HEF) (Komori et al. 2002). Another example is the 
reverse gyrase of thermophilic bacteria, which combines a SF2 helicase domain with a type 
IA topoisomerase domain, and is capable of catalysing the ATP-dependent positive 
supercoiling of DNA. 
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1.3.4 Hexameric Helicases 
Gorbalenya and Koonin (1993) originally described one hexameric superfamily, SF3, and 
two hexameric families, replicative DNA helicase B (DnaB)-like, and rhodopsin (Rho)-
like. Under the Singleton et al. (2007) mode of characterisation SF3 has retained its status 
as a superfamily, DnaB- and Rho-like have been promoted to SF4 and SF5 respectively. 
Furthermore, they are joined by the ATPases Associated with various cellular Activities 
(AAA
+
) proteins (Erzberger et al. 2006), which have been  designated as SF6. All four 
hexameric superfamilies show considerable structural similarity. They are all toroid, 
consisting of six monomers containing either a RecA or an AAA
+
-like ATPase core. The 
sites of nucleotide-interaction are localised at the surfaces that make up the monomer 
interfaces, and the nucleotide binding pockets usually contain an arginine finger which is 
contributed to by neighbouring subunits and is involved in NTP binding and hydrolysis. 
Based on their stark similarity, it could be suggested that the four hexameric superfamilies 
should be combined and condensed into fewer superfamilies, although the system proposed 
by Singleton et al. (2007) refrained from doing so to avoid creating confusion around 
existing literature. 
Hexameric helicases are best represented unwinding at the DNA replication fork. As a 
result, these helicases have to be highly processive as they are required to unwind from a 
few kilobases to several megabases, and in these circumstances processivity can be 
increased in a variety of ways. For example, several studies have shown the resolution of 
specific DNA topologies by various helicases (Webb et al. 2007; Long et al. 2009). 
Linking topology with helicase activity, notably its initiation, greatly increases 
processivity, possibly because topological features are more pronounced and are therefore 
more likely to result in an encounter between enzyme and substrate. 
The closed ringed structure of hexameric helicases, and placement of the nucleotide-
binding pockets on the internal ring surface, means that although some can self-assemble 
around the DNA substrate without additional cofactors, others require that they are loaded 
onto the substrate DNA. Thus, many hexameric helicases have ATP-dependant loading 
partners (Davey et al. 2003). The difference between the two adopted strategies is likely a 
19 
control mechanism for highly processive helicases, which if unchecked could lead to 
detrimental activity within the cell. 
 
1.3.4.1 Superfamily 3 (SF3) 
SF3 consists exclusively of helicases encoded by small DNA and RNA viruses, or by their 
prophage contribution to their host genomes (Iyer et al. 2004). They are associated with 
multiple enzymatic activities, most notably origin recognition and unwinding (Hickman et 
al. 2005). They can form double-hexamers and have a 3’-5’ translocation polarity (type A). 
Originally only three conserved motifs were identified and all were located within a ~100 
amino acid region. These were identified as A, B, and C. However, a fourth motif has been 
identified and coined B’ due to its location between B and C (Koonin 1993) (Figure 1.8).  
Motifs A and B resemble the Walker A and B motifs similar to that of SF1 and SF2 
helicases, B’ contains a looped structure that interacts with the phosphodiester backbone of 
a bound nucleic acid molecule, while C is a SF3 specific motif and contains the Arginine 
finger. 
 
Several SF3 helicases have had their crystal structure solved (Figure 1.9) such as the 
simian virus 40 (SV40) (Li et al. 2003), adeno-associated virus (AAV) type 2 (James et al. 
 
 
 
Figure 1.8 SF3 Motifs Adapted from Hall (1999) and Koonin (1993). Presented with the 
N-terminus on the left and C-terminus on the right, the coloured boxes represent the 
conserved helicase motifs. The letters inside the boxes are those motif’s consensus amino 
acid sequences, and labelling above the boxes are the motif’s assigned names. The colours 
of the boxes are relevant only to the motifs continuing colour theme throughout this text. 
The relative positions of motifs and spacing between them are not representative of actual 
proteins. In all consensus sequences uppercase characters represent highly conserved 
residues while lowercase characters represent lesser conserved residues. + and × represent 
non-specific hydrophobic or residues not constrained to being hydrophobic or hydrophilic 
respectively. 
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2003; James et al. 2004), and human papillomavirus serotype 18 (HPV18) (Abbate et al. 
2004). All three examples are domains of larger initiator proteins; however AAV is also 
expressed individually via an alternative promoter. These structural studies have shown a 
common trait in the helicase domains relative position, in that it is always upstream of an 
origin-binding domain. Furthermore, each of the origin-binding domains possesses the 
same overall fold despite a low sequence similarity (Luo et al. 1996; Enemark et al. 2000; 
Hickman et al. 2002). 
 
In contrast to the SF1 and SF2 helicase domains consisting of RecA-like fold, the common 
feature of the SF3 helicase domain is the presence of a modified AAA
+
 core. The two folds 
are related (Koonin 1993), and like the RecA-like fold, the AAA
+
 contains the nucleotide 
binding motifs within the central β-strands and loop inserts, functioning either in DNA 
binding or in protein-protein interaction. An additional common feature of SF3 helicases is 
a small poorly conserved helicase domain upstream of the AAA
+
 core which may play a 
role in hexamer stabilisation. 
 
 
Figure 1.9 Crystal Structures of SF3 Helicases SV40 (Li et al. 2003) and AAV2 with 
Bound ADP (James et al. 2004). Rendered using PyMol v0.99 PDB codes 1N25 (SV40) 
and 1U0J (AAV2); Illustrates the relative positioning if the conserved motifs and the N and 
C-terminal regions. In both renders A and B the SF3 motifs A, B, B’, and C are shown red, 
green, blue, and yellow respectively. AAV2 [B] shows a bound ADP (cyan) indicating the 
ATP binding site. 
A B 
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1.3.4.2 Superfamily 4 (SF4) 
SF4 helicases were original identified from bacterial and bacteriophage replicative 
systems. In bacterial systems the helicases exist as a separate polypeptide to the primase, 
such as the DnaB helicase and the DnaG primase of E. coli. However, many bacteriophage 
systems code for a single polypeptide which features both helicase and primase activity 
(Ilyina et al. 1992). All SF4 helicases thus far characterised display type B (5’-3’) polatity. 
Ilyina et al. (1992) described five conserved SF4 motifs; H1, H1a, H2, H3, and H4 (Figure 
1.10). Motifs H1 and H2 are comparable to the Walker A and B motifs respectively. Motifs 
H1a, H3 and H4 bear no equivalents in any other helicase family; however H3 does 
contain a functional glutamine, occasionally substituted for histidine, which is functionally 
equivalent to motif 3 of SF1 helicases. Unlike the DEAD/H-box containing motif 2 
(Walker B) of SF1 and SF2 helicases, H2 contains an isolated apsartate (D) among a 
hydrophobic region. Additionally, in SF4 helicases the glutamate (E) is replaced by a 
spatially equivalent residue from H1a. 
 
The best studied example of SF4 helicase is T7 bacteriophage gene 4 protein (gp4). The 
enzyme is composed of both a primase and a helicase domain separated with a flexible 
linker (Toth et al. 2003). Crystal structures elucidated a RecA-type core fold (Sawaya et al. 
1999) and also provided some insight to nucleotide binding (Singleton et al. 2000) (Figure 
 
 
 
Figure 1.10 SF4 Schematic Diagram Adapted from Hall and Matson (1999). Presented 
with the N-terminus on the left and C-terminus on the right, the coloured boxes represent 
the conserved helicase motifs. The letters inside the boxes are those motif’s consensus 
amino acid sequences, and labelling above the boxes are the motif’s assigned names. The 
colours of the boxes are relevant only to the motifs continuing colour theme throughout this 
text. The relative positions of motifs and spacing between them are not representative of 
actual proteins. In all consensus sequences + and ○ represent non-specific hydrophobic or 
hydrophilic residues respectively, while × represents residues not constrained to being 
hydrophobic or hydrophilic. 
Superfamily 4 
H3 
I××I××○LKA+A×○L×P+××+×Q 
   L    RG    T V     C 
H4 
P×××DLR×SG×I×Q×AD×I+ 
V          L   S 
H1 
×+×++×AR××+GKT 
      SG     S 
H1a 
VL×+SLEM 
 G  MM E 
H2 
+I++DYL 
     HI 
22 
1.11). Mutational analysis suggests that H4 projects a loop into the central channel of the 
hexamer that plays a role in ssDNA contact (Washington et al. 1996). While some SF4 
studies support the suggestion of symmetric hexamers (Niedenzu et al. 2001), gp4 studies 
show deviation from the assumed six-fold symmetry with DNA-binding loops and arginine 
fingers occupying alternative conformations in different subunits. Additional observations 
of both symmetric and asymmetric conformations have been observed and it is has been 
proposed that this heterogeneity is representative of the enzyme’s catalytic state (Barcena 
et al. 2001). 
 
1.3.4.3 Superfamily 5 (SF5) 
Despite being closely related to SF4, Rho-like helicases have been designated SF5 based 
on their sequence. Rho binds to a specific sequence on the nascent RNA strand and 
unwinds it from the template DNA strand during transcription termination in bacteria.  
Electron microscopy studies of Rho have revealed both open and closed forms of the 
protein, where the open form has been interpreted as being either incomplete (lacking a 
 
Figure 1.11 Crystal Structure of a pg4 Monomer Bound to ADPNP (Singleton et al. 
2000). Rendered using PyMol v0.99 PDB code 1E0J; the assumed biological molecule of 
pg4. The ATP binding site is shown with the bound ADPNP in cyan, the conserved SF4 
motifs H1, H1a, H2, H3, and H4 are shown in red, green, blue, yellow, and deep purple 
respectively. 
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monomer) or an open toroid (Gogol et al. 1991). The solved crystal structure (Skordalakes 
et al. 2003) also shows the open form. It is likely that this structure represents a loading 
intermediate as it displays adjacent monomers at the break rising away from each other 
providing a gap sufficient enough for the passage of ssRNA into the central channel. 
 
1.3.4.4 Superfamily 6 (SF6) 
A number of AAA+ core containing proteins are not classified as SF3 helicases and so 
have been appointed SF6 helicases by Singleton et al. (2007). One instance is the mini 
chromosome maintenance (MCM) protein complex which consists of six monomers 
(MCM2-7). It is thought to be the main replicative helicase of eukaryotic organisms and 
has shown to be vital for replication initiation and elongation (Labib et al. 2000), although 
helicase activity has only been detected in a heterohexamer of MCM4, 6, and 7 (Kaplan et 
al. 2004). Another SF6 example is prokaryotic resistance to UV (Ruv) B, which is 
involved in homologous recombination along with RuvA and RuvC in the processing of 
Holliday junctions (West 1996). 
No crystal structures for eukaryotic MCM have been reported, and inferences about its 
structure have largely been drawn from homohexameric archaeal MCM homologues 
(Chong et al. 2000). An N-terminal crystal structure (Fletcher et al. 2003) and electron 
microscopy studies (Pape et al. 2003) of archaeal MCM show a large central channel 
through the hexameric ring that is sufficiently wide enough to accommodate dsDNA. 
Monomeric crystal structures of RuvB with a bound nucleotide have been solved (Putnam 
et al. 2001; Yamada et al. 2001). Comparisons to other AAA+ protein crystal structures 
without bound nucleotide suggest a conformational change that might be coupled to 
translocation activity. Superimposition of RuvB to electron microscopic data, combined 
with the MCM data, provides a consistent model which couples the conserved arginine 
fingers with nucleotide hydrolysis, and presents a central channel which accommodates 
dsDNA. 
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The MCM and RuvB AAA+ proteins were chosen only for example purposes, more 
extensive and representational reviews of AAA+ studies are available from Erzberger and 
Berger (2006), and Iyer et al. (2004). 
 
1.3.4.5 Mechanisms of ATP Hydrolysis 
A common feature of hexameric helicases is their multiple NTP-binding sites exhibiting 
strong heterogeneous cooperation (Bujalowski et al. 1993). Debate surrounds the exact 
details of nucleotide-binding and hydrolysis and as a result multiple models have been 
proposed (Figure 1.12). 
The three-site sequential model (Hingorani et al. 1997) involves three of the six NTP-
binding sites equally distributed around the hexamer. Each binding site binds an NTP, 
hydrolyses it into Pi and NDP, and then releases the NDP leaving the site empty. These 
configurations are designated T (triphosphate), D (diphosphate), and E (empty) 
respectively, and no two sites can be in the same configuration. 
The all sites sequential model (Singleton et al. 2000) is similar to the three-site sequential 
model, differing only in that all six NTP-binding sites are occupied meaning that any two 
will be in the same configuration. A variation of this model includes a blocking system by 
neighbouring sites in the same configuration (Enemark et al. 2006). 
The stochastic model (Martin et al. 2005) details all six of the NTP-binding site as 
catalytically active but each site can be in any of the three configurations at any given time. 
Finally, like the stochastic model, the concerted model (Gai et al. 2004) describes all the 
NTP-binding sites as catalytically active but they are all are synchronised in their 
configuration. It is likely that more than one of the proposed models is correct and relates 
to the particular species being described. 
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Figure 1.12 Models for Hexameric Helicase NTP Hydrolysis and Release (Singleton et 
al. 2007). Schematics A-E detail the various models for NTP hydrolysis; they are the three-
site sequential model [A] (Hingorani et al. 1997), the all sites sequential model [B] 
(Singleton et al. 2000), the all sites sequential – block model [C] (Enemark et al. 2006), the 
stochastic model [D] (Martin et al. 2005), and the concerted model [E] (Gai et al. 2004). 
The coloured circles resemble individual monomers of the toroid ring, their colours only 
serve to show that each monomer remains in its relative position and that only it hydrolysis 
state alters, this is indicated by the letters T (NTP bound), D (NDP bound), and E (empty). 
Solid arrows linking the last illustrated stage with the first [A, B, and E], show that there 
are only three stages of the cycle. Broken arrows indicate that there are either an 
indeterminate number of steps [D] or that there are more than three steps [C (has 6 steps)]. 
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1.3.4.6 Coupling NTPase Activity to Translocation 
All of the proposed NTP-hydrolysis models are coupled to translocation of the helicase 
along DNA. Hexameric helicases feature looped projections into the toroid’s central 
channel. Mutational studies of these loops has shown them to be essential for DNA binding 
(Washington et al. 1996). Structural analyses (Singleton et al. 2000; Enemark et al. 2006) 
suggest the loops track the phosphodiester backbone with loop movement driven by NTP-
binding and hydrolysis, however the precise character of the mechanism which drives loop 
movement and controls DNA-binding affinity has not been determined and will probably 
differ between different helicases. Similarly, step size for hexameric helicases has not been 
explicitly determined and although examples do exist (Kim et al. 2002; Galletto et al. 
2004), this too will likely be dependent on the individual helicase. 
 
1.4 Helicases as Antiviral Drug Targets 
Despite considerable progress in the development of antivirals over the last 15 years (De 
Clercq 2004), there is still a call for new drugs to improve existing treatments and to 
combat viral resistance. Although many viral infections can be successfully prevented via 
vaccinations and so this will likely remain the staple for the treatment of these infections, 
there is little effective knowledge of vaccines for many important human pathogens. This 
has resulted in the proposal of alternative strategies, one of which is the emergence of 
helicases as potential novel targets for the antiviral treatments. 
Viruses replicate either by using self-encoded proteins or by hijacking their host cellular 
proteins (Kwong et al. 2005). This presents two distinct strategies which in theory could 
target either a viral or cellular polypeptide with equal effectiveness (De Clercq 2002), 
although each strategy presents alternative repercussions. Targeting viral helicases 
decreases the chance of creating inhibitors that are toxic to the host but also increases the 
requirement for specificity as the viral and cellular helicases catalyse similar enzymatic 
reactions. Nevertheless, viral and cellular helicases are not identical and medicinal 
chemistry and structure-based drug design can take advantage of these differences in 
designing drugs which are highly specific to viral proteins. 
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Under the present strategy, resistance will occur over time unless an antiviral drug is 
extremely potent, so that it rapidly reduces the pool of viral replication, leading to shorter 
treatment time, preventing the proliferation of resistant viruses (Richman 1996). Targeting 
key proteins required for viral replication should eliminate the problem of resistance. 
Hypothetically, a pan-antiviral drug could be designed to inhibit all viruses that depend 
upon a common host factor; however a likely disadvantage would be an increased risk of 
toxicity to the host (Kwong et al. 2005). In practice, drug design is influenced by whether 
the virus’ replication is performed autonomously using self-encoded genes, or whether the 
virus recruits the host protein. 
 
1.4.1 Plasmodium falciparum 
There are approximately 257 species of parasitic protozoan in the Plasmodium genus 
(WHO 2008). Plasmodium falciparum is one of at least 10 human malaria causing 
plasmodium strains, and is responsible for over 90 % of worldwide cases of human malaria 
and has the highest reported complications and mortality rates when compared to any other 
human malaria-causing Plasmodium (WHO 2009; WHO 2010). Unlike other Plasmodium 
species, P. falciparum is restricted to warmer climates due to its temperature dependant 
development (Figure 1.13). 
Malaria infection develops in two stages; the exoerythrocytic which takes place outside the 
red blood cell (RBC), and erythrocytic which takes place inside the RBC. When an 
infected female Anopheles gambiae mosquito takes a blood meal from a host animal, 
sporozoites enter the host bloodstream, migrate to the liver, and infect the host hepatocytes. 
Here they multiply asexually and asymptomatically for between eight and thirty days 
(Bledsoe 2005). Many species of plasmodium have long been known to display a dormant 
stage at this point, and more recently numerous cases of dormancy in P. falciparum have 
been reported (Greenwood et al. 2008; Szmitko et al. 2009; Theunissen et al. 2009). 
After liver-stage development, the parasite differentiates into thousands of merozoites. The 
parasite induces the death and detachment of the hosts’ hepatocytes releasing the 
merozoite-filled vesicles, called merosomes. These rupture and discharge the merozoites 
into the host bloodstream where they infect RBCs (Sturm et al. 2006; Tarun et al. 2006) 
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beginning the erythrocytic stage. In the parasitised RBCs (pRBC) the parasite asexually 
multiplies further, the periodic release and re-infection into neighbouring RBCs is 
associated with the waves of fever described within the classical symptoms of malaria 
(Bledsoe 2005). The pRBC often undergoes membrane modification, forming protrusions 
giving a knobbed appearance. This results in the infected RBCs binding to other cell 
surfaces, such as other RBC and the cells which make up the inner surface of small blood 
vessels (Aley et al. 1984; Newton et al. 2000). This helps protect the parasite harbouring 
 
Figure 1.13 The Plasmodium Life Cycle Adapted from Kappe (2010). Starting at 
mosquito salivary gland infection [A], the motile sporozoites are injected into human skin 
during a mosquito feed where they migrate into the tissue and invade a blood vessel [B]. 
Sporozoites are transported, via the bloodstream into the hepatocytes of the liver through 
the sinusoid vessels [C], initiating liver-stage development. A single sporozoite undergoes 
massive growth to form tens of thousands of merozoites which are subsequently released 
back into the bloodstream. Each merozoite infects an erythrocyte [D], commencing the 
intraerythrocytic cycle comprised of an asexual blood stage replication [E] where repeated 
cycles of infection, replication, and release of next-generation merozoites results in the 
release of sexual-stage gametocytes [F]. The gametes are taken-up during a mosquito feed 
and mate to form a zygote in the mosquito midgut [G]. The zygote develops into a motile 
ookinete which penetrates the mosquito haemolymph where it develops into an oocyst [H]. 
Once fully mature the oocyst releases sporozoites which infect the mosquito salivary gland, 
thus beginning the cycle over. 
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cells from being circulated and destroyed in the spleen, but can also result in microvascular 
blockages causing placental and cerebral malaria (Miller et al. 1994). The pRBCs have 
also been shown to breach the blood-brain barrier in cerebral malaria potentially leading to 
patient coma (Adams et al. 2002). 
Some merozoites differentiate into male and female gametocytes, which can be taken up 
during an A. gambiae mosquitoes’ feed. In the mosquito mid-gut, the gametocytes mature 
and the male microgamete fertilises the female macrogamete, undergoing sexual 
recombination to form the zygotes (Kappe et al. 2010). The zygote develops into an 
ookinete which penetrates the lining of the mid-gut to form the oocyst with a new 
generation of sporozoites under the outer-gut lining. The sporozoites migrate to the 
mosquitos’ salivary gland, completing the parasite life cycle. 
After World War II vigorous efforts to eradicate malaria were put into practice (Litsios 
1996). Despite success over large geographical regions, malaria endures in tropical Africa 
and much of Asia. Subsequent healthcare initiatives which focused responsibility for 
malarial control on peripheral healthcare workers were also largely unsuccessful. Interest 
in the control of malaria has become increasingly focused on the worsening situation in 
sub-Saharan Africa and its contributory factors (Greenwood et al. 2002) such as climate 
instability and global warming (Hay et al. 2002; Tanser et al. 2003), war and civil-unrest 
resulting in healthcare breakdown (Bloland et al. 2002), interaction with and increased 
susceptibility to malaria due to Human Immunodeficiency Virus (HIV) infection 
(Whitworth et al. 2000; French et al. 2001; Mount et al. 2004; Kublin et al. 2005), and 
travel between non-endemic and endemic areas. However, the main cause is likely the 
spread of drug-resistant parasites and insecticide-resistant A. gambiae mosquitoes (Snow et 
al. 2001; Korenromp et al. 2003). 
 
1.4.1.1 Drug-Based Approaches to Combat Malaria 
Despite being largely ineffective and having potentially underestimated side effects, such 
as retinal toxicity (Farrell 2012), chloroquine is still the present strategy against 
uncomplicated P. falciparum malaria in many countries. The consequences of drug-
resistant parasites is such a problem that the World Health Organisation (WHO) advocates 
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a combination of vector control strategies such as insecticidal treated nets (ITNs) and 
indoor residual spraying (IRS), and parasitic interventions such as Intermittent 
Preventative Treatment in Pregnancy (IPTp) and Intermittent Preventative Treatment for 
Infants (IPTi) using sulphadoxine-pyrimethamine (SP) (WHO 2010). However, many 
countries that have substituted for SP have reported parasitic resistance (EANMAT 2003; 
Plowe et al. 2004). 
Kremsner and Krishna (2004) called for a combination therapy approach to be adopted to 
increase efficacy and decrease treatment duration, but despite reported improvement some 
countries have yet to adopt this approach. Questions arise in respect to what combinations 
of anti-malarial drugs to use. Taking into account effectiveness and affordability, 
artemisinin-based combination treatments (ACTs) have been used with good results from 
both Asia (Mayxay et al. 2004) and regions of Africa (Mutabingwa et al. 2005; Piola et al. 
2005). More recently however, resistance to artemisinin has been reported around the Thai-
Cambodian border (Dondorp et al. 2009). 
Approaches in optimising present treatment and devising new ones have been transformed 
in recent years due to more sophisticated laboratory techniques (Vernick et al. 2004) 
looking at more accurate identification of the infecting Plasmodium species (Singh et al. 
2004), and focusing on genetic markers characterising the parasitic virulence (Jensen et al. 
2004; Staalsoe et al. 2004) and drug-resistance (Sutherland et al. 2002; Djimdé et al. 
2003). Studies based on these observations have shown that the relatively long half-lives of 
many drugs, chloroquine and SP for example, provide the parasites with a selective 
advantage (Hastings et al. 2002; Hallett et al. 2004) however it seems that these resistant 
parasites are not transmitted as well as wild-type parasites. This has led to a concept that 
the discontinuation of treatment with these drugs may lead to a decrease in parasitic 
resistance, increasing success rates upon reintroduction of these drugs in a combination 
treatment scheme (Mita et al. 2003). 
 
1.4.1.2 Molecular Approaches to Combat Malaria 
Over a century after Sir Ronald Ross received the 1901 Nobel Prize in medicine for 
demonstrating the role of mosquitoes in the transmission of malaria (Brey 2003), the 
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genome of A. gambiae has been sequenced (Holt et al. 2002). From this have come new 
opportunities for targeted measures of control. Hallem et al. (2004) propose the 
identification of ligand inhibitors to the A. gambiae olfactory system which can then be 
utilised in new insect traps and repellents. Other possibilities have emerged regarding the 
genetic control over the mosquito population by means of introducing a modified strain of 
A. gambiae recalcitrant to Plasmodium into the wild population (Coleman et al. 2004), or 
by introducing germline transformants with genetic modifications that impede the normal 
functioning of female mosquitoes (Alphey et al. 2002). 
Molecular studies have identified innate mosquito immune response proteins that attack 
the plasmodium ookinetes and oocysts (Cirimotich et al. 2010) and could be used as anti-
parasitic molecules. Additionally, studies on sympatric A. gambiae populations show 
reduced P. falciparum infection intensities compared to allopatric populations (Harris et al. 
2012). Studies on bacteria harboured in the mosquito midgut (Cirimotich et al. 2010; 
Rodrigues et al. 2010) have revealed that they play a significant role in tempering 
Plasmodium transmission, providing an alternative line of study focused on blocking 
infection of the insect. 
Alternative to molecular targets elucidated from A. gambiae, many studies have focused on 
Plasmodium proteins themselves. One such stand out study follows P. falciparum 
reticulocyte binding protein homologue 5 (PFRH5) (Crosnier et al. 2011). In order for the 
parasite to gain entry into its human host’s RBCs, PFRH5 relies on the human glycoprotein 
blood system determinant, extracellular matrix metalloproteinase inducer (EMMPRIN). A 
study in animal models demonstrates a cross-strain vaccine induced an antibody response 
to the RH5 antigen, raising anti-PFRH5 immunoglobulin (IgG) which neutralised 
numerous strains of P. falciparum (Douglas et al. 2011). 
A second example is the phase three trial of RTS,S/AS01 (Agnandji et al. 2011), a 
recombinant vaccine which induces an antibody response to a cell surface protein of the P. 
falciparum sporozoite, called circumsporozoite. A potential short-coming in these 
approaches has been highlighted in studies on the erythrocyte membrane modification 
protein P. falciparum Erythrocyte Membrane Protein 1 (PFEMP1). Expressed during the 
erythrocytic stage, is it synthesised and transported from the intracellular parasite to the 
surface of the pRBC leaving them exposed to the host immune system. Protruding 
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PFEMP1 proteins have been identified as the binding interface of pRBCs to the brain 
endothelium of patients who have died from severe malaria (Adams et al. 2002). 
Obviously these make an attractive molecular target, however there are multiple varieties 
within a single parasite and even more within that parasite population (Maier et al. 2009). 
Moreover, as the host immune system responds to the single expressed PFEMP1, sub-
populations within the infecting parasite pool can interchange between their variant 
PFEMP1 surface proteins, restoring the infection and therefore remaining recalcitrant to 
the host immune system or conventional vaccinations (Chen et al. 2000; Pasternak et al. 
2009). 
 
1.4.1.3 Targeting Helicases to Combat Malaria 
Upon the completion of the P. falciparum genome in 2002 (Gardner et al.), a full set of 
helicases were identified and annotated (http://plasmodb.org/plasmo/). Soon after, Tuteja 
(2007) proposed the potential for P. falciparum helicases as novel targets for effective anti-
malarial drugs. Detailed Bioinformatic studies revealed 22 full-length putative DEAD-box 
helicases, and some other non-DEAD-box putative helicases (Seow et al. 2005; 
Suntornthiticharoen et al. 2006; Tuteja et al. 2006; Tuteja 2010). These proteins contain 
the conserved helicase domains and motifs, but vary in the N- and C-terminal regions and 
their coding sequences (Tuteja et al. 2006). At present only a few of these helicases have 
undergone any biochemical characterisation (Gupta et al. 2006; Suntornthiticharoen et al. 
2006; Pradhan et al. 2007; Pradhan et al. 2008; Shankar et al. 2008; Tuteja et al. 2009; 
Prakash et al. 2010; Mehta et al. 2011). 
Included within these characterised proteins is DEAD-box helicase Plasmodium 
falciparum helicase 45 kDa (PFH45, PlasmoDB gene ID: PF14_0655), an eIF4A 
homologue (Pradhan et al. 2007). So far studies have suggested that PFH45 is expressed 
through all the developmental stages of the parasite, binds both DNA and RNA, unwinds 
in both the 3’-5’ and 5’-3’ direction, and parasitic development is inhibited upon 
interference at both the genetic and proteomic level (Pradhan et al. 2007; Tuteja 2010; 
Tuteja et al. 2010). Pradhan et al. (2008) also report an up-regulation of helicase activity 
when phosphorylated with protein kinase C (PKC) and an inhibition of resolving 
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replication fork-like substrates in the presence of DNA-interacting molecules. Truncated 
forms have shown ATPase activity to be localised in the N-terminus while DNA/RNA 
binding is localised in the C-terminus, and neither truncated form is capable of independent 
unwinding activity. Several protein partners have also been identified for PFH45 (Tuteja et 
al. 2010). 
Initial characterisation has also been performed on the 60 kDa truncated version of 
Plasmodium falciparum DEAD-box helicase (PFDH60, PlasmoDB gene ID: PFL310c), 
which shares a high degree of identity with DDX5 (previously named p68) (Pradhan et al. 
2005); a highly conserved helicase from yeast to human. Unlike PFH45, PFDH60 
expression is mainly during the schizont stage of parasitic development (Pradhan et al. 
2005). Also, it exhibits helicase activity across a broad pH range (pH 5.0-10.0), requires a 
ssDNA region (Pradhan et al. 2007), and has been shown to unwind dsDNA, dsRNA, and 
DNA-RNA hybrids (Pradhan et al. 2005). Otherwise, like PFH45, PFDH60 shows 
bidirectional unwinding and displays up-regulated activity upon PKC phosphorylation. 
 
1.5 Aims and Objectives 
The principal purpose of this study is to explore the biochemical and structural properties 
of helicases from P. falciparum with an aim to exploit them as putative drug-targets. This 
will first involve the production of novel recombinants of PFH45 and PFDH60 from clones 
provided by Dr Renu Tuteja (Malaria Group, International Centre for Genetic Engineering 
and Biotechnology, New Deli, India), the purification of the fusion-tagged proteins after 
optimisation of heterologous expression in E. coli to produce yields sufficient enough to 
investigate the storage of the homologous protein samples, and for their characterisation. 
This work is described in chapter three. 
Biochemical characterisation is to be performed on both helicases. Initial in silco 
investigations into both PFH45 and PFDH60 will be undertaken to expand on and confirm 
previous observations. Then in vitro analysis on the helicase and ATPase activities of both 
PFH45 and PFDH60 will be performed to elucidate preferential substrates, conditions, and 
cofactors for unwinding. In addition, a long-standing collaboration between this laboratory 
and Prof. David Bensimon’s laboratory (Ecole Normale Superieure (ENS), Paris, France) 
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offers the opportunity to perform single-molecule biochemical characterisation on both 
helicases. This work is described in chapter four. 
Initial structural studies will be performed to elucidated information on both helicases. In-
house nuclear magnetic resonance (NMR) and X-ray crystallography services at the 
University of Portsmouth (Hampshire, UK) as well as good connections with the Diamond 
Light Source (Diamond House, Harwell Science and Innovation Campus, Didcot, 
Oxfordshire, England) will be taken advantage of to assist in these studies. This work is 
described in chapter five. 
Studies into novel approaches of helicase inhibition will be performed. The effect of a 
novel DNA binding drug, provided as part of a collaborative project with Prof. David 
Thurston (King’s College London, London, UK) on the helicase activity of both helicases 
will be studied. Furthermore, aptamers will be raised against each helicase and their 
subsequent cloning and sequencing of any aptamers generated will be performed. These 
could then be used as a high-throughput generation of potential inhibitors to be 
investigated further. This work is described in chapter six. 
The work carried out in this study is described in detail within each chapter, and the 
conclusions and potential for future studies are discussed in chapter seven. 
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CHAPTER TWO – METHODS AND MATERIALS 
 
2.1 Electrophoresis Protocols 
 
2.1.1 0.8 % TAE Agarose Gel 
Materials 
1. Agarose. 
2. TAE buffer: 50 mM TRIS∙HCl pH 8.0, 0.1 % glacial acetic acid, 1 mM EDTA, 
made up to the desired volume with distilled water and filter sterilised
1
 
immediately. 
3. Ethidium bromide: 50 mg mL-1 in distilled water. 
4. 5 × Agarose gel loading buffer: 50 % (v/v) Glycerol, 100 mM EDTA, 0.125 % w/v 
bromophenol blue, made up to the desired volume with distilled water. 
Method 
0.8 % agarose gels were prepared by adding 0.8 g of agarose to 100 mL of TAE buffer and 
boiling until fully dissolved. Once sufficiently cooled, ethidium bromine was added to a 
final concentration of 1 μg mL-1, mixed by gentle agitation, and poured into the gel plate 
and allowed to set for approximately 30 minutes. The set gel was then submerged in the 
gel tank under TAE buffer. The samples were mixed with 5 × agarose gel loading buffer 
prior to loading alongside the appropriate HyperLadder DNA marker (Bioline) (Figure 2.1) 
and then resolved for 1 hour at 100 V. The resolved samples were visualised and 
photographed using an ultraviolet light box. 
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2.1.2 10 % and 15 % SDS Polyacrylamide Gel Electrophoresis (PAGE) 
Materials 
1. SDS PAGE running buffer: 25 mM TRIS∙HCl pH 8.0, 200 mM glycine, 2.5 mM 
sodium dodecyl sulphate (SDS), made up to the desired volume in distilled water. 
2. Resolving gel solution: 10 % or 15 % Acrylamide (bis-acryl-amide (37:5:1)), 350 
mM TRIS∙HCl pH 8.0, 5 mM SDS, 0.1 % ammonium persulphate (APS), 0.1 % 
tetramethylethylenediamine (TEMED), made up to the desired volume using 
distilled water. 
 
      
Figure 2.1 Size Markers Used in this Study. Adapted from the Bioline HyperLadder I 
product insert (left) and HyperLadder V (centre), 5 µL of HyperLadder I and V markers 
resolved using electrophoresis on a 1 and 3.5 % TAE agarose gel respectively, with 
ethidium bromide staining. The numbers to the left of the markers show the amount of 
DNA per band in nanograms (ng), and the numbers to the right show the corresponding 
size of each DNA band in base pairs (bp). Adapted from the Invitrogen SeeBlue Plus2 
product insert (right), 10 µL of pre-stained SeeBlue Plus2 resolved using electrophoresis on 
a 10 % PAGE gel in tris-glycine running buffer. The labels to the left of the gel show the 
protein standards used in the marker, while the numbers to the right of the gel show the 
corresponding standard proteins size in kilodaltons (kDa). 
ng/Band 
 
 
 
 
 
60 
 
60 
 
60 
 
60 
 
120 
80 
80 
80 
120 
 
80 
 
80 
 
 
80 
 
 
Size (bp) 
 
 
 
 
 
500 
 
400 
 
300 
 
250 
 
200 
175 
150 
125 
100 
 
75 
 
50 
 
 
25 
 
 
Size (bp) 
 
    10000 
    8000 
    6000 
    5000 
    4000 
    3000 
    2500 
    2000 
 
   1500 
 
 
   1000 
 
   800 
 
   600 
 
   400 
 
 
   200 
ng/Band 
 
100 
80 
60 
50 
40 
30 
25 
20 
 
15 
 
 
100 
 
80 
 
60 
 
40 
 
 
20 
  
 
Mysosin 
 
 
Phosphorylase 
 
 
BSA 
 
Glutamate 
Dehydrogenase 
 
Alcohol 
Dehydrogenase 
 
Carbonic 
Anhydrase 
 
 
Myoglobin Red 
 
Lysozyme 
 
 
 
Aprotinin 
 
 
Insulin B Chain 
 
 
Size (kDa) 
 
    250 
 
    148 
 
 
    98 
 
    64 
 
 
    50 
 
 
    36 
 
 
    22 
 
    16 
 
 
 
   6 
 
 
   4 
 
 
 
37 
3. Stacking gel solution: 5 % Acrylamide (bis-acryl-amide (37:5:1)), 125 mM 
TRIS∙HCl pH 6.8, 5 mM SDS, 0.1 % APS, 0.1 % TEMED, made up to the desired 
volume using distilled water. 
4. 70 % Isopropanol. 
5. 5 × SDS gel loading buffer: 50 mM TRIS∙HCl pH 8.0, 100 mM EDTA, 20 mM 
SDS, 50 % (v/v) Glycerol, 0.125 % w/v bromophenol blue, 0.125 % w/v xylene 
cyanol, made up to the desired volume in distilled water. 
6. Coomassie blue staining solution: 40 % Methoanol, 10 % ethanoic acid, 0.1 % w/v 
brilliant blue red-250 (BB∙R-250), made up to the desired volume with distilled 
water. 
Method 
10 % and 15 % SDS PAGE gels were prepared by pouring 6 mL of resolving gel solution 
into the 8 mL PAGE gel cassette, overlaying with 70 % isopropanol and setting aside for 
15 minutes. Once set, the isopropanol was decanted off and the resolving gel was rinsed 
with distilled water. 2 mL of stacking gel solution was then poured onto the set resolving 
gel. A well comb was inserted into the top of the cassette and set aside for another 15 
minutes. The clamps and silicon gasket were then removed from the cassette, the cassette 
was placed into the gel tank, and the tank was filled with SDS PAGE running buffer. The 
well comb was removed from the cassette ready for the samples. The samples were mixed 
with 5 × SDS gel loading buffer and heated at 80 °C for 15 minutes prior to loading 
alongside a SeeBlue Plus2 Protein Marker (Invitrogen) (Figure 2.1). The gel was run for 20 
minutes at 80 V to concentrate the samples in the stacking gel, and then 1 hour at 180 V to 
resolve the samples. The gel was stained with coomassie blue staining solution for 20 
minutes at room temperature, and non-specific staining was removed by soaking in 
distilled water. 
 
2.1.3 6 %, 10 %, and 15 % Native PAGE 
Materials 
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1. TAE buffer: 50 mM TRIS∙HCl pH 8.0, 0.1 % glacial acetic acid, 1 mM EDTA, 
made up to the desired volume with distilled water and filter sterilised
1
 
immediately. 
2. Native gel solution: 6 %, 10 %, or 15 % Acrylamide (bis-acryl-amide (19:1)), 1 
mM dithiothreitol (DTT), 0.1 % APS, 0.1 % TEMED, in TAE buffer. 
3. 5 × Native gel loading buffer: 50 % (v/v) Glycerol. 
Method 
6 %, 10 %, and 15 % native PAGE gels were prepared by pouring 8 mL of native gel 
solution into the 8 mL PAGE gel cassette, inserting the well comb into the top of the 
cassette and setting aside for 15 minutes. The clamps and silicon gasket were then removed 
from cassette, the cassette was placed into the gel tank, and the tank was filled with TAE 
buffer. The well comb was removed from the cassette and the gel was pre-equilibrated for 
1 hour at 100 V at 4 °C. The samples were mixed with 5 × native gel loading buffer prior 
to loading, the gel was run for 60 minutes at 100 V at 4 °C. The gel was visualised 
depending on the sample’s specific requirements. 
 
2.2 Purification Protocols  
 
2.2.1 DNA Restriction Digest 
Materials 
1. DNA substrates; PFH45 and PfDH60 clones in pET-28a (Novagen) and pGEX-6P-
1 (GE Healthcare) expression vectors (Figure 2.2). 
2. Restriction enzymes (Table 2.1) (NEB). 
3. 10 × Restriction digest buffer (NEB). 
4. 10 × Bovine serum albumin (BSA) (NEB). 
5. Distilled water. 
Method 
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The restriction digests were carried in bullet tubes containing the DNA substrate with 1 
unit (U) of enzyme per 1 µM of DNA divided by the number of minutes per reaction. The 
respective restriction digest buffer for the enzymes was added, as well as BSA to act as a 
crowding agent where needed. The reaction was made to a final volume using distilled 
water and incubated at 37 °C for 1 hour. Where applicable, the reactions were terminated 
by heat activation, with aliquots run on a 0.8 % agarose gel (2.1.1) to observe cleavage. 
 
2.2.2 Preparation of Competent Cells (Hanahan et al. 1991) 
Materials 
1. Cell strains2 (Table 2.2): Escherichia coli Dh5α (Invitrogen), E. coli BL21 (DE3) 
pLysS (Novagen).  
2. SOB media: 2 % w/v Tryptone, 0.5 % w/v yeast extract, 10 mM NaCl, 2.5 mM 
KCl, 10 mM MgCl2, 10 mM MgSO4, made with distilled water and autoclave 
sterilised
1
 immediately. 
3. CCMB80: 10 mM KOAc pH 7.0, 80 mM CaCl2∙6H2O, 20 mM MnCl2∙4H2O, 10 
mM MgCl2∙6H2O, 10 % (v/v) Glycerol, made with distilled water, pH down to a 
minimum of 6.4 then autoclave sterilised
1
 immediately. 
Method 
Incubation flasks containing 250 mL SOB media were spiked with 100 µL of stock cells 
and grown overnight at 20 °C. The following day, once an OD600 ~0.3 was reached, the 
cells were collected by centrifugation at 4000 × g at 4 °C for 12 minutes. The pellets were 
then re-suspended in 50 mL of 4 °C CCMB80 buffer and incubated on ice for 20 minutes. 
The cells were then centrifuged at 4000 × g at 4 °C for 12 minutes and re-suspended in 10 
mL of 4 °C CCMB80 buffer. The cells were separated into 500 µL aliquots at stored at -70 
°C.
40 
 
 
 
Figure 2.2 Maps of the Expression Vectors used in this Study. The pET-28a(+) map (left) has been adapted from the Novagen pET-28a(+) product insert 
and the pGEX-6P-1 map (right) is adapted from the GE Healthcare pGEX-6P-1 product insert. For each vector the multiple cloning site (MCS) is highlighted at 
the top, detailing the associated cleavage and restriction sites. The His-Tag coding region of pET-28a(+) is located with the MCS sequence and is under the 
control of a T7 lac promoter, the glutathione S-transferase (GST) coding region of pGEX-6P-1 is located upstream of the MCS and is under the control of a tac 
promoter. 
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Clone 
Restriction Enzyme 
Upstream of Insert 
Restriction Enzyme 
Downstream of 
Insert 
NEBuffer for 
Double Digest 
Optimum Working 
Temperature 
BSA Requirement Heat Inactivation 
pET-28(+)/PFH45 BamHI NotI NEBuffer3 37°C Yes 
65°C 20 minutes 
(NotI) 
Optimised pET-
28(+)/PFH45 
BamHI NotI NEBuffer3 37°C Yes 
65°C 20 minutes 
(EcoRI) 
Optimised pGEX-6P-
1/ PFH45 
BamHI EcoRI NEBuffer EcoRI 37°C Yes 
65°C 20 minutes 
(NotI) 
Optimised pET-
28(+)/PFDH60 
BamHI NotI NEBuffer3 37°C Yes 
65°C 20 minutes 
(EcoRI) 
 
 
 
Table 2.1 Restriction Digests Reagents for the Clones used in this study. Identified from the NEB 2011-12 catalogue, and the Novagen and GE Healthcare 
support material for the pET-28a(+) and pGEX-6P-1 plasmid cloning vectors respectively. Table 2.1 shows the necessary restriction enzymes for cutting both 
upstream and downstream of the gene insert, the buffers compatible for the double digest, the optimum temperature for the digest, if the presence of Bovine 
Serum Albumin (BSA) is required or not, and whether the enzymes can be heat inactivated; the brackets indicate which, if any enzyme is affected. 
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Bacterial Strain Genotype 
Antibiotic 
Resistance 
Working 
Concentration 
E. coli Dh5α (Invitrogen) 
F
-
 endA1 glnV44 thi-1 recA1 relA1 gyrA96 deoR nupG Φ80dlacZΔM15 Δ(lacZYA-
argF)U169, hsdR17(rK
-
 mK
+), λ– 
None Not applicable 
E. coli BL21 (DE3) [pLysS] 
(Novagen) 
F
-
 ompT gal dcm lon hsdSB(rB
-
 mB
-) λ(DE3) pLysS(cmR) Chloramphenicol 
36 µg mL
-1
 in 100% 
dimethylformaldehyde 
(DMF) 
E. coli JM109 (DE3) 
(Promega) 
endA1, recA1, gyrA96, thi, hsdR17 (rk
–
, mk
+
), relA1, supE44, λ–, Δ(lac-proAB), [F´, 
traD36, proAB, lacI
qZΔM15], lDE3 
None Not applicable 
 
 
Plasmid Associated Affinity Tag Tag Cleavage Recognition Protein 
Antibiotic 
Resistance 
Working 
Concentration 
pET-28a(+) (Novagen) Polyhistidine (His6) Thrombin Kanamycin 
40 µg mL
-1
 in distilled 
water 
pGEX-6P-1 (GE Healthcare) Glutathione S-transferase (GST) PreScission Protease Ampicillin 
100 µg mL
-1
 in 
distilled water 
pGEM-T Easy (Promega) None Not applicable Ampicillin 
100 µg mL
-1
 in 
distilled water 
pJS4M None Not applicable Ampicillin 
100 µg mL
-1
 in 
distilled water 
 
Table 2.2 Bacterial Strains and Plasmids used in this Study. The top section of the table shows the bacterial strains used in this study, lists their genotype, 
any antibiotic resistance they have, and the working concentration of that antibiotic. The bottom section of the table shows the plasmid expression vectors used 
in this study, the associated affinity tag which they contribute to the fusion protein, the protein cleavage site to remove the tag from the expressed fusion 
protein, the antibiotic resistance they confer within the transformed cell, and the working concentration of that antibiotic. 
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2.2.3 Transformation 
Materials 
1. Competent cells: E. coli Dh5α (Invitrogen), E. coli Bl21 (DE3) pLysS (Novagen), 
E. coli JM109 (DE3) (Promega). 
2. DNA: Original clones; pET-28a(+)/PFH45, pET-28a(+)/PfDH60. Codon-usage 
optimised clones (GeneArt); pET-28a(+)/PFH45, pET-28a(+)/PfDH60, pGEX-6P-
1/PFH45, pGEX-6P-1/PfDH60. EcoR124I clones; pGEX-6P-1/HsdR and pJS4M. 
3. Lysogeny Broth (LB) media mix (Fisher Scientific): 1.5 % w/v Tryptone, 0.5 % 
w/v yeast extract, 1 % w/v NaCl, made with distilled water and autoclave sterilised
1
 
immediately. 
4. LB agar (Lennox L Agar) plates mix (Fisher Scientific): 1 % w/v Tryptone, 0.5 % 
w/v yeast extract, 5 % w/v NaCl, 1 % w/v agar, made with distilled water and 
autoclave sterilised
1
 immediately. Once sufficiently cooled to touch, the appropriate 
antibiotic (Table 2.2) was added and the molten agar was poured into culture plates 
to a depth of approximately 5 mm. Once set the plates were stored at 4 °C until 
required for a maximum of two weeks. 
Method 
The transformations were performed in bullet tubes containing 100 µL of competent cells 
with 1 µL of DNA by incubating the mixture on ice for 20 minutes. The mix was then 
transferred to a heat block at 42 °C for 90 seconds followed by the addition of 1 mL of 37 
°C pre-warmed LB media and incubated at 37 °C for 1 hour. The growth was then spread 
onto a LB agar plate containing the appropriate antibiotic and grown overnight at 37 °C. 
 
2.2.4 DNA Extraction (Birnboim et al. 1979) 
Materials 
1. Lysogeny Broth (LB) media mix (Fisher Scientific): 1.5 % w/v Tryptone, 0.5 % 
w/v yeast extract, 1 % w/v NaCl, made with distilled water and autoclave sterilised
1
 
immediately. 
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2. Antibiotic (Table 2.2): Kanamycin (Fisher Scientific), ampicillin (Fisher 
Scientific), stock solutions were filter sterilised
1
 immediately. 
3. GTE lysis buffer: 50 mM Glucose, 25 mM TRIS∙HCl pH 8.0, 10 mM EDTA, made 
with distilled water and autoclave sterilised
1
 immediately. 
4. NaOH-SDS: 0.2M NaOH, 1 % SDS, freshly prepared prior to use. 
5. 7.5M Ammonium acetate, pH 7.8 without adjustment. 
6. Isopropanol 
7. 70 % Ethanol: Made with distilled water. 
8. TE-RNase A: 10 mM TRIS∙HCl pH 8.0, 1 mM EDTA pH 8.0, 20 % w/v RNase A. 
Method 
A 37 °C overnight incubation of 3 mL of LB media with the appropriate antibiotic was 
inoculated with a single plate colony of cells. The following morning 1 mL of the culture 
was centrifuged at 15000 × g for 5 minutes. The supernatant was discarded and the cell 
pellet was re-suspended in 200 μL of GTE lysis buffer. After 5 minutes at R/T, 400 μL of 
NaOH-SDS was added and mixed by inversion. After a further 5 minutes on ice, 300 μL 
ammonium acetate was added and mixed by inversion. After 10 minutes on ice the samples 
were centrifuged at 15000 × g for 5 minutes. The clear supernatant was transferred into a 
fresh bullet tube, 500 μL (0.6 vol.) of isopropanol was added then incubated at R/T for 10 
minutes. The samples were then centrifuged at 15000 × g for 10 minutes and the 
supernatants discarded. Then 1 mL of 70 % ethanol was added to the pellet. The samples 
were centrifuged at 15000 × g for 5 minutes and the supernatants were discarded. The 
pellets were then dried by placing the tubes cap-open upside-down on tissue for 15 minutes 
at R/T. The pellets were dissolved in 100 μL TE-RNase and incubated on ice for 15 
minutes. The isolated DNA was cleaned using a DNA spin column. The samples were 
visualised on a 0.8 % agarose gel (2.1.1). 
 
2.2.5 Protein Expression Analysis 
Materials 
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1. Lysogeny Broth (LB) media mix (Fisher Scientific): 1.5 % w/v Tryptone, 0.5 % 
w/v yeast extract, 1 % w/v NaCl, made with distilled water and autoclave sterilised
1
 
immediately. 
2. Antibiotic (Table 2.2): Kanamycin (Fisher Scientific), ampicillin (Fisher 
Scientific), stock solutions were filter sterilised
1
 immediately. 
3. Isopropyl β-D-1-thiogalactopyranoside (IPTG): 1 M made with distilled water and 
filter sterilised
1
 immediately. 
Method 
A 37 °C overnight incubation of 3 mL of LB media with the appropriate antibiotic was 
inoculated with a single plate colony of cells. The following morning 30 µL was seeded 
into 3 mL (1:100 dilution) fresh LB media with antibiotic and grown at 37 °C to an OD600 
0.6-0.8. A 1 mL un-induced control sample was removed and the cells harvested by 
centrifugation at 15000 × g for 5 minutes. The remaining 2 mL of the cell culture was 
induced with 1 mM IPTG and re-incubated at 37 °C. After 3 hours, 1 mL of the culture 
was collected and centrifuged at 15000 × g for 5 minutes to harvest the induced cells. The 
cells were re-suspended in 50 µL 5 × SDS loading buffer and heated at 100 °C for 20 
minutes. The samples were then centrifuged at 15000 × g for 5 minutes. The un-induced 
control was re-suspended in its supernatant while the supernatant of the induced samples 
were transferred into fresh bullet tubes and served as the soluble fractions. The induced 
sample pellets were re-suspended in 50 µL of fresh 5 × SDS loading buffer to serve as the 
insoluble fractions. All the samples were visualised on a SDS PAGE gel. 
 
2.2.6 Western Blotting (Towbin et al. 1979; Burnette 1981) 
Materials 
1. Transfer buffer: 200 mM Glycine, 25 mM TRIS base, 10 % methanol, made up to 
the desired volume with distilled water and filter sterilised
1
 immediately. 
2. TBST: 50 mM TRIS∙HCl pH 8.0, 150 mM NaCl, 0.1 % Tween, made up to the 
desired volume with distilled water and filter sterilised
1
 immediately. 
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3. Bovine serum albumin (BSA) (Fisher Scientific): 10 mg mL-1 made with distilled 
water and stored at -20 °C. 
4. Two-part developing solution: Part 1; 2.5 mM luminol, 0.5 mM p-coumaric acid, 
100 mM TRIS∙HCl pH 8.0, made up to the desire volume in distilled water. Part 2; 
0.05 % v/v hydrogen peroxide, 100 mM TRIS∙HCl pH 8.0, made up to the desire 
volume in distilled water. 
Method 
Samples were run on a SDS PAGE gel (2.1.2). Rather than being stained with coomassie 
blue staining solution, the gel was placed onto a nitrocellulose membrane which had been 
pre-soaked along with two pieces of blotting paper and two sponge sheets in transfer 
buffer. The nitrocellulose was placed between the two pieces of blotting paper which in 
turn were sandwiched between the two sponge sheets. The sandwich was then transferred 
into an electro-transfer box and run for 2 hours at 300 mA. Once transferred, the 
nitrocellulose membrane was washed with three 5 minutes washes with TBST at room 
temperature. It was then incubated with a 1° antibody in TBST with 5 % BSA at room 
temperature for 2 hours or 4 °C overnight. Next the membrane had three consecutive 5 
minute washes with TBST at room temperature before incubation with a 2° horseradish 
peroxidise (HRP) conjugated antibody in TBST with 0.5 % BSA at room temperature for 1 
hour. To finish, the membrane underwent a further three 5 minutes washes in TBST at 
room temperature. The blot was developed using a two-part developing solution and 
incubating for 1 minute before detecting with a Fujifilm LAS-3000 refrigerated camera at -
20 °C under a 1 minute exposure time. 
 
2.2.7 Growth and Cell Harvest 
Materials 
1. Lysogeny Broth (LB) media mix (Fisher Scientific): 1.5 % w/v tryptone, 0.5 % w/v 
yeast extract, 1 % w/v NaCl, made with distilled water and autoclave sterilised
1
 
immediately. 
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2. 2 × YT media mix (Fisher Scientific): 1.6 % w/v Tryptone, 1 % w/v yeast extract, 
0.5 % w/v NaCl, made with distilled water and autoclave sterilised
1
 immediately. 
3. Antibiotic (Table 2.2): Kanamycin (Fisher Scientific), ampicillin (Fisher 
Scientific), stock solutions were filter sterilised
1
 immediately. 
4. IPTG: 1 M made with distilled water and filter sterilised1 immediately. 
Method 
A 37 °C overnight incubation of LB media with the appropriate antibiotic was inoculated 
with a single plate colony of cells. The following morning the overnight seed culture was 
used in a 1:100 inoculation of the desired fresh media (LB or 2 × YT) containing the 
appropriate antibiotic. The culture was grown at 37 °C with agitation to an OD600 of 0.6-
0.8 at which point the cells were induced with a suitable IPTG concentration. After a 3 
hours expression period at 37 °C, or overnight at 20 °C, the cells were harvested by 
centrifugation at 4000 × g for 15 minutes at 4 °C and stored at -20 °C. 
 
2.2.8 Auto-Induction Growth and Harvest (Hanahan et al. 1991)  
Materials 
1. ZY media: 1 % w/v tryptone, 0.5 % w/v yeast extract, made with distilled water 
and autoclave sterilised
1
 immediately. 
2. MgSO4: 1M made with distilled water and filter sterilised
1
 immediately. 
3. 1000 × Metal mix: 50 mM FeCl3∙6H2O, 20 mM CaCl2, 10 mM MnCl2∙4H2O, 10 
mM ZnSO4∙7H2O, 2 mM CoCl2∙6H2O, 2 mM CuCl2∙2H2O, 2 mM NiCl2∙6H2O, 2 
mM Na2MoO4∙2H2O, 2 mM Na2SeO3∙5H2O, 2 mM H3BO3, made with distilled 
water and filter sterilised
1
 immediately. 
4. 20 × NPS: 0.5M (NH4)2SO4, 1M KH2PO4, 1M Na2HPO4, made with distilled water 
and autoclave sterilised
1
 immediately. 
5. 50 × 5052: 25 % w/v Glycerol, 2.5 % w/v glucose, 10 % w/v α-lactose, made with 
distilled water and autoclave sterilised
1
 immediately. 
Method 
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A 37 °C over-day incubation of 8 mL of ZYP-0.8G media (ZY media, 1 mM MgSO4, 1 × 
Metal Mix, 0.8 % Glucose, 1 × NPS) with the appropriate antibiotic was inoculated with a 
single plate colony of cells. That evening, 4 mL of the starter culture was used to inoculate 
400 mL ZYP-5052 (ZY media, 1 mM MgSO4, 1 × metal mix, 1 × 5052, 1 × NPS) with the 
appropriate antibiotic and grown at 20 °C overnight. The following day the cells were 
harvested by centrifugation at 4000 × g for 15 minutes and stored at -20 °C. 
 
2.2.9 Labelled Growth and Cell Harvest 
Materials 
1. Lysogeny Broth (LB) media mix (Fisher Scientific): 1.5 % w/v Tryptone, 0.5 % 
w/v yeast extract, 1 % w/v NaCl, made with distilled water and autoclave sterilised
1
 
immediately. 
2. M9 minimal media: 0.6 % w/v Na2HPO4, 0.3 % w/v KH2PO4, 0.05 % w/v NaCl, 
made with distilled water and autoclave sterilised
1
 immediately. Then add final 
reagents; 0.25 % w/v (NH4)2SO4, 0.25 % w/v D(+) glucose, 1 mM MgSO4, 1 mM 
thiamine. 
3. 1000 × Metal mix: 50 mM FeCl3∙6H2O, 20 mM CaCl2, 10 mM MnCl2∙4H2O, 10 
mM ZnSO4∙7H2O, 2 mM CoCl2∙6H2O, 2 mM CuCl2∙2H2O, 2 mM NiCl2∙6H2O, 2 
mM Na2MoO4∙2H2O, 2 mM Na2SeO3∙5H2O, 2 mM H3BO3, made with distilled 
water and filter sterilised
1
 immediately. 
4. Antibiotic (Table 2.2): Kanamycin (Fisher Scientific), ampicillin (Fisher 
Scientific), stock solutions were filter sterilised
1
 immediately. 
5. IPTG: 1 M made with distilled water and filter sterilised1 immediately. 
Method 
A 37 °C over-day incubation of 5 mL of LB media with the appropriate antibiotic was 
inoculated with a single plate colony of cells. That evening 1 mL of the over-day culture 
was used to inoculate a 37 °C overnight incubation of 100 mL M9 minimal media 
containing 1 × metal mix, the appropriate antibiotic, and the desired isotope. The following 
morning the 100 mL overnight culture was added to 700 mL of fresh M9 minimal media 
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containing 1 × metal mix, the appropriate antibiotic, and the desired isotope. The culture 
was grown at 37 °C to an OD600 of 0.6-0.8 at which point the cells were induced with a 
suitable IPTG concentration. After a 3 hours expression period at 37 °C the cells were 
harvest by centrifugation at 4000 × g for 15 minutes at 4 °C and stored at -20 °C. 
 
2.2.10 Sonication 
Materials 
1. Sonication buffer: 1 × Phosphate Buffered Saline (PBS) (137 mM NaCl, 2.7 mM 
KCl, 8.1 mM Na2HPO4, 1.4 mM K2HPO4), 1 mM DTT, 1 mM benzamidine, 0.1 
mM phenylmethanesulphonylfluoride (PMSF), made up to the desired volume in 
distilled water. 
Method 
The cell pellet was thawed at room temperature, re-suspended in 35 mL sonication buffer 
and sonicated with a Sonics Vibra-Cell VCX-500 sonicator for 3.3s on and 9.9s off, at 40 
% amplitude for 20 minutes at 4 °C. The cell lysate was then centrifuged at 50000 × g for 1 
hour at 4 °C to pellet the insoluble fraction. The soluble fraction was decanted and kept at 
4 °C prior to purification. 
 
2.2.11 Resolubilisation with Sarkosyl 
Materials 
1. Sonication buffer: 1 × PBS (137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.4 
mM K2HPO4), 1 mM DTT, 1 mM benzamidine, 0.1 mM 
phenylmethanesulphonylfluoride (PMSF), made up to the desired volume in 
distilled water. 
2. 10 % Sarkosyl: Made with distilled water. 
3. Triton X-100. 
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4. 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS). 
Method 
The cell pellet was thawed at room temperature, re-suspended in 35 mL sonication buffer 
and sonicated for 3.3s on and 9.9s off, at 40 % amplitude for 30 minutes at 4 °C. The cell 
lysate was then centrifuged at 50000 × g for 1 hour at 4 °C to pellet the insoluble fraction. 
The soluble fraction was removed and the insoluble pellet was resuspended in 5 mL 10 % 
sarkosyl and re-sonicated. The sonicate was centrifuged at 50000 × g for 30 minutes. The 
supernatant was decanted off and diluted to 2 % Sarkosyl, made to 4 % Triton X-100 and 
30 mM CHAPS. The sample was kept at 4 °C prior to purification. 
 
2.2.12 Glutathione Affinity Chromatography 
Materials 
1. 5 mL GSTrap FF column (GE Healthcare). 
2. Distilled water, filter sterilised1 and vacuum degassed prior to use. 
3. TRIS buffer A: 50 mM TRIS∙HCl pH 8.0, 200 mM NaCl, 0.1 mM EDTA, 1 mM 
DTT, made up to the desired volume with distilled water, filter sterilised
1
 and 
vacuum degassed prior to use. 
4. TRIS buffer B: 50 mM TRIS∙HCl pH 8.0, 200 mM NaCl, 0.1 mM EDTA, 1 mM 
DTT, 10 mM glutathione, made up to the desired volume with distilled water, filter 
sterilised
1
 and vacuum degassed prior to use. 
5. 20 % Ethanol: Made with distilled water, filter sterilised1 and vacuum degassed 
prior to use. 
6. PreScission protease (GE Healthcare). 
Method 
The sample was loaded into the superloop and purified as follows. At 4 °C and at a rate of 
5 mL min
-1
 the column was pre-equilibrated with three column volumes of distilled water 
then three column volumes of TRIS A buffer. Collecting 4 mL fractions the sample was 
injected in TRIS buffer A followed by three column volumes of TRIS buffer A to wash 
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through all non-bound protein. An on column cleavage was performed by pausing the 
programme manually injecting 400 U of PreScission protease and incubating at 4 °C 
overnight. The following morning the cleaved protein was washed off the column with 
three column volumes of TRIS buffer A. The bound glutathione S-transferase (GST) 
moiety was eluted with three column volumes TRIS buffer B. Without collecting fractions, 
the column was washed with three column volumes of distilled water followed by three 
column volumes of 20 % ethanol for storage purposes. The fractionated sample was run on 
a SDS PAGE gel (2.1.2) and any protein containing fractions were pooled and stored at 4 
°C. 
 
2.2.13 Nickel Affinity Chromatography (Porath et al. 1975; Sulkowski 
1989) 
Materials 
1. Ni-NTA resin (QIAGEN). 
2. Distilled water, filter sterilised1 and vacuum degassed prior to use. 
3. Disodium phosphate buffer: 50 mM Na2HPO4 pH 7.5, 500 mM NaCl, 1 mM DTT, 
10 % (v/v) Glycerol, made up to the desired volume with distilled water, filter 
sterilised
1
 and vacuum degassed prior to use. 
4. HEPES buffer: 20 mM 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulphonic acid 
(HEPES) pH 7.5, 500 mM NaCl, 1 mM DTT, 10 % (v/v) Glycerol, 200 mM 
imidazole, made up to the desired volume with distilled water, filter sterilised
1
 and 
vacuum degassed prior to use. 
5. 20 % Ethanol: Made with distilled water, filter sterilised1 and vacuum degassed 
prior to use. 
Method 
The sample was loaded onto the superloop and purified as follows. At 4 °C and at a rate of 
5 mL min
-1 
the column was pre-equilibrated with three column volumes of distilled water 
then three column volumes of disodium phosphate buffer . Collecting 4 mL fractions the 
sample was injected in disodium phosphate buffer followed by three column volumes of 
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disodium phosphate buffer to wash through all non-bound protein. The bound protein was 
eluted with three column volumes HEPES buffer. Without collecting fractions, the column 
was washed with three column volumes of distilled water followed by three column 
volumes of 20 % ethanol for storage purposes. The fractionated sample was run on a SDS 
PAGE gel (2.1.2); any protein containing fractions were pooled and stored at 4 °C. 
 
2.2.14 Diethylaminoethyl (DEAE) Cellulose Chromatography 
Materials 
1. 5 mL HiTrap DEAE FF column (GE Healthcare). 
2. Distilled water, filter sterilised1 and vacuum degassed prior to use. 
3. TRIS buffer A: 20 mM TRIS∙HCl pH 8.0, made up to the desired volume with 
distilled water, filter sterilised
1
 and vacuum degassed prior to use. 
4. TRIS buffer B: 20 mM TRIS∙HCl pH 8.0, 250 mM NaCl, made up to the desired 
volume with distilled water, filter sterilised
1
 and vacuum degassed prior to use. 
5. 20 % Ethanol: Made with distilled water, filter sterilised1 and vacuum degassed 
prior to use. 
Method 
The sample was loaded into the superloop and purified as follows. At 4 °C and at a rate of 
5 mL min
-1 
the column was pre-equilibrated with three column volumes of distilled water 
then three column volumes of TRIS buffer A. Collecting 4 mL fractions the sample was 
injected in TRIS buffer A followed by three column volumes of TRIS buffer A to wash 
through all non-bound protein. Protein was eluted during a 0-100 % gradient of TRIS 
buffer B against TRIS buffer A. Without collecting fractions, the column was washed with 
three column volumes of distilled water followed by three column volumes of 20 % 
ethanol for storage purposes. The fractionated sample was run on a SDS PAGE gel (2.1.2) 
and any protein containing fractions were pooled and stored at 4 °C. 
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2.2.15 Desalting Chromatography 
Materials 
1. 5 mL HiTrap Desalting column (GE Healthcare). 
2. Distilled water, filter sterilised1 and vacuum degassed prior to use. 
3. TRIS buffer: 50 mM TRIS∙HCl pH 8.0, 50 mM NaCl, 0.1 mM EDTA, 1 mM DTT, 
made up to the desired volume with distilled water, filter sterilised
1
 and vacuum 
degassed prior to use. 
4. 20 % Ethanol: Made with distilled water, filter sterilised1 and vacuum degassed 
prior to use. 
Method 
The sample was loaded into the superloop and purified as follows. At 4 °C and at a rate of 
5 mL min
-1 
the column was pre-equilibrated with three column volumes of distilled water 
then three column volumes of TRIS buffer A. Collecting 4 mL fractions the sample was 
injected washed through in TRIS buffer A. Without collecting fractions, the column was 
washed with three column volumes of distilled water followed by three column volumes of 
20 % ethanol for storage purposes. The fractionated sample was run on a SDS PAGE gel 
(2.1.2); any protein containing fractions were pooled and stored at 4 °C. 
 
2.2.16 Heparin Affinity Chromatography 
Materials 
1. 5 mL HiTrap Heparin HP column (GE Healthcare). 
2. Distilled water, filter sterilised1 and vacuum degassed prior to use. 
3. HEPES buffer A: 20 mM 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulphonic 
acid (HEPES) pH 7.5, 1 mM DTT, 10 % (v/v) Glycerol, made up to the desired 
volume with distilled water, filter sterilised
1
 and vacuum degassed prior to use. 
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4. HEPES buffer B: 20 mM HEPES pH 7.5, 1 mM DTT, 500 mM NaCl, 10 % (v/v) 
Glycerol, made up to the desired volume with distilled water, filter sterilised
1
 and 
vacuum degassed prior to use. 
5. 20 % Ethanol: Made with distilled water, filter sterilised1 and vacuum degassed 
prior to use. 
Method 
The sample was loaded into the superloop and purified as follows. At 4 °C and at a rate of 
5 mL min
-1 
the column was pre-equilibrated with three column volumes of distilled water 
then three column volumes of HEPES buffer A. Collecting 4 mL fractions the sample was 
injected in HEPES buffer A followed by three column volumes of HEPES buffer A to 
wash through all non-bound protein. Protein was eluted with HEPES buffer B. Without 
collecting fractions, the column was washed with three column volumes of distilled water 
followed by three column volumes of 20 % ethanol for storage purposes. The fractionated 
sample was run on a SDS PAGE gel (2.1.2); any protein containing fractions were pooled 
and stored at 4 °C. 
 
2.2.17 Size Exclusion Chromatography 
Materials 
1. HiLoad 26/60 Superdex 200 Prep Grade column (GE Healthcare). 
2. Distilled water, filter sterilised1 and vacuum degassed prior to use. 
3. HEPES buffer: 20 mM 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulphonic acid 
(HEPES) pH 7.5, 1 mM DTT, 10 % (v/v) Glycerol 50 mM NaCl, made up to the 
desired volume with distilled water, filter sterilised
1
 and vacuum degassed prior to 
use. 
4. 20 % Ethanol: Made with distilled water, filter sterilised1 and vacuum degassed 
prior to use. 
Method 
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The sample was loaded into the superloop and purified as follows. At 4 °C and at a rate of 
3 mL min
-1 
the column was pre-equilibrated with one column volume of distilled water 
then one column volume of HEPES buffer. Collecting 4 mL fractions the sample was 
injected in size exclusion column running buffer followed by one and a half column 
volumes of HEPES buffer to resolve and elute the protein. Without collecting fractions, the 
column was washed with one column volume of distilled water followed by one and a half 
column volumes of 20 % ethanol for storage purposes. The fractionated sample was run on 
a SDS PAGE gel (2.1.2); any protein containing fractions were pooled and stored at 4 °C. 
 
2.2.18 Ammonium Sulphate Fractionation 
Materials 
1. (NH4)2SO4. 
2. TRIS buffer: 50 mM TRIS∙HCl pH 8.0, 200 mM NaCl, 0.1 mM EDTA, 1 mM 
DTT, made up to the desired volume with distilled water and filter sterilised
1
 
immediately. 
Method 
Protein samples were made to 10 % (NH4)2SO4 and incubated with agitation at room 
temperature for 20 minutes. The sample was then centrifuged at 50000 × g for 15 minutes. 
The supernatant was decanted into a fresh centrifuge vessel and kept for the next step 
while the pellet was re-suspended in a suitable volume of TRIS buffer. This was repeated 
for the supernatant increasing the (NH4)2SO4 concentration by 10 % each round to a 
maximum of 50 %. Samples of 0, 10, 20, 30, 40, and 50 % (NH4)2SO4 as well as the last 
supernatant were run on a SDS PAGE gel (2.1.2). 
 
2.2.19 Growth and Purification of GST-PP-HsdR 
Materials 
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1. LB agar (Lennox L Agar) plates mix (Fisher Scientific): 1 % w/v Tryptone, 0.5 % 
w/v yeast extract, 5 % w/v NaCl, 1 % w/v agar, made with distilled water and 
autoclave sterilised
1
 immediately. Once sufficiently cooled to touch, ampicillin was 
added to a final concentration of 100 µg mL
-1
 and the molten agar was poured into 
culture plates to a depth of approximately 5 mm. Once set the plates were stored at 
4 °C until required for a maximum of two weeks. 
2. Lysogeny Broth (LB) media mix (Fisher Scientific): 1.5 % w/v Tryptone, 0.5 % 
w/v yeast extract, 1 % w/v NaCl, made with distilled water and autoclave sterilised
1
 
immediately. 
3. IPTG: 1 M made with distilled water and filter sterilised1 immediately. 
4. TRIS buffer A: 50 mM TRIS∙HCl pH 8.0, 200 mM NaCl, 0.1 mM EDTA, 1 mM 
DTT, made up to the desired volume with distilled water, filter sterilised
1
 and 
vacuum degassed prior to use. 
5. TRIS buffer B: 50 mM TRIS∙HCl pH 8.0, 200 mM NaCl, 0.1 mM EDTA, 1 mM 
DTT, 10 mM glutathione, made up to the desired volume with distilled water, filter 
sterilised
1
 and vacuum degassed prior to use. 
6. PreScission protease (GE Healthcare). 
7. 100 % Glycerol. 
Method 
The purification of HsdR was carried out following the unpublished work performed by Dr 
James Youell (University of Portsmouth, Hampshire, UK). 
The recombinant pGEX-6P-1 plasmid harbouring the HsdR or PreScission Protease (PP) 
gene was transformed (2.2.3) into BL21 (DE3) [pLysS] E. coli cells (Stratagene) (Table 
2.2), and grown overnight on LB agar plates supplemented with 100 µg mL
-1
 ampicillin at 
37 °C. 
37 °C overnight seed cultures were set up, containing single colonies of BL21 (DE3) 
[pLysS] transformants in LB media with 100 µg mL
-1
 ampicillin. These were used a 1:100 
inoculation of LB media growth containing 100 µg mL
-1
 ampicillin and grown at 37 °C to 
an OD600 of 0.6-0.8 at which point the cells were induced with 1 mM IPTG. After an 
overnight expression period at 24 °C the cells were harvested by centrifugation at 4000 × g 
for 15 minutes at 4 °C and stored at -20 °C. 
57 
The cell pellet was sonicated as described in 2.2.10 and the supernatant was additionally 
ultra-centrifuged at 200000 × g for 30 minutes. The supernatant was loaded into the 
superloop and purified as follows. At 4 °C and at a rate of 5 mL min
-1
 the column was pre-
equilibrated with three column volumes of distilled water then three column volumes of 
TRIS A buffer. Collecting 4 mL fractions the sample was injected in TRIS buffer A 
followed by three column volumes of TRIS buffer A to wash through all non-bound 
protein. An on column cleavage of HsdR-PP-GST was performed by pausing the 
programme, and manually injecting 400 U of PreScission protease and incubating at 4 °C 
overnight. The following morning the cleaved protein was washed off the column with 
three column volumes of TRIS buffer A. The bound glutathione S-transferase (GST) 
moiety was eluted with three column volumes TRIS buffer B. Without collecting fractions, 
the column was washed with three column volumes of distilled water followed by three 
column volumes of 20 % ethanol for storage purposes. Fraction samples were run on a 
SDS PAGE gel (2.1.2) and any protein containing fractions were pooled, concentrated with 
a centrifugal concentrator, and made to 50 % glycerol for long term storage at -20 °C. 
 
2.2.20 Purification of MTase 
Materials 
1. LB agar (Lennox L Agar) plates mix (Fisher Scientific): 1 % w/v Tryptone, 0.5 % 
w/v yeast extract, 5 % w/v NaCl, 1 % w/v agar, made with distilled water and 
autoclave sterilised
1
 immediately. Once sufficiently cooled to touch, ampicillin was 
added to a final concentration of 100 µg mL
-1
 and the molten agar was poured into 
culture plates to a depth of approximately 5 mm. Once set the plates were stored at 
4 °C until required for a maximum of two weeks. 
2. Lysogeny Broth (LB) media mix (Fisher Scientific): 1.5 % w/v Tryptone, 0.5 % 
w/v yeast extract, 1 % w/v NaCl, made with distilled water and autoclave sterilised
1
 
immediately. 
3. IPTG: 1 M made with distilled water and filter sterilised1 immediately. 
4. TRIS buffer A: 50 mM TRIS∙HCl pH 8.0, 50 mM NaCl, 0.1 mM EDTA, 1 mM 
DTT, made up to the desired volume with distilled water, filter sterilised
1
 and 
vacuum degassed prior to use. 
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5. TRIS buffer B: 50 mM TRIS∙HCl pH 8.0, 1 M NaCl, 0.1 mM EDTA, 1 mM DTT, 
made up to the desired volume with distilled water, filter sterilised
1
 and vacuum 
degassed prior to use. 
6. TRIS buffer C: 50 mM TRIS∙HCl pH 8.0, 100 mM NaCl, 0.1 mM EDTA, 1 mM 
DTT, made up to the desired volume with distilled water, filter sterilised
1
 and 
vacuum degassed prior to use. 
7. 100 % Glycerol. 
Method 
Purification of MTase was performed as described by Taylor (Taylor et al. 1992) with 
minor modification based on personal correspondence with Dr Peter Coxhead (University 
of Portsmouth, Hampshire, UK). In short, the pJS4M (Patel et al. 1992) plasmid encoding 
wild-type MTase was transformed (2.2.3) into JM109 (DE3) cells (Promega) (Table 2.2) 
and grown overnight on LB agar plates supplemented with 100 µg mL
-1
 ampicillin at 37 
°C. 
37 °C overnight seed cultures were set up, containing single colonies of JM109 (DE3) 
transformants in LB media with 100 µg mL
-1
 ampicillin. These were used a 1:100 
inoculation of 2 × YT media growth containing 100 µg mL
-1
 ampicillin and grown at 37 °C 
to an OD600 of 0.6-0.8 at which point the cells were induced with 1 mM IPTG. After an 6 
hour expression period at 37 °C the cells were harvested by centrifugation at 4000 × g for 
15 minutes at 4 °C and stored at -20 °C. 
The cell pellet was sonicated as described in 2.2.10 and the supernatant was additionally 
ultra-centrifuged at 200000 × g for 30 minutes. The supernatant was then made to 500 mM 
NaCl and 10 mg mL
-1
 of protamine sulphate, gently mixed for 30 minutes at 4 °C and 
centrifuged at 27000 × g for 30 minutes. The supernatant was then made to 70 % 
ammonium sulphate, gently mixed for 30 minutes at 4 °C and centrifuged at 12000 × g for 
30 minutes. The supernatant was discarded and the pellet was resuspended in TRIS Buffer 
A, and then desalted using a HiTrap Desalting column (GE Healthcare). The desalted 
fractions were then loaded on HiTrap DEAE columns (GE Healthcare) and eluted over a 
100 mL gradient of 50 mM to 500 mM NaCl using TRIS Buffer B. Fractions containing 
MTase were pooled and desalted again, this time into TRIS Buffer C. The desalted 
fractions were pooled and loaded onto a HiTrap Heparin column (GE Healthcare) and 
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eluted over a 100 mL gradient of 100 mM to 1 M NaCl using TRIS Buffer B. Fraction 
samples were run on a SDS PAGE gel (2.1.2) and any protein containing fractions were 
pooled, concentrated to with a centrifugal concentrator, and made to 50 % glycerol for long 
term storage at -20 °C. 
 
2.2.21 UV-Visible Spectrophotometry 
Protein and DNA concentrations were measured using a Nanodrop 2000 
spectrophotometer (Thermo Scientific) at 280 nm and 260 nm wavelengths respectively. 
Concentrations were calculated via the Beer-Lambert law: 
      
Where A is the absorbance at a given wavelength, ε is the molar extinction coefficient 
measured in per molar concentration per centimetre (M
-1
 cm
-1
), c is the molar 
concentration of the measured sample and l is the sample path length. 
Duplex DNA concentrations were estimated based on a 50 µg mL
-1
 sample having an 
absorbance of 1 absorbance unit (AU) at 260 nm (Sambrook et al. 2001). Protein 
concentrations were either estimated based on a 1 mg mL
-1
 sample having an absorbance 
of 1 AU, or calculated more accurately using their specific molar extinction coefficients 
and molecular weights. 
 
2.3 Biochemical Characterisation Protocols 
 
2.3.1 Substrate Annealing (Özsoy et al. 2003) 
Materials 
1. Oligonucleotides (Invitrogen) (Appendix 1): 100 µM made with distilled water. 
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2. Annealing buffer: 7 mM TRIS∙HCl pH 8.0, 6.6 mM MgCl2, 50 mM NaCl, 1 mM 
DTT, made up to the desired volume with distilled water and filter sterilised
1
 
immediately. 
Method 
Substrates annealing follows the protocol described by Özsoy et al. (2003) with minor 
modification. Equimolar ratios of the substrates component oligonucleotides were 
incubated together in annealing buffer at 95 °C for 20 minutes then allowed to slowly cool 
to room temperature and stored at -20 °C. 
 
2.3.2 Triplex Formation (Firman et al. 2000) 
Materials 
1. Triplex forming oligonucleotide (TFO) (Invitrogen): 
TTC TTT TCT TTC TTC TTT CTT T 
100 µM made with distilled water. 
2. DNA duplex. 
3. Triplex buffer: 25 mM 2-(N-morpholino)ethanesulphoic acid (MES) pH 5.5, 10 
mM MgCl2, made with distilled water and autoclave sterilised
1
 immediately. 
Method 
The duplex substrate, prepared as described in 2.3.1, was incubated with the TFO at an 
equimolar ratio in Triplex buffer at 57 °C for 20 minutes then allowed to slowly cool to 
room temperature and stored at -20 °C. 
 
2.3.3 Helicase Assay (Özsoy et al. 2003) 
Materials 
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1. Substrates (Table 2.3). 
2. Helicase. 
3. 10 × Assay buffer: 250 mM TRIS∙HCl pH 8.0, 200 mM NaCl, 50 mM MgCl2, and 
10 mM DTT, made up to the desired volume with distilled water and filter 
sterilised
1
 immediately. 
4. Adenosine triphosphate (ATP) (Fisher Scientific): 20 mM made with distilled water 
and stored at -80 °C. 
5. Bovine serum albumin (BSA) (Fisher Scientific): 10 mg mL-1 made with distilled 
water and stored at -20 °C. 
6. 5 × Termination buffer: 1.5 % SDS, 50 mM EDTA, 25 % (v/v) Glycerol, made up 
to the desired volume with distilled water and filter sterilised
1
 immediately. 
Method 
Reactions set up in bullet tubes containing a 0.1 µM phosphoflorescent substrate, the 
necessary concentration of helicase, 1 mM ATP, and 0.8 mg mL
-1
 BSA, in 1 × assay buffer 
were incubated at 37 °C for 1 hour. The reactions was stopped by the addition of 5 × 
termination buffer and incubated at 37 °C for 5 minutes. The reactions were run on a SDS 
PAGE gel (2.1.2) and visualised using a Fujifilm FLA-5000 phosphoimager with a blue 
laser (473 nm) at 550 V and a green filter (532 nm). 
Gel densitometry was performed using the image processing and analysis software ImageJ 
(Schneider et al. 2012). The following equation was used to quantify the degree of 
unwinding and used for graphical representation generated using GraFit5 (Erithacus 
Software): 
                   
       
              
        
Where P represents the unwound product and PB represents any product background 
(unannealed product present in the 0min time-point control sample), S represents the 
primary substrate and SB represents any thermal degradation of the primary substrate 
(calculated from the difference in primary substrate between the 0min and final time-point 
control samples). 
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19-31bp 
19-31bp 
19-31bp 
19-31bp 
* 
* 
19-31bp 
19-31nt 
19-31bp 
19nt 
31bp 19bp 
* 
3’ 
19nt 
31bp 
19bp 
5’ * 
23bp 23bp 
4nt * 
 
19bp 19bp 
12nt * 
 
18bp 
* 
3’ 
18nt 
31nt 
19bp 
* 
3’ 
* 
19bp 
19bp 
31bp 
* 
19nt 
19nt 
31bp 
Number Name Description Structure 
Oligonucleotides 
Used 
1 Holliday Junction 
Holliday junction with 
4 blunt ends 
 
1*+2+3+4 
2 3 Strand Junction 
3 strand junction with 2 
blunt ends and 2 single 
stranded ends 
 
1+3+4* 
3 3’ Flap 
Blunt ended duplex 
with an incorporated  3’ 
flap 
 
1+4*+7 
4 5’ Flap 
Blunt ended duplex 
with an incorporated 5’ 
flap 
 
1+4*+8 
5 4 bp Bubble 
Blunt ended duplex 
with a 4 nucleotide 
bubble  
1*+5 
6 12 bp Bubble 
Blunt ended duplex 
with a 12 nucleotide 
bubble  
1*+6 
7 
36/18 Partial 
Duplex 
Partial duplex with 1 
blunt end and an 18 
nucleotide single 
stranded overhang 
 
9*+10 
8 
50/19 Partial 
Duplex 
Partial duplex with 1 
blunt end and a 31 
nucleotide single 
stranded overhang 
 
4*+7 
9 3 Way Junction 
3 way junction with 3 
blunt duplex ends  
1+4*+7+8 
10 Fork 1 
Duplex with a blunt end 
and a 3’ forked end 
 
1+4* 
63 
* 19nt 
19nt 
31bp 
* 
80bp 
11 Fork 2 
Duplex with a blunt end 
and a 5’ forked end 
 
3+4* 
12 
80 bp Blunt 
Duplex 
80 bp dsDNA with 2 
blunt ends 
 11*+12 
13 
Hairpin Duplex 
(HPD) 1 
5’ hairpin with a 5’ 
single-stranded 
overhang and a 1 
nucleotide 3’ flap  
13+14* 
14 HPD2 
5’ hairpin with a 5’ 
single-stranded 
overhang and a 1 
nucleotide 3’ flap, 
alternative hairpin 
sequence 
 
14*+15 
15 HPD3 
5’ hairpin with a 5’ 
single-stranded 
overhang and a 1 
nucleotide 3’ flap, 
deleted loop sequence 
 
14*+16 
16 HPD4 
5’ hairpin with a 5’ 
single-stranded 
overhang 
 
13+17* 
17 HPD5 
5’ hairpin with a 1 
nucleotide 3’ flap 
 
14*+18 
18 HPD6 
5’ hairpin no single-
stranded overhang 
 
17*+18 
19 HPD7 
3’ hairpin with a 3’ 
single-stranded 
overhang and a 1 
nucleotide 5’ flap  
19+20* 
20 HPD8 
3’ hairpin with a 3’ 
single-stranded 
overhang 
 
19+21* 
* 
5’ 
3’ 
* 5’ 
3’ 
* 
3’ 
5’ 
* 
3’ 
5’ 
3’ 
5’ 
* 
3’ 
5’ 
* 
* 
3’ 
5’ 
* 
3’ 
5’ 
64 
* 
5’ 
3’ 
31nt 
19bp 
* 3’ 
31nt 
19bp 
* 5’ 
21 HPD9 
3’ hairpin with a 1 
nucleotide 5’ flap 
 
20*+22 
22 HPD10 
3’ hairpin no single-
stranded overhang 
 
21*+22 
23 
50/19 Partial 
Duplex (3’-5’) 
Partial duplex with 1 
blunt end and a 3’ 31 
nucleotide single 
stranded overhang 
 
 
 
4+7* 
24 
50/19 Partial 
Duplex (5’-3’) 
Partial duplex with 1 
blunt end and a 5’ 31 
nucleotide single 
stranded overhang 
 
 
 
23*+24 
25 
45/19 Partial 
Duplex (3’-5’) 
Partial duplex with 1 
blunt end and a 3’ 26 
nucleotide single 
stranded overhang 
 
4*+25 
26 
40/19 Partial 
Duplex (3’-5’) 
Partial duplex with 1 
blunt end and a 3’ 21 
nucleotide single 
stranded overhang 
 
4*+26 
27 
35/19 Partial 
Duplex (3’-5’) 
Partial duplex with 1 
blunt end and a 3’ 16 
nucleotide single 
stranded overhang 
 
4*+27 
28 
30/19 Partial 
Duplex (3’-5’) 
Partial duplex with 1 
blunt end and a 3’ 11 
nucleotide single 
stranded overhang 
 
4*+28 
29 
25/19 Partial 
Duplex (3’-5’) 
Partial duplex with 1 
blunt end and a 3’ 6 
nucleotide single 
stranded overhang 
 
4*+29 
30 
20/19 Partial 
Duplex (3’-5’) 
Partial duplex with 1 
blunt end and a 3’ 1 
nucleotide single 
stranded overhang 
 
4*+30  
19bp 
* 
3’ 
 
19bp 
* 3’ 
 
19bp 
* 
3’ 
 
19bp 
* 3’ 
 
19bp 
* 
3’ 
 
19bp 
* 3’ 
* 5’ 
3’ 
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* 
19nt 
19nt 
31bp 
* 
19nt 
19nt 
31bp 
* 
19nt 
19nt 
31bp 
50bp 
* 
 
31 
DNA:RNA Hybrid 
Fork 
DNA:RNA hybrid 
duplex with a blunt end 
and a 3’ forked end 
 
 
 
1+31* 
32 
RNA:DNA Hybrid 
Fork 
RNA:DNA hybrid 
duplex with a blunt end 
and a 3’ forked end 
 
 
 
4*+32 
33 
dsRNA Hybrid 
Fork 
dsRNA duplex with a 
blunt end and a 3’ 
forked end 
 
 
 
31*+32 
34 5’ TFO duplex 
52 bp duplex with a 5’ 
triplex binding site  
33+34 
35 3’ TFO duplex 
52 bp duplex with a 3’ 
triplex binding site  
35+36 
36 ds50mer Fork 1 
Full complimentary 
sequence of Fork 1 
 
4*+37 
 
 
2.3.4 BOXTO Helicase Assay 
Materials 
1. BOXTO-substrate adducts: prepared by incubating BOXTO with the substrate at a 
5:1 molar ratio. 
Table 2.3 Helicase Substrates. The substrates are constructed from the oligonucleotides 
detailed in Appendix 1. The left most column contains the substrates assigned number, 
while the second and third columns contain their name and description respectively. The 
fourth column contains a schematic of each of the substrates, and the fifth column has the 
constituent oligonucleotide numbers (Appendix 1). The structures are depicted with the 
upper-left most strand in the 5’-3’ (left to right) orientation. Oligonucleotides marked with a 
* indicate that they are 5’ flouroscein labelled. The red lines in the schematics of substrates 
31 to 33 depicted the RNA strands, while the blue portions of substrates 34 and 35 highlight 
the triplex binding sites. 
52bp 
52bp 
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2. Helicase. 
3. 10 × Assay buffer: 250 mM TRIS∙HCl pH 8.0, 200 mM NaCl, 50 mM MgCl2, and 
10 mM DTT, made up to the desired volume with distilled water and filter 
sterilised
1
 immediately. 
4. 10 × Negative control buffer: 250 mM TRIS∙HCl pH 8.0, 200 mM NaCl, 50 mM 
EDTA, and 10 mM DTT, made up to the desired volume with distilled water and 
filter sterilised
1
 immediately. 
5. Adenosine triphosphate (ATP) (Fisher Scientific): 20 mM made with distilled water 
and stored at -80 °C. 
6. Bovine serum albumin (BSA) (Fisher Scientific): 10 mg mL-1 made with distilled 
water and stored at -20 °C. 
Method 
Three 10 µL reactions containing 2 × the necessary concentration of helicase and 1.6 mg 
mL
-1
 BSA, two in 2 × assay buffer and the third in 2 × negative control buffer were aliquot 
into a 96-well plate. 10 µL of the start solution containing 0.2 µM substrate and 2 mM 
ATP were added two one of the assay buffer samples and the negative control buffer 
sample. A third start solution with a boiled substrate, incubated at 95 °C for 20 minutes 
then rapidly cooled on ice to prevent reannealing, was added to the second assay buffer 
sample to serve as a positive control. The reaction was followed by exciting at 485/20 and 
detecting at 530/25 nm using a Bio-Tek FL600 fluorescence plate reader at 37 °C for 1 
hour. 
 
2.3.5 Phosphorylation of Helicase 
Materials 
1. Helicase. 
2. Protein Kinase C (PKC) (Thermo Scientific). 
3. PKC buffer: 20 mM 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulphonic acid 
(HEPES) pH 7.5, 2 mM CaCl2, 10 mM MgCl2, 1 mM ATP, made up to the desired 
volume with distilled water and filter sterilised
1
 immediately. 
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4. Adenosine triphosphate (ATP) (Fisher Scientific): 20 mM made with distilled water 
and stored at -80 °C. 
Method 
Helicase was phosphorylated by incubating with 1ng of PKC for every 200 ng of helicase 
at room temperature for 30 minutes in PKC buffer with 1 mM ATP. The phosphorylated 
protein was then used in the helicase and ATPase assays. 
 
2.3.6 Electrophoretic Mobility Shift Assay (EMSA) (Fried et al. 1981; 
Garner et al. 1981) 
1. Substrates (Table 2.3). 
2. Helicase. 
3. 10 × Assay buffer: 250 mM TRIS∙HCl pH 8.0, 200 mM NaCl, 50 mM MgCl2, and 
10 mM DTT, made up to the desired volume with distilled water and filter 
sterilised
1
 immediately. 
4. Adenosine 5’-(β,γ-imido)triphosphate (AMP-PnP) (Fisher Scientific): 20 mM made 
with distilled water and stored at -80 °C. 
5. Bovine serum albumin (BSA) (Fisher Scientific): 10 mg mL-1 made with distilled 
water and stored at -20 °C. 
Method 
Reactions set up in bullet tubes containing a 0.1 µM phosphoflorescent substrate, the 
necessary concentration of helicase, 1 mM AMP-PnP, and 0.8 mg mL
-1
 BSA, in 1 × assay 
buffer were incubated at room temperature for 5 minutes. The reactions were run on a 
native PAGE gel (2.1.3) and visualised using a Fujifilm FLA-5000 phosphoimager with a 
blue laser (473 nm) at 550 V and a green filter (532 nm). 
Gel densitometry was performed using the image processing and analysis software ImageJ 
(Schneider et al. 2012). The following equation was used to fit the data to a single site 
saturation curve, where the amount of ligand bound is plotted as a function of the amount 
of free ligand, using GraFit5 (Erithacus Software): 
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Where [Bound] represents the concentration of the bound ligand, capacity is the interaction 
product maxima, [Free] is the concentration of the unbound ligand, and Kd is the 
dissociation constant. 
 
2.3.7 Malachite Green ATPase Assay (Chan et al. 1986; D'Angelo et al. 
2001) 
Materials 
1. Substrates (Table 2.3). 
2. Helicase. 
3. 10 × Assay buffer: 250 mM TRIS∙HCl pH 8.0, 200 mM NaCl, 50 mM MgCl2, and 
10 mM DTT, made up to the desired volume with distilled water and filter 
sterilised
1
 immediately. 
4. Adenosine triphosphate (ATP) (Fisher Scientific): 100 mM made with distilled 
water and stored at -80 °C. 
5. Bovine serum albumin (BSA) (Fisher Scientific): 10 mg mL-1 made with distilled 
water and stored at -20 °C. 
6. Ammonium molybdate tetrahydrate: 5.72 % w/v of 6 M HCl 
7. Polyvinyl alcohol (PVA): 2.32 % w/v of boiling distilled water. 
8. Malachite green: 0.0812 % w/v of distilled water. 
9. Distilled water. 
Method 
10 µL time-points of a reverse time-course reaction, containing 2 × the necessary 
concentration of helicase and 1.6 mg mL
-1
 BSA in assay buffer were aliquot into a 96-well 
plate and incubated at 37 °C. At each reverse time-point, 10 µL of the start solution 
containing 2 µM substrate and 20 mM ATP in assay buffer was added. The reactions were 
stopped with 150 µL of a 1:1:2:2 mixture of ammonium molybdate, PVA, malachite green 
and distilled water at the 0 minute time-point. After a 10 minutes incubation at room-
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temperature the inorganic phosphate (Pi) was detected using an Apollo-8 LB-912 
spectrophotometer (Berthold Technologies) reading the absorbance at 590-650nm. The 
concentration of the inorganic phosphate (Pi) was determined by comparison against a 
standard line derived from serial dilutions of KH2PO4 (Figure 2.3). 
 
2.3.8 Luciferase ATPase Assay 
Materials 
1. Substrates (Table 2.3). 
2. Helicase. 
3. 10 × Assay buffer: 250 mM TRIS∙HCl pH 8.0, 200 mM NaCl, 50 mM MgCl2, and 
10 mM DTT, made up to the desired volume with distilled water and filter 
sterilised
1
 immediately. 
4. Adenosine triphosphate (ATP) (Fisher Scientific): 20 mM made with distilled water 
and stored at -80 °C. 
5. Bovine serum albumin (BSA) (Fisher Scientific): 10 mg mL-1 made with distilled 
water and stored at -20 °C. 
6. Standard Reaction Solution: Prepared as described in the ATP Determination Kit 
(Invitrogen); 1.25 µg mL
-1
 luciferase with 0.5 mM D-luciferin in 25 mM Tricine 
(pH 7.8), 5 mM MgSO4, 0.1 mM EDTA, 1 mM DTT, and 0.1 mM sodium azide, 
stored short term at 4 °C protected from light. 
7. Distilled water. 
Method 
10 µL time-points of a reverse time-course reaction, containing 2 × the necessary 
concentration of helicase and 1.6 mg mL
-1
 BSA in assay buffer were aliquot into a 96-well 
plate and incubated at 37 °C. At each reverse time-point, 10 µL of the start solution 
containing 2 µM substrate and 2 mM ATP in assay buffer was added. The reactions were 
stopped with 100 µL Standard Reaction Solution at the 0 minute time-point and the 
luminescence was taken using a 1450 MicroBeta TriLux luminescence counter. The 
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Figure 2.3 ATPase Assay Standards. Created with GraFit5 (Erithacus Software), the graphs show example standard lines for the malachite green, luciferase, 
and NADH-coupled ATPase assays. Derived from the serial dilutions of potassium dihydrogen phosphate (KH2PO4), the leftmost graph line equation can be 
used to fit the raw data obtained from the malachite green ATPase assay to elucidate the amount of inorganic phosphate released from the hydrolysis of ATP. 
The central graph shows an ATP standard line equation that can be used to calculate the amount of unused ATP from the raw data obtained from the luciferase 
ATPase assay. The rightmost graph was generated using NADH standards and can be used for a direct comparison for the amount of ATP hydrolysed during 
the NADH-coupled ATPase assay. 
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concentration of the ATP was determined by comparison against a standard line derived 
from serial ATP dilutions (Figure 2.3). 
 
2.3.9 NADH-Coupled ATPase Assay (Kiianitsa et al. 2003) 
Materials 
1. Substrates (Table 2.3). 
2. Helicase. 
3. 10 × Assay buffer: 250 mM TRIS∙HCl pH 8.0, 200 mM NaCl, 50 mM MgCl2, and 
10 mM DTT, made up to the desired volume with distilled water and filter 
sterilised
1
 immediately. 
4. Adenosine triphosphate (ATP) (Fisher Scientific): 100 mM made with distilled 
water and stored at -80 °C. 
5. Bovine serum albumin (BSA) (Fisher Scientific): 10 mg mL-1 made with distilled 
water and stored at -20 °C. 
6. Phosphoenolpyruvate (PEP) (Sigma-Aldrich): 150 mM made with distilled water 
and stored at -20 °C. 
7. 1000 U mL-1 Pyruvate kinase (PK)/L-lactate dehydrogenase (LDH) (Sigma-
Aldrich). 
8. Reduced β-Nicotinamide adenine dinucleotide (NADH) (Sigma-Aldrich): 30 mM 
made with distilled water and stored at -20 °C. 
9. Distilled water. 
Method 
Reaction containing a 0.1 µM phosphoflorescent substrate, 5 mM ATP, 0.8 mg mL
-1
 BSA, 
3 mM PEP, 20 U mL
-1
 PK/LDH, 2.5 mM NADH, and the appropriate volume of helicase 
in 1 × assay buffer were set up in bullet tubes. A 0 minute time-point was taken 
immediately by monitoring the absorbance at 339 nm at NADHs extinction coefficient of 
6220 M
-1
 cm
-1
, and at appropriate time-points thereafter. The concentration of the ATP 
hydrolysed was directly comparable to the decrease in NADH concentration, and was 
determined from a standard line derived from serial dilutions of NADH (Figure 2.3). 
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2.3.10 EcoR124I Cleavage Assay 
Materials 
1. pCFD30. 
2. MTase. 
3. HsdR. 
4. Adenosine triphosphate (ATP) (Fisher Scientific): 20 mM made with distilled water 
and stored at -80 °C. 
5. 10 × Cleavage Buffer: 500 mM Tris∙HCl pH 8.0, 500 mM NaCl, 100 mM MgCl2 
and 10 mM DTT, made up to the desired volume with distilled water and filter 
sterilised
1
 immediately. 
Method 
10 µL reactions containing a 10:1 HsdR to Mtase ratio to favour the R2 complex (2.5 µM 
HsdR and 250 nM Mtase), 2 mM ATP, and 2.5 nM pCFD30, in 1 × cleavage buffer were 
set up and incubated at 37 °C. The reactions were terminated after the desired time period 
by heat inactivation of the enzyme at 65 °C for 20 minutes. The reactions were run on a 0.8 
% agarose gel to observe cleavage. 
 
2.4 Structural Characterisation Protocols 
 
2.4.1 Analytical Ultracentrifugation (AUC) 
AUC experiments provide information on shape and molecular mass as well as 
stoichiometry and macromolecular interactions (Schuck 2005; Brown et al. 2006). 
Macromolecules will be ubiquitously dispersed throughout a given solution, however when 
centrifugal force was applied to the macromolecules their intrinsic tendency to settle out of 
their entrained solvent, called sedimentation, was accelerated. Sedimentation was opposed 
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by the frictional force acting upon the macromolecules, these opposing forces can be 
characterised in an AUC experiment through the Svedberg equation: 
  
 
   
 
       
   
 
Where s is the sedimentation coefficient, v is the rate of sedimentation, ω is the angular 
velocity, r is the radius (distance from the centre of rotation), M is the molar mass,   is the 
partial specific volume, ρ is the solvent density, NA is Avogadro's constant, and f is the 
frictional coefficient. The sedimentation coefficient is expressed in Svedberg units (S), 
with 1 S being equal to exactly 10
-13
 seconds. 
During an AUC experiment, the sedimentation of the macromolecules was followed by 
optically monitoring a sample cell. When studying proteins, they have distinct absorbance 
maxima at 200 and 280 nm; conferred primarily by peptide bonds and aromatic residues 
respectively. However, an individual protein species maximum absorbance can be altered 
by primary, secondary, tertiary, and quaternary structure, but was typically between (230 
and 280 nm). This can be exploited during AUC analysis to locate their radial position in 
the sample cell using the appropriate light wavelength. The absorbance was then recorded 
relative to a reference cell. 
AUC analysis was performed on protein samples at concentrations that gives an 
absorbance at 280 nm of 1 AU, at approximate rotor speeds based on their molecular 
weight as described by Holladay (1980) using a Beckman Coulter Optima XL-A 
Analytical Ultracentrifuge with an An-50 Ti Analytical Rotor (Figure 2.4). 
 
2.4.2 1D and 2D Nuclear Magnetic Resonance (NMR) Spectroscopy 
NMR Spectroscopy can be used to determine the physical and chemical characteristics of a 
molecule by exploiting the magnetic properties of their constituent atomic nuclei (Keeler 
2011). 
Protons and neutrons within an atom spin. In many atoms, such as 
13
C, the nucleus 
possesses an net spin (I) which can be determined when considering that; an atom with an 
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Figure 2.4 Approximate Rotor speed and the 
Construction of an analytical ultracentrifugation 
cell. Above, adapted from Holladay (1980), is a plot 
of suggested rotor speeds for two data collection 
periods times. Left, Adapted from the An-50 Ti and 
An-60 Ti Analytical Rotor, Cells, and 
Counterbalance manual from Beckman Coulter, the 
schematic shows the individual components which 
contribute to the sample cell. A window gasket, 
window liner, and quartz window are placed in that 
order into each of the window holders. One of these 
is then placed into the cell housing followed by the 
12 mm Epon charcoal-filled centrepiece guided by 
its keyway. The second window holder is placed in 
above the centrepiece followed by the greased screw 
ring washer and the greased screw ring and 
tightened to 700 kPa. A 250 μL sample is injected 
into the left filling hole and a 200 μL solvent 
reference is injected into the right filling hole. The 
disparity between in the sample and reference 
volumes allows for discrimination between the two 
menisci. To finish, the plug gaskets and housing 
plugs are screwed into the cell housings. 
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even number of protons and neutrons has no net spin, an atom where the total number of 
protons and neutrons were odd has a half-integer net spin, and an atom which has an odd 
number of both protons and neutrons has a whole-integer net spin (Doucleff et al. 2011). A 
nucleus with a net spin has a fixed number of orientations based on: 
     
Therefore a nucleus with an overall spin of ½ (
1
H) has 2 possible orientations of equal 
energy. However, nuclei in each orientation can be separated into discrete energy levels by 
applying a magnetic field. Thermodynamics dictates that the nuclei population in the lower 
energy level is greater than that in the higher level. The extent of inequality is linked the 
degree of the separation with larger separation between the spin energy levels giving a 
greater population difference (Keeler 2011). 
The nuclei in the lower energy population can be excited to the higher energy level, thus 
affecting their orientation, if a magnetic field which is greater than the energy difference 
(the transition energy) is applied. This is possible as the positive charged spinning nucleus 
generates its own small magnetic field and has an associated magnetic moment in the 
associated orientation. If the nucleus absorbs energy from an applied magnetic field the 
magnetic moment flips into the opposite orientation to oppose the field. Electrons around 
the nucleus shield it, so that the resonant frequency of the opposing nuclear magnetic field 
is not equal to that of the applied field. 
The difference between the resonant and applied magnetic frequency is termed the 
chemical shift (Keeler 2011). The position and number of chemical shifts produced in an 
NMR experiment is affected by spin coupling, a small interaction between neighbouring 
groups of protons within a molecule. For example, a methylene (CH2) group has two 
protons (
1
H), each of which can has two possible orientations, either with or opposed to the 
applied magnetic field, giving four combinations; protons in both positions orientated with 
the applied field, both protons opposed, the proton in one position with and the other 
opposed, or the proton in one position opposed and the other with. Neither of the latter 
combinations has an effect on neighbouring proton groups. However, where both proton 
orientations were with the applied field, their own magnetic fields increase the field 
exerted on the neighbouring proton group, likewise if they oppose they reduce it. 
Therefore, the neighbouring proton group affectively receives three different magnetic 
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field frequencies, the uninterrupted applied frequency, and the increased and reduced 
frequencies. This results in a spectrum for the neighbouring proton group with a three peak 
profile, with a larger central peak corresponding to the two non-affecting proton 
combinations, and two half sized peaks up and downfield of the central peak, correlating to 
the frequency increasing and reducing proton combinations. It is these chemical shifts and 
peak widths that were indicative of a molecules structure. 
All NMR experiments were performed using a Varian 600 MHz NMR Spectrometer. 1D 
NMR was carried out using protein from a standard growth and cell harvest as detailed 
previously. The sample was concentrated to the desired concentration and contained 10 % 
2
H2O in a final volume of 350 µL into a glass NMR sample tube. 
2D NMR was performed using protein obtained from a labelled growth and cell harvest as 
previously described. Similar to the 1D NMR, the sample was concentrated to the desired 
concentration and contained 10 % 
2
H2O in a final volume of 350 µL, but differing to the 
1D sample preparation in that the sample was placed into a Shigemi tube. 
 
2.4.3 Small Angle X-ray Scattering (SAXS) 
SAXS is a technique used to obtain low-resolution structural data of macromolecules in 
solution. Resolution is approximately 13 Å due to the molecules within the solution 
constantly tumbling which results in an average scattering pattern. Theoretically SAXS 
could be used to produce higher angle diffraction generating higher-resolution data, 
however interpretation of this data would be difficult due to the fast decay rate of the X-
rays combined with high levels of experimental noise. Despite its low resolution, SAXS 
experiments can be performed on macromolecules of larger size and increased levels of 
disorder or flexibility, which were often limiting factors in more high resolution techniques 
such as NMR and X-ray crystallography. 
During SAXS analysis a collimated X-ray beam is fired through a mono-dispersed sample. 
Collisions with the sample cause the X-rays to scattered onto 2-dimentional (2D) detector 
(Figure 2.5). The intensities of each scattered beam, I(s), were radially averaged and its log 
is plotted against the scattering vector (s), which is the distance between the detection spot  
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Figure 2.5 Beamline I22 at the Diamond Light Source. Adapted from the Diamond website, the schematic shows the undulator at the far left, where the X-
rays are generated. The aperture and various slits serve as collimation pinholes, while the double crystal monochromator removes any extraneous wavelengths 
from the incident beam. The Kirkpatrick-Baez Mirrors focus the X-rays prior to the final collimation, before passing through the sample and onto the 2D 
detector. 
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of the unscattered X-ray (incident) beam and the detection spot of the scattered X-ray beam 
on the 2D detector, represented by the equation: 
  
     
 
 
Where 2sinθ is the angle of scattered X-ray and λ is the wavelength (0.01 to 10 nm). The 
low resolution of SAXS produces high intensities at small-angle and low intensities and 
large-angle diffraction. Isotropic scattering intensities at the small-angle region were given 
as I(Q) and defined by the following equation: 
             
   
   
 
  
Where I(0) is the intensity at 0 scattering angle, Rg is the radius of hydration, and Q is the 
momentum transfer and is defined as 4πsinθ/λ where 2θ and λ were the scattering angle 
and the X-ray wavelength respectively (Kamatari et al. 1998). This can then be used to 
elucidate information on the macromolecules structural-state (degree of globular shape) 
(Putnam et al. 2007), pair-distribution functions, P(r), maximum dimension (Dmax), and 
real space Rg. Moreover, from this low resolution reconstructions can be made, aligned, 
averaged and subtracted for areas of low density to produce an average model. 
SAXS experiments were carried out on the I22 beamline at the Diamond Light Source 
(Diamond House, Harwell Science and Innovation Campus, Didcot, Oxfordshire, England) 
with a wavelength (λ) of 1 angstrom (Å) at 12.4 kiloelectronvolts (keV), with a photon 
counting detector 3.25 m from the sample cell. 
 
2.4.4 Dynamic Light Scattering (DLS) 
DLS is commonly used to estimate a proteins’ hydrodynamic radius (Rh) in solution, which 
is related to the diffusion constant (D) as described by the Stokes-Einstein equation: 
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Where k is the Boltzmann constant, T is temperature (K), and η is the solvent viscosity. Rh 
can also be used to estimate molecular weight (Mr), albeit roughly, as the shape of the 
molecule is not considered, using the following equation provided in the Dynamics version 
5.26.60 software package (Protein Solutions): 
            
     
DLS experiments were performed using a Protein Solutions DynaPro MSTC 800 (Wyatt) 
light scattering instrument. Protein solutions were allowed to equilibrate at the desired 
temperature prior to at least 20 measurements being taken to obtain the hydrodynamic 
radius (Rh). 
 
2.5 Miscellaneous Protocols 
 
2.5.1 Systematic Evolution of Ligands by Exponential Enrichment 
(SELEX) (Tuerk et al. 1990) 
Materials 
1. Ni-NTA resin (QIAGEN). 
2. Centrifuge columns (Thermo Scientific). 
3. 1 × PBS: 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.4 mM K2HPO4, made 
with distilled water and autoclave sterilised
1
 immediately. 
4. 100 µM DNA library: A pool of oligonucleotides consisting of a random 30 
nucleotide (nt) sequence flanked by know primer sequences: 
CCG CCG CAT AAT AT (N)30 GCG CTA TAT AGG GCC 
5. 1 M NaCl, made with distilled water and autoclave sterilised1 immediately. 
6. Microspin G-25 Desalting columns (GE Healthcare). 
Method 
80 
All centrifugation was performed at 100 × g for 30 seconds unless otherwise stated. 200 
µL Ni-NTA resin was applied to a centrifuge column, placed into a bullet tube and packed 
by centrifugation at 100 × g for 1 minute. The column was then washed with three 
consecutive centrifuge spins in 200 µL of 1 × PBS. 
Then a pre-screened library was prepared by loading 100 µL of a 10 µM dilution of the 
random library in 1 × PBS onto the column and incubated at room temperature for 30 
minutes. The column was then centrifuged in a fresh bullet tube and the flow-through (pre-
screened library) was collected and put aside. Any bound DNA molecules were eluted after 
5 minutes incubation with 200 µL of 1 M NaCl, centrifuged and discarded. 
The column was then reconditioned back into 1 × PBS with three washes as described 
previously. His-tagged protein was immobilised by applying to the column, mixing by 
gentle agitation and incubating on ice for 20 minutes, any unbound protein was eluted by 
centrifugation and discarded. The immobilised protein was then screened against by adding 
50 µL of the pre-screened library to the column and incubating on ice for 20 minutes 
before centrifuging and discarding the flow-though. Non-specifically bound DNA library 
molecules were removed with three washes of 1 × PBS performed as previously described. 
Any aptamers were eluted in by incubating the column in 100 µL 1 M NaCl for 5 minutes 
on ice, and then collected in a fresh bullet tube in the flow-though during centrifugation. 
A Microspin G-25 Desalting column (GE Healthcare) was prepared by resuspending the 
resin by agitation and repacked by loosening the cap and removing the bottom closure 
prior to centrifugation for 1 minute at 735 × g. The flow-though was discarded and the 
column was placed into a new bullet tube. The aptamer sample was slowly applied to the 
desalting column then eluted by centrifugation a 735 × g for 2 minutes. The aptamer 
sample can be amplified using the polymerase chain reaction, or should be store at -20 °C 
until required. 
 
2.5.2 Polymerase Chain Reaction (PCR) 
Materials 
1. 2 × GoTaq Master Mix (Promega). 
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2. Template DNA. 
3. Forward and reverse primers: 
Forward Primer: GGC GGC GTA TTA TA 
Reverse Primer: GGC CCT ATA TAG CGC 
100 µM made with distilled water. 
Method 
PCR reactions containing 1μM (0.5 μL of 100 µM) of each primer, the appropriate volume 
of template DNA, 25μl of 2 × GoTaq Master Mix, were made up to a final volume of 50 
μL in distilled water and placed into a Robocycler Gradient 90 (Stratagene) PCR machine. 
PCR reactions were performed with an initial 95 °C denaturation for 1 minute followed by 
35 cycles consisting of a 95 °C denaturing step for 30 seconds, a 60 °C annealing step for 
30 seconds, and a 72 °C elongating step for 30 seconds. 
 
2.5.3 pGEM-T Easy Vector (Promega) Cloning of PCR Products 
Materials 
1. 2 × Rapid Ligation Buffer (Promega). 
2. Linear pGEM-T Easy Vector (50 ng µL-1) (Figure 2.6). 
3. DNA inserts. 
4. T4 DNA Ligase (3 U µL-1) 
5. LB agar (Lennox L Agar) plates mix (Fisher Scientific): 1 % w/v Tryptone, 0.5 % 
w/v yeast extract, 5 % w/v NaCl, 1 % w/v agar, made with distilled water and 
autoclave sterilised
1
 immediately.. 
6. IPTG: 1M made with distilled water and filter sterilised1 immediately. 
7. X-gal: 20 mg mL-1 made with 100 % dimethylformaldehyde (DMF). 
Method  
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Ligation reactions were prepared in bullet tubes containing 5 µL of 2 × Rapid Ligation 
Buffer, 1 µL of pGEM-T Easy Vector, 1 µL of T4 DNA Ligase, the appropriate volume of 
insert DNA, and made to a final volume of 10 µL with distilled water. Typically a 3:1 
insert to vector molar ratio was used and can be calculated by: 
                              
                 
                                       
The ligation was performed at room temperature for 1 hour before being transformed 
(2.2.3) into E. coli Dh5α (Invitrogen) cells (Table 2.2) and grown at 37 °C overnight on LB 
agar plates supplemented with 100 µg mL
-1
 ampicillin, 1 mM IPTG, and 20 µg mL
-1
 X-gal. 
White colonies signify the successful incorporation of the insert, interrupting the lacZ gene 
and preventing the formation of functional β-galactosidase. 
 
 
Figure 2.6 pGEM-T Easy Vector Map. Adapted from the Promega pGEM-T and pGEM-T 
Easy Vector Systems manual, the multiple cloning site (MCS) is highlighted at the top and 
details the associated restriction sites and the T-overhang cloning system. The MCS is 
under the control of a T7 lac promoter in the 5’ direction and the SP6 promoter in the 3’ 
direction. 
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2.5.4 Dot Blotting 
Materials 
1. TBST: 50 mM TRIS∙HCl pH 8.0, 150 mM NaCl, 0.1 % Tween, made up to the 
desired volume with distilled water and filter sterilised
1
 immediately. 
2. Bovine serum albumin (BSA) (Fisher Scientific): 10 mg mL-1 made with distilled 
water and stored at -20 °C. 
3. Two-part developing solution: Part 1; 2.5 mM luminol, 0.5 mM p-coumaric acid, 
100 mM TRIS∙HCl pH 8.0, made up to the desire volume in distilled water. Part 2; 
0.05 % v/v hydrogen peroxide, 100 mM TRIS∙HCl pH 8.0, made up to the desire 
volume in distilled water. 
Method 
Protein was immobilised to a nitrocellulose membrane by adsorption and drying for 15 
minutes at room temperature. It was then incubated with a 1° probe in TBST with 5 % 
BSA at room temperature for 2 hours or 4 °C overnight. Next the membrane had three 
consecutive 5 minutes washes with TBST at room temperature before incubation with a 2° 
horseradish peroxidase (HRP) conjugated probe in TBST with 0.5 % BSA at room 
temperature for 1 hour. To finish, the membrane underwent a further three 5 minutes 
washes in TBST at room temperature. The blot was developed using a two-part developing 
solution and incubating for 1 minute before detecting with a Fujifilm LAS-3000 
refrigerated camera at -20 °C under a 1 minute exposure time. 
 
2.5.5 Drug Adduct Preparation 
Materials 
1. GWL-78 in 50% v/v methanol. 
2. Duplex DNA Substrate. 
3. Distilled water. 
Method 
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The drug was incubated with the DNA substrate at the desired molar ratios at room 
temperature for 6 hours then transferred to -20 °C overnight. 
 
2.6 Footnotes 
 
2.6.1 
1
Sterilisation 
Autoclave sterilisation was performed in a Midas 40 Priorclave autoclave at 121 °C and 
100 kPa for 20 minutes. Plastic ware was then dried in a 65 °C oven for at least 24 hours. 
Filter sterilisation was performed by flowing the solution through a 0.2 µm filter 
membrane (Millipore) by means of either a vacuum pump (large volumes) or a syringe 
(small volumes). Any glassware intended for culture growths were autoclave sterilised, 
prior to making any media, containing only distilled water to remove residual detergents 
that can inhibit cell growth and transformation. 
2.6.2 
2
Cell Strain Maintenance 
All strains were stored at -70 °C. Every six months cells were maintained by growing 20 
mL overnight cultures in Lysogeny Broth (LB) media. The following morning the cells 
were washed and stored in 1 freezing medium (36 mM K2HPO4, 13.2 mM KH2PO4, 0.4 
mM MgSO4∙7H2O, 1.7 mM Na3C6H5O7, 6.8 mM (NH4)2SO4, 4.4% (v/v) glycerol). 
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CHAPTER THREE – PROTEIN PURIFICATION 
 
3.1 Introduction 
With approximately 60 % of the hypothetical proteins within the P. falciparum genome 
still to be annotated (Birkholtz et al. 2008) the lack of biological knowledge of the malaria 
parasite is abundantly apparent. Despite bioinformatic tools lending some idea of 
biochemical and structural properties to hypothetical proteins (Tuteja et al. 2006; Tuteja 
2009; Tuteja 2010), this information can only be confidently revealed from biological 
experimentation which relies on the isolation of relatively large amounts of homogenous 
protein. 
It is generally recognised that isolation of sufficient quantities of protein from native cell 
lines is unusual. Furthermore, the inherent risk associated with working, in this case, with 
Plasmodium species is relatively great. Therefore, the most common approach to purifying 
these proteins for studying is via heterologous expression in a host cell line such as 
Escherichia coli. 
This chapter will describe the adaptations made to the original cloning and purification 
strategies for PFH45 (Pradhan et al. 2007) and PFDH60 (Pradhan et al. 2005) and the 
subsequent investigation into their storage conditions. 
 
3.2 PFH45 
PFH45 was one of the helicases proposed as potential drug-targets (Tuteja 2007) due to its 
origin from the most virulent malaria parasite, Plasmodium falciparum. PFH45 had been 
previously purified, and some characterisation had been undertaken (Pradhan et al. 2007; 
Pradhan et al. 2008). Due to the relative ease of the purification strategy to produce protein 
that displayed helicase activity, a clone for the His-tagged recombinant of PFH45 used in 
the aforementioned studies was obtained from Dr Renu Tuteja (Malaria Group, 
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International Centre for Genetic Engineering and Biotechnology, New Deli, India) with the 
intention to explore drug-target interactions using single-molecule studies. 
 
3.2.1 Clone Confirmation by Restriction Digest 
The pET-28a/PFH45 clone, expressing a hexa-histidine (His6) fusion of PFH45 with a 
thrombin (T) cleavage site (His6-T-PFH45), obtained from Dr Renu Tuteja was digested 
with restriction enzymes BamHI and NotI to confirm the expected gene size of 1197 bp 
(Figure 3.1). 
 
3.2.2 Pradhan and Tuteja (2007) Purification 
An initial purification trial of pET-28a/PFH45 was performed following the published 
purification strategy (Pradhan et al. 2007). In short, a 37 °C overnight seed culture of BL21 
(DE3) [pLysS] transformants in LB media containing 40 µg mL
-1
 kanamycin was used to 
inoculate a 500 mL LB media growth, also containing 40 µg mL
-1
 kanamycin. The cells 
kbp 
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1.5 
 
1.0 
5.0 
 1          2         3 
 
Figure 3.1 Restriction Digest of the pET-28a(+)/PfH45 clone from R. Tuteja. 0.8 % 
agarose gel showing the double restriction digest of pET-28a(+)/PfH45 by BamHI and 
NotI. Lane 1 shows the HyperLadder I marker (Bioline), lane 2 shows the undigested 6566 
bp recombinant plasmid; in open circular (red) and supercoiled (green) conformations, and 
lane 3 shows double digest products; the 5369 bp linerised plasmid (blue) and the 1197 bp 
PfH45 gene (yellow). 
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were grown and induced with 1 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) at 37 
°C, harvested by centrifugation at 4000 × g for 12 minutes, lysed by sonication, and 
purified by binding to a 5 mL His Trap FF column (GE Healthcare) in 20 mM TRIS (pH 
7.5), 50 mM NaCl, and 1 mM DTT, and eluted with the addition of 200 mM imidazole. 
The eluted fractions were visualised by SDS PAGE (Figure 3.2). 
 
Due to the apparently low yield and multiple highly expressed bands in the flow-through, a 
more thorough protein expression analysis was performed. The uninduced and induced 
samples were analysed by Western blot with a monoclonal Anti-polyHistidine Peroxidise 
Conjugate (Sigma), which identified the presence of the His6-T-PFH45 containing band 
(Figure 3.3). 
 
3.2.3 Cloning of Codon-Optimised PFH45 
As a result of the low yields and poor reproducibility of the purification strategy described 
by Pradhan et al. (2007), the PFH45 gene was codon-optimised for E. coli codon bias in an 
                                      1        2       3       4       5       6       7       8 
 
Figure 3.2 Ni-column purification of Original His6-T-PFH45. 10 % SDS PAGE gel 
showing the flow-through, washed, and eluted fractions from a His Trap FF column (GE 
Healthcare) purification of His6-Tagged PFH45. Lane 1 shows a SeeBlue Pre-stained 
Ladder (Invitrogen). Lane 2 shows the unbound flow-through, lanes 3 and 4 show the non-
specifically bound fractions from the wash steps, and lanes 5 to 8 show the 200 mM 
Imidazole eluted fractions.  
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attempt to increase PFH45 expression (Fox et al. 2010). Codon-optimised PFH45 was 
synthesised by GENEART (Regensburg, Bavaria, Germany), and cloned back into pET-
28a(+) as well as the pGEX-6p-1 vector due to previous local successes. 
 
3.2.4 Purification of Codon-Optimised GST-PP-PFH45 
Codon-optimised pGEX-6p-1/PFH45, encoding a Glutathione S-tranferase (GST) fusion 
of PFH45 with a PreScission Protease (PP) cleavage site (GST-PP-PFH45), was 
transformed into BL21 (DE3) [pLysS] competent cells. A single colony was then used to 
spike a 37 °C overnight seed culture of LB media containing 100 µg mL
-1
 ampicillin which 
was in turn used to inoculate 500 mL LB media containing 100 µg mL
-1
 ampicillin. The 
cells were grown and induced with 1 mM IPTG at 37 °C, harvested by centrifugation at 
4000 × g for 12 minutes, lysed by sonication and purified as described in the glutathione 
affinity protocol. The eluted fractions were visualised by SDS PAGE (Figure 3.4). 
Like the original pET-28a(+) clone, there were multiple highly expressed bands that were 
difficult to determine the identity of. The first approach to overcome the low purity was to 
increase the overall expression of GST-PP-PFH45. Optimising the growth conditions by 
adjusting IPTG concentration, time and temperature proved ineffective. Therefore an 
alternative protocol exploiting a lactose-sucrose auto-induction was employed. 
            1       2 
 
Figure 3.3 Detection of His6-T-PFH45 with an Anti-His Antibody. Western blot analysis 
of the crude lysate from un-induced and induced pET-28a(+)/PFH45 transformants in lanes 
1 and 2 respectively. 
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Auto-induction was performed as a 6 hours 37 °C incubation of pGEX-6p-1/PFH45 in 
ZYP-0.G media with 100 µg mL
-1
 ampicillin was used to inoculate 400 mL ZYP-5052 
media containing 100 µg mL
-1
 ampicillin and grown overnight at 20 °C. The cells were 
harvested by centrifugation at 4000 × g for 12 minutes, lysed by sonication and purified as 
described above. Although greatly increasing the yield of GST-PP-PFH45, the majority of 
the fusion protein was insoluble and centrifuged into the pellet prior to the sample being 
loaded onto the column. 
Further changes to lactose, sucrose, and glucose concentration, as well as time and 
induction temperature failed to improve solubility. Instead, the insoluble GST-PP-PFH45 
was resolubilised in sarkosyl. This consisted of resuspending and sonicating the insoluble 
pellet obtained from centrifugation of the bacterial lysate in 5 mL 10 % sarkosyl. The 
sonicate was then centrifuged at 50000 × g for 30 minutes, the supernatant kept, diluted to 
2 % sarkosyl, and made to 4 % triton X-100 and 30 mM CHAPS. This was used as the 
analyte for the purification protocol and the eluted fractions were visualised on a 10 % 
SDS PAGE gel (Figure 3.5). 
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Figure 3.4 GST-column purification of GST-PP-PFH45. 10 % SDS PAGE gel showing 
the purified product obtained from an ÄKTA purification of GST-tagged PFH45. Lane 1 
shows a SeeBlue Pre-stained Ladder (Invitrogen) while lane 2 shows the glutathione 
eluted protein. The eluted moiety shows the cleaved PFH45 circled in red. 
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An attempt to further purify the protein product was carried out including DEAE cation-
exchange chromatography, ammonium sulphate fractionation, and size exclusion. However 
there was no observable resolution of the contaminants (not shown). 
The resolubilisation with sarkosyl greatly increased the yield; however the protein product 
had an optimum solubility of ~1 mg mL
-1
. Furthermore, screening for helicase activity 
using a helicase substrate specificity screen, as detailed in chapter four, failed to produce 
any observable activity. Due to the limited solubility and no observable helicase activity 
the focus was again shifted, this time to the codon-optimised pET-28a(+) clone. 
 
3.2.5 Purification of Codon-Optimised His6-T-PFH45 
Purification of the His6-T-PFH45 fusion protein expressed from the codon-optimised pET-
28a(+) clone was initially approached with both an auto induction protocol, as detailed 
above for the pGEX-6p-1 clone, and an IPTG induction as per the original purification 
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Figure 3.5 Re-solubilised GST-PP-PFH45. 10 % SDS PAGE gel showing SeeBlue Pre-
Stained protein ladder (Invitrogen) in lane 1, and the purified GST-PP-PFH45 from Figure 
3.3 in lane 2. Lane 2 has three highlighted bands; circled in red was the GST-PP-PFH45 
fusion protein, while the further two bands have likely resulted from the degradation of the 
fusion protein into the PFH45 (green) and GST-PP moieties (blue). Lane 3 shows the 
sample after digestion with PreScission protease (yellow). Lanes 4 and 5 show the soluble 
and resolubilised fractions from the auto-induction respectively, while lanes 6 to 10 show 
the eluted fractions containing GST-PP-PFH45. 
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strategy described by Pradhan and Tuteja (2007). Varying temperatures and levels of 
induction, and the use of different growth media had little effect on the overall expression. 
It was also noted that His6-T-PFH45 was expressed in small amounts prior to IPTG 
induction. The addition of 1 % glucose in the 37 °C overnight seed culture and 0.5 % in the 
growth was used to minimise any affects of leaky expression from the pET-28a vector 
(Loomis et al. 1967). The yield was largely unaffected by the presence of glucose, but a 
final protocol was established. 
In short, a 37 °C growth in 400 mL 2 × YT and a 1 mM IPTG induction were used. 
However, unacceptable levels of contaminants were being co-purified. The 5 mL His Trap 
FF column (GE Healthcare) was replaced with a 10 mL Ni-NTA (Hochuli 1990) 
Superflow column (Qiagen) and additional steps to the purification protocol were explored. 
Varying imidazole concentrations revealed that lower concentrations had little observable 
affect on resolving His6-T-PFH45 from the column contaminants, whereas 200 mM 
imidazole assured total elution of the His6-T-PFH45 fusion protein. The introduction of a 
NaCl gradient appeared to have no observable affect, however a pH gradient from pH 7.5 
down to 4.0 in Na2HPO4 buffer showed substantial reduction of the contaminants (Figure 
3.6). 
It was calculated from the pH gradient that some of His6-T-PFH45 fusion began to 
dissociate from the column at a pH of less than 6.0. Therefore, subsequent purifications 
incorporated a pH 6.0 wash and the bound His6-T-PFH45 was eluted in 200 mM 
imidazole. Protein product achieved from the Nickel affinity chromatography was further 
purified using size exclusion chromatography. This yielded a final His6-T-PFH45 product 
(Figure 3.7) which showed good helicase activity at a 10:1 ratio of helicase to substrate. 
Although a vast improvement on the overall purity of the PFH45 fusion protein, several 
contaminants still persisted. With resolving these contaminants in mind, samples of the 
protein product were applied to either DEAE or heparin columns. Although the DEAE 
made no noticeable difference, the heparin column did appear to resolve some of the 
contaminants. It was therefore decided to include heparin ion exchange chromatography 
after the nickel affinity chromatography but before the size exclusion chromatography. The 
heparin analyte carried forward from the nickel affinity chromatography step was dialysed 
against HEPES buffer A used in the heparin affinity protocol. The His6-T-PFH45 moiety 
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Figure 3.6 pH Gradient across His6-T-PFH45 Bound Ni-NTA Column. 10 % SDS PAGE gel showing the SeeBlue Pre-Stained protein ladder (Invitrogen) 
in lane 1, the total cell lysate in lane 2, and the soluble and insoluble lysate fractions in lanes 3 and 4 respectively. Fractions collected during the pH gradient 
are shown in lanes 6 to 21, with lane 6 at pH 7.5 and lane 21 at pH 4.0. Lanes 22 to 24 show the fractions containing the residual bound protein eluted with 200 
mM imidazole. The bands boxed in red are those that correspond to His6-T-PFH45 based on size and expression. 
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of the analyte remained in the mobile phase and was collected in the flow through, while 
the contaminants bound to the column (Figure 3.8). 
Purified PFH45 samples from a heparin treated and a non-heparin treated preparation were 
screened for helicase activity. The heparin treated sample showed a marked decrease in 
helicase activity relative to that of the non-heparin treated sample. Succeeding purifications 
performed in the same way as described above for the heparin treated sample also showed 
this trend. Therefore it was decided to screen the contaminants from the heparin column 
for helicase activity. The predominant contaminants were separated using size exclusion 
chromatography (Figure 3.9). When each purified protein was screened for helicase 
activity, the higher molecular weight proteins (~90 kDa) conferred activity, whereas the 
lower molecular weight protein (~55 kDa) did not (not shown). Therefore it would seem 
that the removal of the contaminants during the heparin column treatment (the 90 kDa 
proteins) may be responsible for the decrease in helicase activity. It may also be the case 
that the two 90 kDa bands were the same protein, eluted from the size exclusion column in 
different oligomeric states. 
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Figure 3.7 Purification with a pH 6.5 wash and Size Exclusion Chromatography of His6-
T-PFH45. 10 % SDS PAGE gel showing the SeeBlue Pre-Stained protein ladder 
(Invitrogen) in lane 1, while lane 2 shows the protein product obtained first from nickel 
affinity chromatography incorporating a pH 6.5 wash  and eluted with 200 mM imidazole, 
then passed through a HiLoad 26/60 Superdex S200 Prep Grad column (GE healthcare). 
His6-T-PFH45 was circled in red. 
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Figure 3.8 Heparin Column Chromatography of Nickel Column Protein Product. 10 % SDS PAGE gel A shows the SeeBlue Pre-Stained protein ladder 
(Invitrogen) in lane 1, while lane 2 shows the protein product obtained from nickel affinity chromatography and lane 3 shows it concentrated prior to loading 
onto the heparin column. Lanes 4 to 10 show the heparin flow through fractions containing the His6-T-PFH45 fusion protein (red), and lanes 11 to 13 show the 
heparin eluted contaminants. 10 % SDS PAGE gel B shows the SeeBlue Pre-Stained protein ladder (Invitrogen) in lane 1, the protein product obtained from 
heparin ion exchange chromatography in lane 2 and again after being concentrated prior to loading onto the size exclusion column in lane 3. Lastly, the purified 
His6-T-PFH45 obtained from the size exclusion chromatography was shown in lane 4. 
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Western blot analysis was carried out using the same monoclonal Anti-polyHistidine 
Peroxidise Conjugate (Sigma) as described earlier (3.2.2.) to trace the presence of His-
tagged PFH45 during each of the purification steps employed (Figure 3.10). 
 
3.2.6 Final Purification Strategy of PFH45 
The final growth and purification strategy (Figure 3.11) yielding ~12.5 mg of >95 % 
homogenous His6-T-PFH45 per litre of growth media (~4.2 mg g
-1
 of wet weight of cells), 
based on a molar extinction coefficient of 29715 M
-1
 cm
-1
 and molecular weight of 
48711.8 calculated using ProtParam (Wilkins et al. 1999), which exhibited helicase 
activity and had an A260:A280 ratio of <0.6 was as follows. 
The recombinant pET-27a(+) plasmid harbouring the codon-optimised PFH45 gene for 
expression in E. coli was transformed into BL21 (DE3) [pLysS] E. coli cells (Stratagene). 
Bacterial cultures were grown in 400 mL of 2 × YT to an OD600 ~0.6 at 37 °C, at which 
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Figure 3.9 Size Exclusion Chromatography of the Heparin Column Bound Phase 
during His6-T-PFH45 Purification. 10 % SDS PAGE gel showing the SeeBlue Pre-
Stained protein ladder (Invitrogen) in lane 1, while lanes 2, 3 and 4 show the isolated 
dominant contaminants from the bound phase of the heparin chromatography step. Both the 
bands circled in red and green exhibit helicase activity; however the band circled in blue 
does not. 
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point the cells were induced with 0.5 mM IPTG and the growth continued for 3 hours at 37 
°C. The cells were harvested by centrifugation at 4000 × g for 15 minutes at 4 °C, and 
stored at -20 °C. 
 
The cell pellet from the 400 mL growth was thawed, resuspended and lysed in 1 × PBS, 1 
mM DTT, 1 mM Benzamidine, and 0.1 mM PMSF by sonication (40 % amplitude at a 
max temperature of 10 °C for a duration of 3.3 seconds on and 9.9 seconds off for a total 
time of 20 minutes). The sonicate was clarified by centrifugation at 50000 × g for 1 hour at 
4 °C. 
The resulting supernatant was loaded onto a 10 mL Ni-NTA agarose resin (Qiagen) 
column pre-equilibrated in disodium phosphate buffer (50 mM Na2HPO4 pH 7.5, 500 mM 
NaCl, 1 mM DTT, and 10 % glycerol). The column was washed with three column 
volumes of disodium phosphate buffer, followed by three column volumes of modified pH
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Figure 3.10 Western Blot Tracing His6-T-PFH45 throughout its Purification. 10 % 
SDS PAGE gel A shows a SeeBlue Pre-Stained protein ladder (Invitrogen) in lane 1, and 
lane 2 shows the cell lysate. Lane 3 shows the eluant from the Ni-NTA column. Lane 4 
shows the flow through of the heparin column while lane 5 shows the bound phase eluted 
with high salt. Lane 6 shows the pure His6-T-PFH45 obtained from size exclusion 
chromatography. Panel B shows the nitrocellulose membrane with the electro-transferred 
samples representative of lanes 2 to 6 shown on gel A, western blotted against with 
monoclonal Anti-polyHistidine Peroxidise Conjugate (Sigma). 
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Figure 3.11 Chromatagrams Obtained from the Three-Stage Purification Strategy of His6-T-PFH45. In the first of three purification protocols, the 
clarified supernatant obtained from the centrifugation of the bacterial lysate was injected onto a Ni-NTA agarose resin (Qiagen) column. Non-specifically 
bound contaminants were removed with a pH 6.0 wash (green arrow). The His6-T-PFH45 was eluted from the bound phase with 200 mM imidazole (red 
arrow). The eluate from the nickel column was buffer exchanged for a NaCl concentration of <100 mM and then injected onto a HiTrap Heparin HP column 
(GE Healthcare) where the His6-T-PFH45 remained into the mobile phase (red arrow). The heparin bound contaminants were eluted in 500 mM NaCl (green 
arrow). The His6-T-PFH45 containing flow through fractions were concentrated down to a suitable volume (2 mL) and injected onto a HiLoad 26/60 Superdex 
S200 Prep Grad column (GE Healthcare) where the pure His6-T-PFH45 eluted at approximately 200 mL (red arrow). 
98 
disodium phosphate buffer (50 mM Na2HPO4 pH 6.0, 500 mM NaCl, 1 mM DTT, and 10 
% glycerol). The bound phase was conditioned back into pH 7.5 with three column 
volumes of disodium phosphate buffer, and then eluted with 200 mM imidazole in HEPES 
buffer as described in the nickel affinity protocol. 
The eluted sample was buffer exchanged into HEPES buffer A used in the heparin affinity 
protocol to achieve an overall salt concentration of 20 mM or more but less than 100 mM 
(20≤NaCl<100 mM). The sample was further purified by applying the sample to a 5 mL 
HiTrap Heparin HP column (GE Healthcare) pre-equilibrated in HEPES buffer A.  
Flow through from the column was then concentrated using a 30 kDa molecular weight 
cut-off (MWCO) centrifugal concentrator (GE Healthcare) and applied to a HiLoad 26/60 
Superdex S200 Prep Grad column (GE Healthcare) in HEPES buffer used in the size 
exclusion protocol. Fractions containing pure His6-T-PFH45 were concentrated to 50 µM 
and stored as 50 µL aliquots at -20 °C. 
 
3.2.7 Thrombin Cleavage 
Thrombin was used for an on-column (Ni-NTA) cleavage of His6-T-PFH45 using a 
1:2000, mass to mass ratio of thrombin to His6-T-PFH45 at 20 °C for 16 hours. Thrombin 
was removed from the eluted PFH45-thrombin mixture using a benzamidine affinity 
column, yielding pure untagged PFH45 in the flow-through. There was no observable 
change in PFH45 activity as a result of the cleavage and due to the additional steps to the 
already convoluted purification strategy, His-tag cleavage was not performed prior to the 
biochemical analysis of PFH45. 
 
3.2.8 Storage Conditions 
Repeated helicase activity assays were performed over consecutive days using purified 
His6-T-PFH45 stored at various temperatures and glycerol concentrations. Loss of activity 
was observed in protein stored at 4 °C regardless of the glycerol concentration, while 
proteins stored at -20 °C and subjected to multiple freeze-thaw cycles did not show a 
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significant loss of activity providing the storage buffer contained at least 10 % glycerol to 
serve as a cryoprotectant. Successive freeze-thaws of -20 °C stocks in 10 % glycerol did 
result in decrease in SDS PAGE running size of <5 kDa. This was determined to be the 
loss of the His-tag, illustrated by a lack of anti-His detection using Western blotting. Long 
term storage (greater than one week) at 4 °C of His6-T-PFH45 resulted in the consistent 
degradation into two polypeptides of approximately 30 kDa and 25 kDa which could be 
separated by size exclusion (Figure 3.12). 
 
3.3 PFDH60 
In addition to PFH45, Tuteja et al. (2007) also proposed PFDH60 as a novel drug-target. 
The 60 kDa truncated namesake of the protein has been previously purified (Pradhan et al. 
2005; Pradhan et al. 2005) and a clone was obtained from Dr Renu Tuteja (Malaria Group, 
International Centre for Genetic Engineering and Biotechnology, New Deli, India). Again 
yields suitable for the proposed biochemical and structural experimentation were 
unattainable. As for PFH45, a codon-optimised version of PFDH60 (GENEART, 
Regensburg, Bavaria, Germany) was cloned into pET-28a(+) and pGEX-6P-1. A single-
step GST-fusion capture purification protocol failed to yield any discernible GST-PP-
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Figure 3.12 Purified Products from the Consistent Degradation of PFH45. 10 % SDS 
PAGE showing a SeeBlue Pre-Stained protein ladder (Invitrogen) in lane 1, the smaller 
(~25 kDa) of the two products in lane 2, and the larger (~30 kDa) of the two products in 
lane 3. 
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PFDH60. Therefore due to the success of the codon-optimised clone of His6-T-PFH45, the 
pET-28a(+) clone was chosen to pursue viable PFDH60. 
 
3.3.1 Clone Confirmation by Restriction Digest 
The codon-optimised pET-28a(+)/PfDH60 clone, expressing a hexa-histidine (His6) fusion 
of PFDH60 with a thrombin (T) cleavage site (His6-T-PFDH60), was digested with 
restriction enzymes BamHI and NotI confirming the expected gene size of 2229 bp (Figure 
3.13). 
 
3.3.2 Purification of Codon-Optimised His6-T-PFDH60 
Due to the difficulty originally experienced with PFH45, expression analysis was carried 
out following the induction of pET-28a(+)/PfDH60 with various IPTG concentrations and 
at different temperatures. Expression was not significantly affected by IPTG concentration 
 1          2         3 
 
Figure 3.13 Restriction Digest of the pET-28a(+)/PfDH60 codon-optimised clone. 0.8 % 
agarose gel showing the double restriction digest of pET-28a(+)/PfDH60 by BamHI and 
NotI. Lane 1 shows the HyperLadder I marker (Bioline), lane 2 shows the undigested 7598 
bp recombinant plasmid; in open circular (red) and linear (green) confirmations, and lane 3 
shows double digest products; the 5369 bp linerised plasmid (blue) and the 2229 bp 
PfDH60 gene (yellow). 
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or incubation temperature, and an auto-induction protocol had little effect; therefore further 
growths were induced with 1 mM IPTG at 37 °C for 3 hours. 
Purification of the His6-T-PFDH60 fusion protein expressed from the codon-optimised 
pET-28a(+) clone was performed as per the final purification strategy for His6-T-PFH45, 
but with minor modifications. Like the His6-T-PFH45 nickel affinity step of purification, 
several histidine-containing proteins were captured from the PFDH60 bacterial sonicate. 
Two approaches to eliminate this were explored, including the incorporation of either a pH 
wash or a routine imidazole wash. A pH gradient did not provide any resolution of the 
His6-T-PFDH60 from the contaminants, but an isocratic gradient of imidazole showed 
removal of the vast majority of contaminants at 30 mM imidazole (Figure 3.14). Therefore, 
the nickel affinity step in future preparations included a 30 mM imidazole wash prior to 
eluting the His6-T-PFDH60 fusion protein with 100 mM imidazole. 
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Figure 3.14 Nickel Affinity Chromatography with an Isocratic Imidazole Gradient. 
The 10 % SDS PAGE gel shows the soluble fraction of the lysate, flow-through, and 
various imidazole concentration eluted fractions from a Ni-NTA affinity column (GE 
Healthcare) purification of His6-Tagged PFDH60. Lane 1 shows a SeeBlue Pre-stained 
Ladder (Invitrogen). Lane 2 shows the total soluble fraction from the cell pellet lysate, lane 
3 shows the flow-through, and lanes 4 to 11 show the eluted bound phase fractions by 10, 
20, 30, 40, 50, 100, and 200 mM imidazole respectively. The band corresponding in size (~ 
90.4 kDa) to His6-T-PFDH60 is present in the fractions eluted in 40 to 100 mM imidazole 
(red). 
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Based on the observation that the heparin affinity removed native E. coli helicases during 
the His6-T-PFH45 purification, it was considered prudent to include it in the PFDH60 
purification strategy. Similar to the PFH45 heparin affinity step, His6-T-PFDH60 remained 
in the mobile phase and was collected in the flow-through while a ~90 kDa protein was 
eluted from the bound phase resembling that described in the PFH45 heparin affinity step. 
Size exclusion chromatography was included as the final purification step. The 
corresponding His6-T-PFDH60 band was traced during the described purification strategy 
by western blot analysis with the monoclonal Anti-polyHistidine Peroxidise Conjugate 
(Sigma) as described in 3.2.2 (Figure 3.15). 
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Figure 3.15 Western Blot Tracing His6-T-PFDH60 throughout its Purification. 10 % 
SDS PAGE gel A shows a SeeBlue Pre-Stained protein ladder (Invitrogen) in lane 1, and 
lane 2 shows the cell lysate. Lane 3 shows the eluant from the Ni-NTA column. Lane 4 
shows the flow through of the heparin column while lane 5 shows the bound phase eluted 
with high salt. Lane 6 shows the pure His6-T-PFH45 obtained from size exclusion 
chromatography. Panel B shows the nitrocellulose membrane with the electro-transferred 
samples representative of lanes 2 to 6 shown on gel A, western blotted against with 
monoclonal Anti-polyHistidine Peroxidise Conjugate (Sigma). 
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3.3.3 Final Purification Strategy of PFDH60 
The final growth and purification strategy (Figure 3.16) yielding ~0.7 mg of >95 % 
homogenous His6-T-PFDH60 per litre of growth media (~0.2 mg g
-1
 of wet weight of 
cells), based on a molar extinction coefficient of 80985 M
-1
 cm
-1 
and molecular weight of 
90421.9 calculated using ProtParam (Wilkins et al. 1999), which exhibited helicase 
activity and had an A260:A280 ratio of <0.6 was as follows. 
The recombinant pET-27a(+) plasmid with the PFDH60 gene was transformed into BL21 
(DE3) [pLysS] E. coli (Stratagene). Bacterial cultures were grown in 400 mL of 2 × YT to 
an OD600 ~0.6 at 37 °C, at which point the cells were induced with 0.5 mM IPTG and the 
growth continued for 3 hours at 37 °C. The cells were harvested by centrifugation at 4000 
× g for 15 minutes at 4 °C, and stored at -20 °C. 
The cell pellet from the 400 mL growth was thawed, resuspended and lysed in 1 × PBS, 1 
mM DTT, 1 mM Benzamidine, and 0.1 mM PMSF by sonication (40 % amplitude at a 
max temperature of 10 °C for a duration of 3.3 seconds on and 9.9 seconds off for a total 
time of 20 minutes). The sonicate was clarified by centrifugation at 50000 × g for 1 hour at 
4 °C. 
The supernatant was treated on a 10 mL Ni-NTA agarose resin (Qiagen) column as 
described in the nickel affinity protocol, with an additional three column volumes of 15 % 
HEPES buffer against disodium phosphate buffer to provide the 30 mM imidazole wash 
prior to eluting with 100 mM imidazole (50 % HEPES buffer against disodium phosphate 
buffer). 
The eluted sample was buffer exchanged into HEPES buffer A used in the heparin affinity 
protocol to achieve an overall salt concentration 20 mM or more but less than 100 mM 
(20≤NaCl<100 mM). The sample was further purified using a 5 mL HiTrap Heparin HP 
column (GE Healthcare) as described in the heparin affinity protocol. 
Flow through from the column was then concentrated using a 50 kDa molecular weight 
cut-off (MWCO) centrifugal concentrator (GE Healthcare) and applied to a HiLoad 26/60 
Superdex S200 Prep Grad column (GE Healthcare) as detailed in the size exclusion 
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Figure 3.16 Chromatagrams Obtained from the Three-Stage Purification Strategy of His6-T-PFDH60. In the first of three purification protocols, the 
clarified supernatant obtained from the centrifugation of the bacterial lysate was injected onto a Ni-NTA agarose resin (Qiagen) column. Non-specifically 
bound contaminants were removed with a 30 mM imidazole wash (green arrow). The His6-T-PFDH60 was eluted from the bound phase with 100 mM 
imidazole (red arrow). The eluate from the nickel column was buffer exchanged for a NaCl concentration of <100 mM and then injected onto a HiTrap Heparin 
HP column (GE Healthcare) where the His6-T-PFDH60 remained into the mobile phase (red arrow). The heparin bound contaminants were eluted in 500 mM 
NaCl (green arrow). The His6-T-PFDH60 containing flow through fractions were concentrated down to a suitable volume (2 mL) and injected onto a HiLoad 
26/60 Superdex S200 Prep Grad column (GE Healthcare) where the pure His6-T-PFDH60 elutes at approximately 180 mL (red arrow). 
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protocol. Fractions containing pure His6-T-PFDH60 were concentrated to 10 µM and 
stored at 4 °C. 
 
3.3.4 Thrombin Cleavage 
As for PFH45, an on-column (Ni-NTA) cleavage of His6-T-PFDH60 using a 1:2000, mass 
to mass ratio of thrombin to His6-T-PFDH60 was performed at 20 °C for 16 hours. 
Thrombin was removed from the eluted PFDH60-thrombin mixture using a benzamidine 
affinity column, yielding pure untagged PFDH60 in the flow-through. There was no 
observable change in PFDH60 activity resulting from cleavage. Therefore, as for PFH45 
His-tag cleavage was not performed prior to the biochemical analysis of PFDH60. 
 
3.3.5 Storage Conditions 
Repeated helicase activity assays were performed over consecutive days using purified 
His6-T-PFDH60 stored at various temperatures and glycerol concentrations. Loss of 
activity was observed after 1 week in protein stored at any temperature (4 to -20 °C) 
regardless of the glycerol concentration (0-50 % v/v). 
 
3.4 Discussion 
Due to the cooperative nature of helicase activity and their capability to bind nucleic acids, 
helicases can prove difficult to purify to a high degree of homogeneity, and Plasmodium 
proteins have been identified as being particularly difficult to purify from heterologous 
expression systems (Birkholtz et al. 2008). Additionally, most proteins benefit from quick 
and uncomplicated purification strategies to reduce susceptibility to proteolysis and 
denaturation. However, single column chromatography rarely yields proteins with greater 
than 90 % purity (Tahmaseb et al. 2010). There are at least 11 different DNA helicases in 
Escherichia coli (Matson et al. 1990; Matson 1991; Matson et al. 1994), and therefore the 
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production and purification of proteins using expression strains of E. coli means that there 
was always the possibility of contaminating native helicase being carried forward into the 
biochemical analysis, resulting in inaccurate results. This justified the more rigorous 
strategy of purification, not only to yield a more homogenous protein sample but also to 
minimise the potential of helicase contamination. 
 
3.3.1 PFH45 
Prior to the codon-optimisation, PFH45 expression was too poor for it to be detected in the 
eluent from nickel affinity chromatography. Use of the Sequence Manipulation Suite: 
Codon Usage tool (Stothard 2000) and ALIGN (Myers et al. 1988)  on the native and 
codon optimisation sequences (Appendix 2), indicated that codon optimisation for 
expression in E. coli resulted in a change of approximately 26 % of the 1197 nucleotide 
native P. falciparum sequence, corresponding to 104 codon triplets (Appendix 3). This 
resulted in an apparent increase of expression which gave rise to usable yields for 
biochemical and structural analysis. 
The lack of observable activity from the sarkosyl resolubilised GST-PP-PFH45 obtained 
from the codon-optimised pGEX-6p-1 clone may have been due to the protein being 
rendered inactive due to misfolding (Goldberg 2003), coinciding with its initial 
insolubility. It may also have been that the helicase was being inhibited by any sarkosyl 
carried through from the purification protocol (Kovelman et al. 1990). These observations 
justified moving onto the codon-optimised pET-28a(+) clone. 
The pH wash incorporated in the His6-T-PFH45 purification strategy did not appear to 
affect the helicase activity, which is detailed in chapter four. Even protein eluted after the 
pH 4.0 gradient showed activity, although it should be noted that exposure to the relatively 
low pH was not prolonged. Although not common, there have been reported cases of 
helicases remaining active across a broad pH range (Lam et al. 2004; Pradhan et al. 2005), 
lending credibility to pH adjustment as a purification tool. 
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3.3.2 PFDH60 
Similar to observations on PFH45 expression prior to codon optimisation, PFDH60 
expression in E. coli was equally poor and therefore difficult to detect in the eluent from 
nickel affinity chromatography. Again, analysis of PFDH60 native and codon optimised 
sequences (Appendix 4) using the Sequence Manipulation Suite: Codon Usage tool 
(Stothard 2000) and ALIGN (Myers et al. 1988) indicated that codon optimisation for 
expression in E. coli resulted in a change of approximately 23 % of the 2229 nucleotide 
native P. falciparum sequence, corresponding to 168 codon triplets (Appendix 5). 
Although codon optimisation did increase the yield, its effect was not as noticeable as it 
was for PFH45. It should be noted that expression of the native PFDH60 was poorer than 
that of the native PFH45, and so any increase in yield may be relative. However, the yield 
was still sufficient for further biochemical and structural analysis. 
The difficulty in maintaining PFDH60 activity under different storage conditions is similar 
to that observed by Pradhan et al. (2007). As a result, subsequent biochemical and 
structural analysis of PFDH60 would have to be performed within three days of its 
purification. 
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CHAPTER FOUR: BIOCHEMICAL CHARACTERISATION 
 
4.1 Introduction 
Before studies into the exploitation of a protein for biotechnological or pharmaceutical 
applications can be undertaken, the specific activities of that protein need to be identified. 
The better understood a protein is, the easier it is to exploit it. A recent study on Human 
Immunodeficiency Virus (HIV) 1 reverse transcriptase (RT) detailing its inhibition 
mechanism (Das et al. 2012) would not have been possible had its activities not been 
investigated over the past 25 years (Tanese et al. 1986; Farmerie et al. 1987; Larder et al. 
1987; Hizi et al. 1988; Mous et al. 1988; Müller et al. 1989). Although the availability and 
advancement of technologies have made the investigation of protein activities faster, this 
example demonstrates the level of biochemical characterisation that needs to be performed 
if a protein is to be exploited as, in the case of this study, a novel drug-target. 
Singleton et al. (2007) described the biochemical properties of helicases in terms of rate, 
processivity, directionality, step size, and active or passive mechanisms, and that the 
classification  nomenclature should be representative of a particular helicase activity. For 
example, a helicase superfamily one member which translocates in the 3’-5’ direction 
should be classified as a SF1A helicase. Furthermore, if that same helicase were only 
capable of acting on a substrate containing a single-stranded nucleic acid region it would 
be referred to as a SF1Aα helicase. Due to the clarity and comprehensiveness of the 
Singleton et al. (2007) paper, it was decided that the biochemical characterisation in this 
study would incorporate experiments which could attempt to address each of these 
biochemical properties. 
This chapter will describe these experiments, how they compare with the previous 
experimentation carried out by the Tuteja group, and how precisely PFH45 and PFDH60 
can been described based on the Singleton et al. (2007) mode of classification. 
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4.1 PFH45 
Although the intention was to explore drug-target interactions using single-molecule 
studies of PFH45, it was felt that due to the alternative purification strategy outlined in 
chapter three, it would be prudent to repeat and expand on the preliminary biochemical 
characterisation by the Tuteja group. The biochemical analysis carried out by the Tuteja 
group had concluded that PFH45 depends on ATP and Mg
2+
 cofactors for optimum 
helicase activity (Pradhan et al. 2007), but can utilise the hydrolysis of dATP, dCTP, and 
to a lesser extent UTP (Pradhan et al. 2008). Additionally, they had shown PFH45 to bind 
radiolabelled ATP and that it was capable of unwinding fork-like dsDNA and dsRNA in 
both the 5’-3’ and the 3’-5’ directions (Pradhan et al. 2007). They had also demonstrated 
that PFH45s ability to bind ATP resides in the N-terminal residues of the protein, while the 
C-terminal residues retain 75 and 78 % of the full-length proteins’ propensity for RNA and 
DNA binding respectively, and that phosphorylation of its serine and threonine residues 
results in a two to three-fold up-regulation in helicase activity (Pradhan et al. 2008). 
 
4.1.1 In silico Analyses 
Prior to laboratory experimentation, PFH45 was scrutinised using a variety of in silico 
techniques. An initial search using the unspliced, spliced, and codon-optimised DNA 
sequences of PFH45 (Appendix 2) with the Basic Local Alignment Search Tool (BLAST) 
server (Altschul et al. 1990; Johnson et al. 2008) revealed sequence identity to numerous 
DEAD box helicases. Most notably similar was eukaryotic initiation factor (EIF) 4A from 
the closely related cattle parasitic protozoan Theileria annulata (taxon Class Aconoidasida 
(Mehlhorn et al. 1980)), as well as other EIF4A orthologues in different species. An 
alignment of the PFH45 protein sequence with that of human EIF4A1 (NCBI accession 
number: NP_001407), one biologically active form of EIF4As’ three isoforms (Conroy et 
al. 1990; Yoder-Hill et al. 1993), using ALIGN (Myers et al. 1988) (Appendix 6) revealed 
a sequence identity of 66.7 %, with significant conservation of the core SF2 family motifs 
between the two sequences (Figure 4.1). These observations support those of Pradhan et al. 
(2007), while more recently Tuteja et al. (2010) have renamed PFH45 as PFEIF4A. For 
these reasons, this body of work will continue to refer to PFH45 as PFEIF4A. 
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Expanding on this observation, the sequences of PFEIF4A and the three human EIF4A 
isoforms (Appendix 7) were input into the multiple alignment tool of the Clustal program 
(Thompson et al. 1994; Larkin et al. 2007) (Appendix 8). This showed that PFEIF4A is 
most similar to human EIF4A1 and is least similar to human EIF4A3. These results are 
summarised in Table 4.1. 
 
4.1.2 Substrate Specificity Screen 
Helicases have often been shown to have specific preferences for particular substrates, 
whether favouring DNA over RNA (Lohman et al. 1996; de la Cruz et al. 1999) or in their 
resolution of specific nucleic acid topologies (Webb et al. 2007; Long et al. 2009). 
Therefore, PFEIF4A purified as detailed in chapter three was used to screen a variety of 
nucleic acid substrates. An initial screen for helicase activity following the helicase assay 
as first described by Özsoy et al. (2003) was carried out. This was performed with non-
phosphorylated PFEIF4A and PFEIF4A phosphorylated at Serine (S) and Threonine (T) 
residues in response to observations made by Pradhan et al. (2008). In short, 20 μL 
 
 
 
 
Figure 4.1 Schematic Based on ALIGN results of PFH45 and EIF4A1. Each diagram 
represents the SF2 motifs present in PFH45 (top) and EIF4A1 (bottom), showing the N-
termini on the left and C-termini on the right. Open boxes represent the conserved helicase 
motifs, and letters inside the boxes are the amino acid sequences of each motif. Green 
letters (motifs IV and VI) indicate that the amino acid differs but its biochemical properties, 
and therefore its affect on the peptide is similar. However, yellow letters (motif IV) indicate 
that the differing amino acids do not have similar biochemical properties, and might 
therefore have an effect of the peptide. Labels above the open boxes are the names assigned 
to the motifs. The spaces between motifs are arbitrary and not representative of either 
protein. 
Conserved Helicase Motifs of PFH45 and Human EIF4A1 
Q 
GFEKPSAIQ 
GG 
Doublet 
GG 
Ib 
TPGR AQSGTGKT 
I 
DEAD 
II 
SAT 
III 
IIYCNTRK 
IV 
ARGID 
V 
HRIGRSGR 
VI 
PTRELA 
Ia 
GFEKPSAIQ AQSGTGKT PTRELA GG TPGR DEAD SAT VIFINTRR ARGID HRIGRGGR 
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reactions were performed on 12 substrates with various topologies (Figure 4.2), with 5 µM 
PFEIF4A and 100 nM DNA substrate (50:1 ratio). Reactions were incubated at 37 °C for 1 
hour and stopped with 5 µL of 5 × termination buffer prior to running on SDS PAGE gels 
(Figure 4.3). In addition, a series of PFEIF4A titrations to these substrates were also 
carried out at 10, 20, 30, 40, and 50:1 ratios (Figure 4.4). 
 
   1      2     3      4     5      6     7      8      9    10    11    12 
 
Figure 4.2 Substrate Specificity Screen Substrates. 15 % SDS PAGE of substrates 1 to 
12 as described in Table 2.3. In lanes 1 to 12 respectively, they are; Holliday Junction, 3 
Strand Junction, 3’ Flap, 5’ Flap, 4 bp Bubble, 12 bp Bubble, 36/18 Partial Duplex, 50/19 
Partial Duplex, 3 Way Junction, Fork 1, Fork 2, and 80 bp Blunt Duplex. 
Protein A Length A Protein B Length (B) Homology (%) 
EIF4A1 406 EIF4A2 407 89 
EIF4A1 406 PFEIF4A 398 68 
EIF4A2 407 PFEIF4A 398 67 
EIF4A1 406 EIF4A3 411 66 
EIF4A2 407 EIF4A3 411 66 
EIF4A3 411 PFEIF4A 398 63 
Table 4.1 Clustal Results Summary of PFEIF4A and Human EIF4A Isoforms. The 
table is arranged in descending percentage homology from top to bottom. The most similar 
among all four sequences are the human EIF4A isoforms 1 and 2. The second most similar 
proteins are human EIF4A1 and PFEIF4A, and the third most similar proteins is human 
EIF4A2 and PFEIF4A. The fourth and fifth most similar proteins are the human isoforms 1 
and 2 with isoform 3, and the least similar proteins are PFEIF4A and human EIF4A3. 
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Figure 4.3 PFEIF4A Substrate Specificity Screen. 15 % SDS PAGE gels visualised using a Fujifilm FLA-5000 phosphoimager with a blue laser (473 nm) at 
550 V and a green filter (532 nm), showing PFEIF4A activity on fluorescein labelled substrates with various topologies as described by Özsoy et al. (2003). 
Above each gel is a representative diagram of the substrate relating to that gel and its associated name as designated by Özsoy et al. (2003). The solid black 
triangle identifies the corresponding band for each of the primary substrates being screened against. Each gel lane is numbered 1 to 4; lanes 1 and 2 contain the 
room temperature control and the 37°C control respectively, while lane 3 contains the substrate after treating with PFEIF4A, and lane 4 contains the substrate 
after being treated with phosphorylated PFEIF4A. Repeat experiments show that six of the gels show complete unwinding of the primary substrate after 1 hour 
at 37°C; 3 Strand Junction, 3’ Flap, 36/18 Partial Duplex, 50/19 Partial Duplex, Fork 1, and Fork 2. The 5’ Flap also displays unwinding, however this is 
incomplete after 1 hour. All of the unwound substrates, including the 5’ Flap, have a single-stranded overhang. 
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From these experiments it appears that PFEIF4A unwinding activity required a single-
stranded overhang and that increasing the concentration of PFEIF4A resulted in increased 
levels of unwinding on substrates containing single-stranded overhangs; 3 Strand Junction, 
3’ Flap, 5’ Flap, 39/18 Partial Duplex, 50/19 Partial Duplex, Fork 1, and Fork 2 substrates. 
Curiously, the single-stranded regions of the bubble substrates were not sufficient to 
stimulate PFEIF4A unwinding. Furthermore, under these conditions the 5’ Flap substrate 
 
Figure 4.4 PFEIF4A Substrate Specificity Screen Titrations. The graph shows the effect 
of increasing concentration of PFEIF4A on the various substrates used in the substrate 
specificity screen. The points in the dark grey zone represent those substrates that do not 
show significant unwinding (<30 %) of the primary substrate at any given concentration. 
The points in the medium grey zone represent the primary substrates that although show 
discernible unwinding do not reach completion (30-55 %). Points in the light grey zone 
represent the primary substrates that reach completion during a 1 hour incubation at a 50:1 
PFEIF4A to substrate ratio. Finally, the points in the white zone represent the primary 
substrates that are unwound to completion at lower PFEIF4A to substrate ratios within the 
1hr incubation. The 36/18 Partial Duplex being observed to fully unwind at as low as a 10:1 
PFEIF4A to substrate ratio although more reliably at a 30:1 ratio, while the Fork 1 substrate 
was only ever observed to unwind completely at as low as 30:1 PFEIF4A to substrate ratio. 
Curiously, Fork 2 is not unwound to the same degree as Fork 1 at the lower ratios. When 
scrutinised using the OligoAnalyser software, the loose ends of Fork 2 show low levels of 
complementarity which imparts a more bubble-like rather than forked structure. All zones 
are drawn arbitrarily based on observable trends; however the given percentages are taken 
directly from the raw data. 
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did not appear fully unwound whereas the 3’ Flap substrate did, suggesting a potential 3’ 
polarity bias. 
PFEIF4A was phosphorylated at the hydroxyl groups of its serine and threonine residues 
with Protein Kinase C (PKC). The efficacy of phosphorylation was checked by 
incorporation of 3.4 fmol 
32
P-labeled ATP, equating to 1 nanocurie (nCu), and visualised 
on a SDS PAGE gel (not shown). However, phosphorylation did not appear to affect 
PFEIF4As specificity to substrates with single-stranded overhangs. As a result, the affects 
of phosphorylation was not pursued within this study. 
 
4.1.3 PFEIF4A Specific Substrate Screen 
After Observing PFEIF4A resolving relatively simple DNA topologies, an additional set of 
more elaborate substrates inspired by Anand et al. (2004) were created (Figure 4.5). 
 
These substrates incorporated common features of the unwound Özsoy substrates used in 
the substrate specificity screen (4.1.2) as well as incorporating hairpin structures. The 
screen itself was carried out under the same conditions of the substrate specificity screen, 
described under the helicase assay and run on SDS PAGE gels (Figure 4.6). 
  1 2 3  4   5  6 7   8  9 10 
 
Figure 4.5 Annealed HPD Substrates. 15 % SDS PAGE of substrates 13 to 22 as 
described in Table 2.3. Lanes 1 to 10 represent HPD1 to HPD10 respectively. 
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Figure 4.6 PFEIF4A Substrate Specificity Screen. 15 % SDS PAGE gels visualised using a Fujifilm FLA-5000 phosphoimager with a blue laser (473 nm) at 
550 V and a green filter (532 nm), showing PFEIF4A activity on fluorescein labelled substrates with various topologies. Above each gel is a representative 
diagram of the substrate relating to that gel and its associated name. The solid black triangle identifies the corresponding band for each of the primary 
substrates being screened against. The lanes on each gel are numbered 1 or 2; lane 1 contains the no helicase control, while lane 2 contains the substrate after 
being incubated with PFEIF4A. Repeat experiments show that only the gels corresponding to HPD7 and HPD8 show complete unwinding of the primary 
substrate after 1 hour at 37°C. HPD1, 2, 3, and 5 show partial unwinding, and HPD4, 6, 9, and 10 show no unwinding. The common features of HPD7 and 
HPD8 is an extending 3’ single-stranded overhang, whereas the partially unwound substrates only have a single nucleotide overhang on the 3’. The substrates 
that showed no unwinding completely lack any form of a 3’ single-stranded overhang. 
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These experiments confirmed that PFEIF4A requires a single-stranded overhang, and blunt 
ended substrates do not support unwinding. Interestingly, the substrates with 5’ single-
stranded overhangs or 5’ single-nucleotide flaps did not appear to undergo partial 
unwinding as seen for the 5’ Flap substrate described previously (4.1.2). Only substrates 
with a 3’ single-stranded overhang showed complete unwinding by PFEIF4A, while 
substrates with a 3’ single-nucleotide flap were partially unwound, at an average of ~48 %. 
 
4.1.4 Substrate Polarity Screen 
The observation that PFEIF4A unwound the 3’ Flap more effectively than the 5’ Flap, and 
its inability to resolve the structured substrates with the free 5’ single-stranded ends, 
suggested a potential polarity bias despite previous studies describing PFEIF4A as equally 
bipolar (Pradhan et al. 2007). Therefore a further experiment to investigate polarity was 
devised. 
Two redesigned 50/19 Partial Duplex substrates were used for the polarity experiments. 
The 3’-5’ substrate was identical in sequence to that described by Özsoy et al. (2003), 
however the fluorescein was on the 5’ end of the 19mer. This solved the observation of the 
fluorescein label displacement at the 5’ end of oligonucleotides attributing the 3’ single-
stranded overhang of the substrate (seen for both the 50/19 Partial Duplex and the Fork 2 
substrates). This also supports the conclusion that the duplex is being unwound rather than 
being digested by a contaminating nuclease. The oligonucleotides that made up the 5’-3’ 
substrate were the reverse complement of those that made up the 3’-5’ substrate so that the 
sequence itself could not be accountable for any difference observed. The experiment was 
performed as a time course with 20 μL 5 minute time points. Each time point reaction was 
carried out as described for the helicase assay with a 50:1 helicase to substrate ratio (5:0.1 
µM), at 37 °C and stopped with 5 µL of 5 × termination buffer (Figure 4.7). 
These experiments showed that although both the 3’-5’ and the 5’-3’ substrates were 
unwound when incubated with PFEIF4A, only PFEIF4A unwinding activity in the 3’-5’ 
direction was stimulated approximately two-fold in the presence of ATP, from 30.56 ± 
1.06 × 10
-5
 to 62.19 ± 1.65 fmol min
-1
. 
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4.1.5 Single-Stranded Overhang Requirements 
As the single-stranded regions within the bubble substrates did not appear sufficient to 
support PFEIF4A unwinding activity, and the 3’ single-nucleotide structured substrates 
were not unwound to completion, the absolute requirement for a single-stranded overhang 
needed to be explored. Given PFEIF4As preferential unwinding activity in the 3’-5’ 
direction, a series of oligonucleotides were designed to create multiple partial duplex 
substrates with decreasing single-stranded overhangs based on truncated forms of the 3’-5’ 
substrate used in the substrate polarity screen (Figure 4.8). 
 
Figure 4.7 PFEIF4A Substrate Polarity Screen. Graph A shows the active and passive 
unwinding activity of PFEIF4A on substrates 23 and 24 as described in Table 2.3. The 
white circles represent the percentage of the actively unwound 3’-5’ primary substrate at 
the given time points, and the solid line represents their line of best fit. The black circles 
represent the percentage of the passively unwound 3’-5’ primary substrate at the given time 
points, and the wide-spaced dashed line represents their line of best fit. The white squares 
represent the percentage of the actively unwound 5’-3’ primary substrate at the given time 
points, and the wide-spaced dotted line represents their line of best fit. Finally, the black 
squares represent the percentage of the passively unwound 5’-3’ primary substrate at the 
given time points, and the close-spaced dashed line represents their line of best fit. Graph B 
shows the active and passive unwinding rate (fmol min
-1) of PFEIF4A for the 3’-5’ 50/19 
Partial Duplex (dark grey) and the 5’-3’ 50/19 Partial Duplex (light grey). 
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Figure 4.9 Single-Stranded Overhang Requirements of PFEIF4A. Graph A shows the 
initial unwinding rates of PFEIF4A on the various Partial Duplex substrates. The 
percentage of the primary substrate for the 50, 45, 40, 35, 30, 25, and 20/19 Partial Duplex 
substrates at the given time points are represented by the white circles, black circles, white 
squares, black squares, white triangles, black triangle, and the inverted white triangles 
respectively. The initial rates of the reactions for each substrate are represented by the solid 
(50/19), the wide-spaced dashed (45/19), the wide-spaced dotted (40/19), the close-spaced 
dashed (35/19), the close-spaced dotted (30/19), the dot-dashed (25/19), and the dot-dot-
dashed lines (20/19). The comparative unwinding rates (fmol min
-1
) of PFEIF4A for each 
of the Partial Duplex substrates are shown in Graph B. 
   1 2 3 4 5 6 7 
 
Figure 4.8 Truncated Partial Duplex Substrates. 15 % SDS PAGE gel of substrates 23 
and 25 to 30 as described in Table 2.3. In lanes 1 to 7 respectively, they are; 50/19 Partial 
Duplex, 45/19 Partial Duplex, 40/19 Partial Duplex, 35/19 Partial Duplex, 30/19 Partial 
Duplex, 25/19 Partial Duplex, and 20/19 Partial Duplex. 
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Time course experiments were carried out as described for the polarity experiments, with 
20 μL 5 minute time points (Figure 4.9). These showed that PFEIF4A unwinding 
experiments on substrates with shorter single-stranded overhangs reached completion 
quicker than those with longer single-stranded overhangs. The exception was the 20/19 
Partial Duplex substrate with a 1 nucleotide (nt) overhang (187.59 ± 24.30 fmol min
-1
), 
which took longer than both the 30/19 (198.02 ± 28.42 fmol min
-1
) and 25/19 (294.01 ± 
14.21 fmol min
-1
) Partial Duplex substrates with 11 and 6 nt overhangs respectively. 
 
4.1.6 Ribonucleic Acid (RNA) Unwinding Activity 
EIF4A is a well researched RNA helicase with plant and animal orthologues, and was first 
purified in the 1970s (Rogers et al. 2002). Despite EIF4As ability to unwind RNA:DNA 
and DNA:RNA hybrid substrates, it does not seem capable of unwinding dsDNA (Rogers 
et al. 2001). Given that all the substrates used in this study so far had been dsDNA, new 
substrates, based on the Fork 1 substrate, were designed to reveal any difference between 
PFEIF4A activity against DNA:RNA and RNA:DNA heteroduplexes, and dsRNA (Figure 
4.10). 
 
 1 2     3     4      5     6 
 
Figure 4.10 DNA and RNA Fork 1 Substrates. 15 % SDS PAGE gel of substrates 31 to 
33 as described in Table 2.3. Lanes 1 to 4 show the dsDNA, the DNA:RNA and RNA:DNA 
hybrids, and the dsRNA Fork substrates respectively. Lane 5 and 6 show the 5’ fluorescein 
labelled oligonucleotides 4 and 31 respectively (Appendix 1). 
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Time course experiments were performed to examine PFEIF4A activity against the DNA, 
RNA and hybrid Fork 1 substrates. Due to the observed thermal instability of the 
RNA:DNA hybrid, a single room-temperature time point control at zero minutes and 37 °C 
controls at the subsequent time points were taken. In addition, due to concerns about the 
hybrid substrates stability, the reactions were stopped with 5 µL of 5 × modified 
 
 
 1 2 3 4 5 6 7 8 9 
 
Figure 4.11 PFEIF4A Ribonucleic Acid (RNA) Unwinding Activity. Graph A shows the 
unwinding activity of PFEIF4A on DNA, RNA, and DNA:RNA and RNA:DNA hybrids. 
The white circles represent the percentage of the primary substrate for the RNA:DNA 
hybrid substrate at the given time points, and the solid line represents their line of best fit. 
The black circles represent the percentage of the primary substrate for the dsDNA substrate 
at the given time points, and the wide-spaced dashed line represents their line of best fit. 
Graph B shows the comparative unwinding rates (fmol min
-1
) of PFEIF4A on the 
RNA:DNA hybrid and dsDNA forked substrates. The 6 % native PAGE gel (C) is an 
example result for the dsRNA substrate. Lane 1 shows the 0 minute control, lanes 2, 4, 6, 
and 8 show the 5, 10, 15, and 20 minute control samples respectively, while lanes 3, 5, 7, 
and 9 show the samples incubated with PFEIF4A at 5, 10, 15, and 20 minutes respectively.  
C 
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termination buffer, which did not contain SDS. Furthermore, the reactions were run on 
native PAGE gels at 100 V for 1 hour at 4 °C (Figure 4.11). 
These experiments show that PFEIF4A unwinds DNA:RNA and RNA:DNA hybrids, and 
dsDNA substrates of equal topology to the same degree; 65.58 ± 2.25, 68.49 ± 3.12, and 
74.49 ± 2.76 fmol min
-1
 respectively. However, it appeared that the dsRNA substrate was 
not unwound in the presence of PFEIF4A. 
 
4.1.7 Cofactor Requirement 
Interest in the general requirements of PFEIF4A for full activity led to experiments being 
designed to elucidate PFEIF4As divalent metal cofactor requirement. In these experiments, 
rather than using the assay buffer as described under the helicase assay, buffers where the 
MgCl2 was substituted with alternative biologically relevant metal salts were used. Under 
these modified conditions, a series of 50:1 PFEIF4A to 36/18 Partial Duplex ratio (5:0.1 
µM) time courses with 20 μL 5 minute time points were performed (Figure 4.12). 
These showed that the most effective cofactor for PFEIF4A helicase activity was Mg
2+
 
cations (175.48 ± 2.04 fmol min
-1
), and although unwinding activity was observed in the 
presence of Mn
2+
 cations it was notably down-regulated (34.39 ± 1.57 fmol min
-1
). Neither 
Zn
2+
 or Ca
2+
 cations supported unwinding, and the EDTA control show total inhibition of 
helicase activity. 
 
4.1.8 Optimum Working Temperature 
Additional experiments were also carried out to determine PFEIF4A’s optimum working 
temperature range. Reagents were pre-incubated at various temperatures (22, 27, 30, 34, 
37, 40, and 45 °C) prior to carrying out the time course reactions. 
20 μL 5 minute time points were set-up under the conditions described under the helicase 
assay with a 50:1 PFEIF4A to 36/18 Partial Duplex ratio (5:0.1 μM) (Figure 4.13). 
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The results show that PFEIF4A has a broad active temperature range between 27-37 °C 
where the extent of unwinding was similar, although 37 °C appears to be the optimum 
(175.42 ± 2.01 fmol min
-1
). Interesting, despite the flexibility in the lower range 
temperatures, activity was markedly lower at 40 °C and above (50.64 ± 2.83 fmol min
-1
). 
Furthermore, experiments carried at 37 °C using PFEIF4A pre-incubated at 40 °C reveals 
that the loss in activity was not recoverable. 
 
Figure 4.12 PFEIF4A Cofactor Requirements. Graph A shows the unwinding activity of 
PFEIF4A on substrate 7 as described in Table 2.3. The white circles represent the 
percentage of the primary substrate at the given time points in the presence of Mg
2+
, and the 
solid line represents their line of best fit. The black circles represent the percentage of the 
primary substrate at the given time points in the presence of Mn
2+
, and the wide-spaced 
dashed line represents their line of best fit. The white squares represent the percentage of 
the primary substrate at the given time points in the presence of Zn
2+
, and the wide-spaced 
dotted line represents their line of best fit. The black squares represent the percentage of the 
primary substrate at the given time points in the presence of CaCl2, and the close-spaced 
dashed line represents their line of best fit. The white triangles represent the percentage of 
the primary substrate at the given time points in the presence of EDTA, and the close-
spaced dotted line represents their line of best fit. The comparative unwinding rates (fmol 
min
-1
) of PFEIF4A in the presence of MgCl2 and MnCl2 are shown in Graph B. 
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4.1.9 Nucleotide Triphosphate (NTP) Usage 
The 3’-5’ 50/19 Partial duplex described in Figure 4.7 was used to explore PFEIF4As NTP 
usage. Time course reactions with 20 μL 5 minute time points were set-up under the 
conditions described for the helicase with a 50:1 ratio (5:0.1 μM) of PFEIF4A to 50/19 
Partial Duplex (3’-5’). These experiments were supplemented with or without the presence 
of ATP, TTP, GTP, CTP, UTP, dATP, dTTP, dGTP, dCTP, di (ADP) and mono (AMP) 
adenosine phosphate, and the ATP analogues adenosine 5’-O-(3-thio)triphosphate 
(ATPγS) and adenosine 5’-(β,γ-imido)triphosphate (AMP-PnP) (Figure 4.14). 
These experiments showed in addition to ATP (63.55 ± 2.67 fmol min
-1
), dCTP (53.04 ± 
1.24 fmol min
-1
) and dGTP (37.89 ± 0.89 fmol min
-1
) showed a marked increase in 
 
Figure 4.13 PFEIF4A Optimum Working Temperatures. Graph A shows the degree of 
unwinding at various temperatures by PFEIF4A on substrate 7 as described in Table 2.3. 
The percentage of the primary substrate at the given time points for the reaction 
temperatures 22, 27, 30, 34, 37, 40, and 45 °C, are represented by the white circles, black 
circles, white squares, black squares, white triangles, black triangles, and inverted white 
triangles respectively. The initial rates of the reactions at each temperature are represented 
by the solid (22 °C), the wide-spaced dashed (27 °C), the wide-spaced dotted (30 °C), the 
close-spaced dashed (34 °C), the close-spaced dotted (37 °C), the dot-dashed (40 °C), and 
the dot-dot-dashed lines (45 °C). Graph B illustrates in the increased rate of unwinding 
(fmol min
-1
) from 22 to 37 °C followed by the dramatic decrease at 40 °C. 
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Figure 4.14 PFEIF4A Nucleotide Triphosphate (NTP) Usage. Graphs showing PFEIF4A unwinding 50/19 Partial Duplex (3’-5’) (substrate 23 in Table 2.3) 
in the presence of various NTPs, dNTPs, and ATP analogues. Graph A shows the percentage of the primary substrate at the given time points under passive and 
active (ATP) unwinding conditions, represented by the white circles with the solid line of best fit and the black circles with the wide-spaced dashed line of best 
fit respectively. On the same graph, the percentage of the primary substrate at the given time points for unwinding in the presence of TTP, GTP, CTP, and 
UTP, are represented by the white squares, black squares, white triangles, and black triangles respectively. Their lines of best fit are represented by the wide-
spaced dots (TTP), close-spaced dashes (GTP), close-spaced dots (CTP), and dot-dashes (UTP). Graph B shows the percentage of the primary substrate at the 
given time points in the presence of dATP (white circles), dTTP (black circles), dGTP (white squares), and dCTP (black squares). Their lines of best fit are 
represented by the solid line, the wide-spaced dashes, the wide-spaced dots, and the close-spaced dashes respectively. Graph C shows the percentage of the 
primary substrate at the given time points in the presence of ADP (white circles), AMP (black circles), ATPγS (white squares), and AMP-PnP (black squares). 
The solid, wide-spaced dashes, wide-spaced dots, and the close-spaced dashes illustrate their lines of best fit respectively. The unwinding rates (fmol min
-1
) of 
PFEIF4A in the presence of each NTP, dNTP, and ATP analogues are represented graph D. PFEIF4As passive rate is shown in white as the left-most column 
and the dashed line represents its rate for easy comparison. All other columns are shaded according to their respective graphs; light grey columns are the rates 
taken from graph A, medium grey columns are the rates taken from graph B, and the dark grey columns are the rates taken from graph C. 
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PFEIF4As unwinding activity when compared to its passive activity (31.28 ± 0.75 fmol 
min
-1
). Furthermore, a marked inhibition of PFEIF4As passive activity was observed when 
in the presence of ATPγS (15.61 ± 0.36 fmol min-1) and AMP-PnP (9.24 ± 0.14 fmol min-
1
). 
 
4.1.10 Electrophoretic Mobility Shift Assay (EMSA) 
Based on the observations made in the previous section (4.1.9) that PFEIF4A passive 
activity was inhibited in the presence of AMP-PnP, gel shifts exploring PFEIF4As’ 
binding affinity for ssDNA and dsDNA, and for substrates with one single-stranded 
overhang and two single-stranded overhangs were performed. 20 μL reactions were set-up 
under the conditions described for the helicase assay, differing only in that ATP was 
substituted for AMP-PnP. Based on low interactions observed previously at ratios less than 
50:1, reactions for each substrate were performed at 50, 100, 200, 300, and 400:1 PFEIF4A 
to DNA concentrations (Figure 4.15). 
This showed that PFEIF4A has a relatively high affinity for DNA substrates with one or 
more free single-stranded ends (Kd = 4.0313 ± 0.9076 µM) compared to a blunt ended 
dsDNA substrate (Kd = 45.7427 ± 11.6439 µM). 
Helicase assays have shown that PFEIF4A unwinds DNA, RNA, and hybrid substrates to 
the same extent (4.1.6). Additional gel shift experiments were carried out in order to 
scrutinise any binding preference to DNA or RNA. Experiments were performed as 
described above, using single-stranded and double-stranded DNA and RNA substrates. 
These experiments revealed that PFEIF4As’ binding affinity for RNA is similar to that of it 
binding affinity for DNA. With a Kd of 5.4272 ± 0.4457 and 4.6803 ± 0.7250 µM for 
ssRNA and dsRNA respectively, compared to 8.974 ± 0.8325 and 5.7759 ± 0.9235 µM for 
ssDNA and dsDNA respectively (Figure 4.16). 
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Figure 4.15 Comparative Analysis of PFEIF4A Binding. Graph A shows the percentage 
of DNA bound by PFEIF4A at the given concentrations along the x-axis (µM). The white 
circles represent the percentage of ssDNA (oligonucleotide 11, Appendix 1) bound, and the 
solid line represents their line of best fit. The black circles represent the percentage of 
dsDNA (substrate 12, Table 2.3) bound, and the wide-spaced dashes represent their line of 
best fit. The white squares represent the bound percentage of the 50/19 Partial Duplex 
substrate (substrate 23, Table 2.3), and the wide-spaced dots represent their line of best fit. 
The black squares represent the bound percentage of the Fork 1 substrate (substrate 10, 
Table 2.3), and the close-spaced dashes represent their line of best fit. Data is fit to a single 
site ligand binding curve. Graph B shows the associated Kd measurements (µM). This 
reveals a relatively higher affinity of PFEIF4A to DNA substrates with ssDNA regions; 
7.1142 ± 1.1836, 8.7037 ± 1.4786, and 4.0313 ± 0.9076 for ssDNA, the 50/19 Partial 
Duplex, and the Fork1 substrate respectively, versus blunt ended DNA substrates (45.7427 
± 11.6439). 
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4.1.11 ATPase Activity 
PFEIF4A’s ATPase activity in the presence of single-stranded and double-stranded DNA, 
as well as the Fork 1 substrate was measured with a series of reverse time courses at 50:1 
molar ratios of PFEIF4A (50 µM) to substrate (1 µM). Each time course was performed as 
described under the malachite green ATPase assay. The resulting data was corrected for 
background ATP degradation, calculated from successive time points using the same 
parameters as the Fork 1 time course, only without any helicase present (Figure 4.17). 
 
Figure 4.16 Comparative Analysis of PFEIF4A Binding to DNA and RNA Substrates. 
Graph A shows the percentage of the substrates bound by PFEIF4A at the given 
concentrations along the x-axis (µM). The white circles represent the percentage of ssDNA 
(oligonucleotide 4, Appendix 1) bound, and the solid line represents their line of best fit. 
The black circles represent the percentage of ssRNA (oligonucleotide 25, Appendix 1) 
bound, and the wide-spaced dashes represent their line of best fit. The white squares 
represent the bound percentage of the dsDNA Fork 1 substrate (substrate 10, Table 2.3), 
and the wide-spaced dots represent their line of best fit. The black squares represent the 
bound percentage of the dsRNA Fork 1 substrate (substrate 27, Table 2.3), and the close-
spaced dashes represent their line of best fit. Data is fit to a single site ligand binding curve. 
Graph B shows the associated Kd measurements (µM). This reveals that PFEIF4A has the 
lowest affinity to the ssDNA substrates, with a Kd of 8.974 ± 0.8325, while its affinity for 
ssRNA and both the dsDNA and dsRNA Fork 1 substrates are all similar; 5.4272 ± 0.4457, 
5.7759 ± 0.9235, and 4.6803 ± 0.7250 respectively. 
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These experiments show that PFEIF4A has a background ATP turnover rate of 23.16 ± 
1.74 pmol min
-1
. Despite previous observations suggesting that blunt end dsDNA was not 
unwound, the comparative levels of evolved Pi from ATPase activity in the presence of 80 
bp Blunt Duplex, as well as ssDNA and the Fork 1 substrate, doubles to 42.92 ± 3.21 pmol 
min
-1
. 
The luciferase ATPase assay was carried out alongside the malachite green ATPase assay. 
However, due to its higher level of sensitivity it could be performed under the standard 
 
Figure 4.17 PFEIF4A ATPase Activity measured using the Malachite Green Assay. 
Graph A shows the amount of evolved inorganic phosphate (Pi) from the hydrolysis of ATP 
by PFEIF4As ATPase activity. The white circles represent the amount of Pi evolved in the 
presence of ssDNA (oligonucleotide 11, Appendix 1), and the solid line represents their 
line of best fit. The black circles represent the amount of Pi evolved in the presence of 
dsDNA (substrate 12, Table 2.3), and the wide-spaced dashes represent their line of best fit. 
The white squares represent the amount of Pi evolved in the presence of the Fork 1 substrate 
(substrate 10, Table 2.3), and the wide-spaced dots represent their line of best fit. The black 
squares represent the amount of Pi evolved without any DNA present, and the close-spaced 
dashes represent their line of best fit. Graph B shows the rate of inorganic phosphate 
evolved (pmol min
-1
), revealing an idle ATPase rate (without DNA) of 23.16±1.74 pmol 
min
-1
. The turnover rate was enhanced by the addition of DNA, with a comparative increase 
to 40.38±2.12 pmol min
-1 
in the presence of ssDNA, 37.50±3.51 pmol min
-1 
for dsDNA, 
and 42.92±3.21 pmol min
-1 
for the Fork 1 substrate. 
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helicase conditions of 5 µM PFEIF4A, 0.1 µM DNA substrate, and 1 mM ATP (Figure 
4.18). 
 
Despite giving slightly higher ATP hydrolysis rates (6.00 ± 0.90 pmol min
-1
), when taking 
into account initial ATP concentrations for each assay, it also showed that PFEIF4A 
ATPase activity was not affected by DNA substrate topology. However, it did not report 
any background ATP turnover. 
 
 
Figure 4.18 PFEIF4A ATPase Activity measured using the Luciferase Assay. Graph A 
shows the amount of unused ATP during PFEIF4A ATPase activity. The white circles 
represent the concentration of ATP (nmol) at the given time points in the presence of 
dsDNA (substrate 12, Table 2.3), and the solid line represents their line of best fit for 
minutes 0 to 35. The black circles represent the concentration of ATP at the given time 
points in the presence of ssDNA (oligonucleotide 11, Appendix 1), and the wide-spaced 
dashes represent their line of best fit for minutes 0 to 35. Finally, the white squares 
represent the concentration of ATP at the given time points in the presence of the Fork 1 
substrate (substrate 10, Table 2.3), and the wide-spaced dots represent their line of best fit 
for minutes 0 to 35. Graph B shows the initial rates of ATP hydrolysis (pmol min
-1
); 6.00 ± 
0.90, 6.30 ± 1.50, and 6.60 ± 1.70 pmol min
-1 
in the presence of dsDNA, ssDNA, and the 
Fork 1 substrate respectively. 
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4.1.12 Triplex Displacement Assay 
Based on the observation that PFEIF4A ATPase activity is stimulated in the presence of 
the 80 bp Blunt Duplex substrate, despite appearing not to unwind blunt end DNA 
duplexes, helicase assays were performed on blunt ended dsDNA substrates with either a 
5’ or 3’ triplex. The triplex forming oligonucleotide (TFO) was 32P-radiolabelled by 
Mervyn Middleton (University of Portsmouth, Hampshire, UK) and the triplexes were 
formed as described by Firman et al. (2000) using the blunt end dsDNA substrates 34 and 
35, containing a 5’ and 3’ triplex binding site respectively (Table 2.3). 
 
A 1 2  3 4 5 6  7 
 
B   1   2   3   4  5 6  7 
 
Figure 4.19 Triplex Displacement from a Blunt-End dsDNA Substrate by PFEIF4A.  
6% native PAGE gels showing dsDNA substrates (substrates 34 and 35, Table 2.3) with 
either a 3’ bound triplex (A) or a 5’ bound triplex (B). The lanes on both gels are labelled 1 
to 7. Lane 1 contains the 0 minute control sample, while lanes 2 to 7 contain the 10, 20, 30, 
40, 50, and 60 minute time point samples. For both gels, the triplex substrate is indicated by 
the black arrow, while the free 
32
P-TFO is indicated by the red arrow. Triplex displacement 
is not observed on either the 3’ or 5’ triplex substrate. 
► 
► 
► 
► 
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1 hour time course experiments with 10 minute time points were carried out at a 50:1 
PFEIF4A to substrate molar ratio (500:10 nM). The reactions at each time point were 
stopped with 5 × modified termination buffer, did not contain SDS, and the samples were 
run on native PAGE gels (Figure 4.19). 
The results show that the TFO was not displaced from either of the two duplex DNA 
substrates when incubated with PFEIF4A. 
 
4.1.13 Developing a High-Throughput Helicase Assay 
The gel based nature of the helicase assay used thus far made it a relatively drawn out 
process. Now that sufficient biochemical characterisation had been performed, an 
alternative high-throughput protocol was sought after for future work. 
DNA binding dyes can be detected and recorded in real-time using a fluorescence 
microplate reader, effectively eliminating the error-prone aspect of extracting the gel data 
using densitometry. Several DNA reporter compounds were researched, leading to DNA 
binding dyes; Hoechst (Latt et al. 1975), PicoGreen (Ahn et al. 1996), and BOXTO 
(Eriksson et al. 2003; Karlsson et al. 2003) being investigated. In preliminary experiments, 
20 µL reactions containing the dyes with various duplex DNA substrates were assessed. 
These used the same conditions and buffer parameters of the gel based helicase assay 
(excluding the presence of a helicase) and were carried out and visualised on native PAGE 
gels using a Fujifilm FLA-5000 phosphoimager with a blue laser (473 nm) at 550 V and a 
green filter (532 nm). BOXTO gave the best measurable results, with a distinguishable 
difference between the boiled samples (in ssDNA from) and the intact (dsDNA) substrates 
at a 5:1 BOXTO to DNA molar ratio. Furthermore, this relationship could be reproduced 
on the fluorescent microplate reader (Figure 4.20). 
When a helicase assay was attempted, the presence of the protein affected the fluorescence 
of BOXTO, making the helicase unwinding sample and the non-helicase control sample 
difficult to compare during data interpretation. This was overcome based on the 
observation that Mg
2+
 was required for unwinding to take place (4.1.7), by making up the 
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control sample with the helicase present but substituting the Mg
2+
 for EDTA in the assay 
buffer (Figure 4.21). The final protocol is outlined in chapter two. 
 
4.2 PFDH60 
Some characterisation of PFDH60 had been undertaken (Pradhan et al. 2005; Pradhan et 
al. 2006; Pradhan et al. 2007; Pradhan et al. 2008), but as mentioned previously, these 
studies used a truncated form of the protein (58.8 kDa). In silico techniques revealed 
shared identity with the DEAD-box containing helicases. Optimal activity was observed in 
the presence of 1 mM ATP, 30 mM KCl, and 1 mM MgCl2 (Pradhan et al. 2005; Pradhan 
et al. 2007). However it has comparable activity in the presence Mn
2+
 in place of Mg
2+ 
(Pradhan et al. 2007). It was active across a broad pH range (Pradhan et al. 2005; Pradhan 
et al. 2007), it was expressed in the Schizont life stage of the Plasmodium falciparum 
parasite (Pradhan et al. 2005; Pradhan et al. 2007), it was bipolar, unwinds duplex DNA 
 
Figure 4.20 BOXTO Incubated with the Fork 1 Substrate. The graph shows the relative 
fluorescence of the Fork 1 substrate (dsDNA) shown in white and its boiled counterpart 
(ssDNA) shown in grey. The 5:1 BOXTO to Fork 1 substrate incubation shows the greatest 
discrimination between single- and double-stranded DNA, while the 1:1 shows very little, 
and the 10:1 shows similar discrimination but also shows an increase in background 
fluorescence associated with ssDNA. 
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Figure 4.21 BOXTO Helicase Assay of PFEIF4A Titrations against the Fork 1 Substrate. Graph A shows a single experimental output obtained from the 
BOXTO helicase assay at 50:1, PFEIF4A to Fork 1 substrate molar ratio, while graph B shows the line of best fit for the average of three sets of output data 
with the error bars shown in grey. The data is corrected for any photobleaching, by subtracting its corresponding negative control, and its end point 
determined from its corresponding positive (boiled) control. Data is fit to a single exponential decay curve. Graph C shows the lines of best fit for the 
averaged results from a series of titrations of PFEIF4A to the Fork 1 substrate, ranging from 10:1 to 50:1 molar ratios; the solid, wide-spaced dashed, wide-
spaced dotted, close-spaced dashed, and the close-spaced dotted line represents their line of best fit. The error bars and a 0:1 ratio experiment, that showed no 
unwinding, has been omitted for clarity. 
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and RNA (Pradhan et al. 2005), and it was stimulated upon phosphorylation at serine and 
threonine residues (Pradhan et al. 2005). Its helicase activity can be supported by dATP 
instead of ATP and was inhibited by ATPγS (Pradhan et al. 2005; Pradhan et al. 2007). 
Moreover, ATPase and ATP binding was stimulated in the presence of ssDNA (Pradhan et 
al. 2007). 
 
4.2.1 In silico Analyses 
Like PFEIF4A, PFDH60 was analysed using a variety of in silco techniques. An initial 
search using its codon-optimised DNA sequences (Appendix 9) with the BLAST server 
(Altschul et al. 1990; Johnson et al. 2008) revealed sequence identity to multiple DEAD 
box helicases. Its most similar was ATP-Dependant RNA Helicase from Theileria parva, 
echoing PFEIF4A highest BLAST hit from T. annulata. An alignment of PFDH60 
sequence with that of ATP-Dependant RNA Helicase (NCBI accession number: 
XP_762954.1), using ALIGN (Myers et al. 1988) (Appendix 10) reveals a sequence 
identity of 30.8 %, with the conservation mostly located around the core SF2 family motifs 
(Figure 4.22). 
 
 
 
 
 
Figure 4.22 Schematic Based on ALIGN results of PFDH60 and ATP-Dependant RNA 
Helicase. Each diagram represents the SF2 motifs present in PFDH60 (top) and ATP-
Dependant RNA Helicase (bottom), showing the N-termini on the left and C-termini on the 
right. Open boxes represent the conserved helicase motifs, and letters inside the boxes are 
the amino acid sequences of each motif. With only motifs Ia, the GG doublet, II, and VI 
sharing 100 % identity, there is a lot of sequence variation between PFDH60 and even it 
most similar BLAST result. Labels above the open boxes are the names assigned to the 
motifs. The spaces between motifs are arbitrary and not representative of either protein. 
Conserved Helicase Motifs of PFDH60 and ATP-Dependant RNA Helicase 
Q 
KFSEPTAIQ 
GG 
Doublet 
GG 
Ib 
TPGR AETGSGKT 
I 
DEAD 
II 
TAT 
III 
ILIFCDTK 
IV 
SRGLD 
V 
HRIGRTGR 
VI 
PTRELC 
Ia 
NFTEPTPIQ SQTGSGKT PTRELC GG TPGR DEAD SAT VLIFSDLK ARGLD HRIGRTGR 
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Its highest human protein BLAST result was DEAH-box peptide 16 (DHX16; NCBI 
accession number: CAP58465.1) (Appendix 11), which when compared using ALIGN 
(Myers et al. 1988) reveals a sequence identity of only 13.3 %. 
 
4.2.2 Substrate Specificity Screen 
An initial screen for helicase activity was carried out on all 12 substrates shown in Figure 
2.6. In short, 20 μL reactions were performed with 1 µM PFDH60 and 100 nM DNA 
substrate (10:1 ratio). Reactions were incubated at 37 °C for 1 hour and stopped with 5 µL 
of 5 × termination buffer prior to running on SDS PAGE gels (Figure 4.23). These 
experiments showed PFDH60 to unwind all of the substrates with no apparent 
discrimination to substrate topology. 
 
4.3 Discussion 
The biochemical analysis described in this chapter has confirmed much of the original 
characterisation performed by the Tuteja group (Pradhan et al. 2005; Pradhan et al. 2006; 
Pradhan et al. 2007; Pradhan et al. 2007; Pradhan et al. 2008).  However, it has also 
expanded and elucidated further information regarding the helicase and ATPase activities 
of PFEIF4A and PFDH60 which can be used when considering both proteins as novel anti-
malarial drug-targets. 
 
4.3.1 PFEIF4A 
In silico techniques revealed that PFEIF4A is significantly similar to human EIF4A1 with 
the core helicase domains and motifs. The biological importance of EIF4A to the 
eukaryotic cell is well established (Rogers et al. 1999; Rogers et al. 2001; Rogers et al. 
2001; Rogers et al. 2002; Rozovsky et al. 2008) and if PFEIF4A is revealed to be equally 
vital to P. falciparum, it would make an attractive anti-malarial target. 
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Figure 4.23 PFDH60 Substrate Specificity Screen. 15 % SDS PAGE gels visualised using a Fujifilm FLA-5000 phosphoimager with a blue laser (473 nm) at 
550 V and a green filter (532 nm), showing PFDH60 activity on fluorescein labelled substrates with various topologies as described by Özsoy et al. (2003) 
(Figure 4.3). Above each gel is a representative diagram of the substrate relating to that gel and its associated name as designated by Özsoy et al. (2003). The 
solid black triangle identifies the corresponding band for each of the primary substrates being screened against. Each gel lane is numbered 1-4; lane 1 contains 
the 37°C control while lane 2 contains the substrate after treating with PFDH60. All of the gels show complete unwinding of the primary substrate after 1 hour 
at 37°C. 
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The standard helicase unwinding assay performed by the Tuteja group incorporated a 
PFEIF4A to substrate ratio of 750:1 with only ~65-70 % of the substrate being unwound 
after 1 hour at 37 °C (Pradhan et al. 2007). However, the work in this chapter with protein 
from codon-optimised clones has shown complete unwinding of preferential substrates at 
PFEIF4A to substrate ratios at as low as 30:1 under the same conditions. A possible 
explanation for the discrepancy was that the Tuteja work was done at the femtomole (fmol) 
range, while the work presented here was in picomole (pmol) range. Therefore the 
frequency of interaction would be higher. 
The titrations of PFEIF4A to the various substrates elucidated six preferentially unwound 
substrates. Apparent unwinding at higher concentrations of non-preferential substrates was 
likely due to opportunistic binding of thermally-frayed ends. Based on the preferential 
substrates, it appeared that PFEIF4A required a single-stranded overhang, and consistent 
with Pradhan (2007), this can be either a 3’ or 5’ overhang. However, the 5’ overhang 
substrate (5’ Fork) was not fully unwound after the 1 hour incubation. Interestingly, based 
on the observations on the 4 bp and 12 bp bubble substrates, a single-stranded region was 
not adequate to stimulate nucleic acid unwinding, but instead PFEIF4A requires a free 
single-stranded overhang. The discrepancy between unwinding of Fork 1 and Fork 2 might 
be explained by the bubble-like structure conferred by small regions of complementary 
sequence in the Fork 2 free single-stranded ends (Table 4.2). Any observable unwinding 
may be due to a dynamic equilibrium of forked and bubble-like substrates, with only the 
former supporting unwinding. 
The PFEIF4A Specific Substrate Screen showed that PFEIF4A can resolve DNA 
substrates containing hairpin structures providing they have a free single-stranded 
overhang. Similar to the Substrate Specificity Screen and helicase titrations however, the 
degree of unwinding of substrates with a 3’ single-stranded overhang and those of a 5’ 
single-stranded overhang were not equal. The Substrate Polarity Screen, contrary to 
previous observations made by Pradhan (2007), suggests that only unwinding activities in 
the 3’-5’ direction were stimulated approximately two-fold in the presence of ATP. 
The Single-Stranded Overhang Requirements show that PFEIF4A duplex unwinding is 
supported by the presence of a single nucleotide overhang, albeit slower than for a 
substrate with a 6 nucleotide overhang. This was likely because one nucleotide was a 
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smaller ‘target’, affectively decreasing the likelihood of a chance encounter between 
PFEIF4A and the substrate. The associated increase in unwinding rate with the shortening 
of the overhang also suggest that PFEIF4A ‘threads’ over the single-stranded overhand, 
offering credibility to its absolute requirement for a free single-stranded overhang and that 
a single-stranded region, as exampled by the 4 bp and 12 bp bubble substrates, was not 
sufficient to support unwinding. 
 
Other work from the Tuteja group has shown PFEIF4A to bind (Pradhan et al. 2008) and 
unwind (Pradhan et al. 2007) both DNA and RNA. Likewise, the results presented here 
have shown that its unwinding activity was unaffected by the incorporation of an RNA 
strand to form a both DNA:RNA and RNA:DNA hybrid substrates, but curiously the 
dsRNA substrate was not unwound. Although PFEIF4As activity on other dsRNA 
substrates or differing sequence and topologies would be beneficial, this observation does 
present a stark difference between the P. falciparum and human forms of EIF4A. 
 
 
Constituent Oligonucleotide Sequences Revised Structure 
 
5’ GACGCTGCCGAATTCTGGCTTGCTAGGACATCTTTGCCCACGTTGACCCG 
   |||||||||||||||||||||||||||||||  :  :    :   : : 
3’ CTGCGACGGCTTAAGACCGAACGATCCTGTACGACAGATCTCTGATAGCG 
 
 
 
5’ GACGTCATAGACGATTACATTGCTAGGACATGCTGTCTAGAGACTATCGC 
   ::::     ::    :   ||||||||||||||||||||||||||||||| 
3’ CTGCGACGGCTTAAGACCGAACGATCCTGTACGACAGATCTCTGATAGCG 
 
 
 
Table 4.2 Revised Structure of Fork 2. The oligonucleotide sequences used to construct 
the Fork 1 and 2 substrates described by Özsoy (2003) (substrate 10 and 11 in Table 2.3 
respectively) were scrutinised using OligoAnalyzer 3.1 (Intergrated DNA Technologies). 
The predicted heterodimers with the highest Gibbs functions (∆G), -63.52 and -54.78 kcal 
mol
-1
 for the Fork 1 and Fork 2 substrates respectively, are shown in the first column. The 
solid line between the upper and lower sequence represent strong base pair interactions, 
whereas the dotted lines represent weak base pair interactions. The second column contains 
the relative schematic for each substrates structure. The structure for Fork 1 is the same as 
described in Table 2.3; however the structure for Fork 2 is revised based on the heterodimer 
sequence. 
* 
19nt 
19nt 
31bp 
31bp 
* 
 
143 
Both the results presented here and in those previously reported by Pradhan (2007) identify 
PFEIF4As reliance and optimal unwinding activity in the presence of Mg
2+
. 
Approximately 20 % of PFEIF4As activity can be recovered by Mn
2+
, the inability of the 
other cations studied here to stimulate helicase activity may be due to their increased 
atomic radii when compared to Mg
2+
. 
In addition, this work has recognised PFEIF4A’s broad active-temperature range either 
side of its 37 °C optimum. However, a decrease in helicase activity was observed at 40 °C. 
Furthermore, this loss in activity appears to be unrecoverable. 
As per Pradhan et al. (2008) this work also reports an optimal unwinding activity in the 
presence of ATP. However, the Tuteja group described dATP, dCTP, and UTP as 
alternative hydrolysis substitutes, whereas work presented here only identifies dCTP and 
dGTP as being capable of supporting significant helicase activity. It should be noted that 
the Tuteja group did not identify any passive (without ATP) activity of PFEIF4A, making 
comparative observations as to the degree of significant unwinding difficult. 
The EMSA experiments show that PFEIF4A has comparative dissociation constants (Kd) 
for ssDNA (JS80), the 50/19 Partial Duplex, and the Fork 1 substrate. This correlates with 
the previous observation that PFEIF4A helicase activity has an absolute requirement for a 
single-stranded overhang. The reported Kd for the dsDNA (80 bp Blunt Duplex) obtained 
from the GraFit5 software package appears relatively high when compared to a visual 
reading from the graph (A), which places the Kd between 20 and 25 µM. This was likely 
due to the incompleteness of the data, where the percentage bound of dsDNA never 
reaches 100 %, making it harder to forecast an accurate Kd. The reported Kd for the ssRNA 
was similar to that of the ssDNA, supporting the observation that DNA:RNA and 
RNA:DNA hybrid substrates were unwound to the same degree as dsDNA substrates of 
equal topology. However, the reported Kd for the equivalent dsRNA substrate was equally 
similar despite a lack of observable unwinding. 
The hydrolysis of ATP by PFEEIF4A has been reported by Pradhan (2007). However, this 
work has expanded on this to show nucleic acid presence stimulates PFEIF4As ATPase 
activity, and that despite preferential substrates for unwinding, DNA substrate topology 
does not affect it. The apparent background ATP turnover suggested by the no DNA 
control may be due to residues with hydrophobic side chains, as hydrophobic groups have 
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been shown to interact with ammonium molybdate causing it to crash out of solution 
giving false positives (Feng et al. 2011). Arginine (R), Asparagine (N), Glutamine (Q), and 
Lysine (K) make up 5.6, 2.8, 4.6, and 6.7 % of PFEIF4A’s amino acid composition and all 
contain hydrophobic side chains. 
When considering that the malachite green assay was performed at ten-fold higher 
concentrations of PFEIF4A, DNA substrates, and ATP to those used during the luciferase 
ATPase assays, they gave proportionally similar results regarding DNA topology. The 
initial rates taken from the luciferase assay were slightly higher and background ATP 
turnover was not apparent. This was likely due to the luciferase assay reportedly being a 
more sensitive technique. The NADH ATPase assay did not yield any discernible data. 
The triplex displacement assays did not show any apparent displacement of the TFO on 
either of the substrates. This could be due to PFEIF4A not being capable of translocating 
dsDNA, or that due to its high Kd for dsDNA when it encounters the TFO it simply 
dissociates from the duplex leaving the TFO bound. Further experiments at increasing 
concentrations of PFEIF4A might show displacement of the TFO, offering weight to the 
latter theory. 
BOXTO concentration used in the high-throughput assay was similar to the 3:1 BOXTO to 
dsDNA optimum ratio described by Ahmad (2007). The ability to discriminate between 
ssDNA and dsDNA at a 3:1 was not largely improved, and a 5:1 ratio gave a greater 
overall fluorescence output. It was for these reasons that a 5:1 was used to perform the 
assay thereafter. 
The assay itself showed comparable amounts of unwinding to those obtained from the gel 
based assay, with both the assays showing 100 % of the substrate being unwound at 
approximately 30 minutes at a molar ratio of 50:1, PFEIF4A to the Fork 1 substrate. 
However, the initial rates obtained over the first 15 minutes from each method are notably 
different; 74.49 ± 2.76 fmol min
-1
 for the gel based assay, and 113.18 ± 3.93 fmol min
-1
 for 
the BOXTO based assay. The difference is likely due to the better resolution of the 
BOXTO based unwinding. 
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Based on the Singleton et al. (2007) mode of classification, PFEIF4A is a SF2Aα helicase 
due to its 3’-5’ polarity bias (A) and its absolute requirement for a single-stranded 
overhang, indicating a passive helicase mechanism (α). 
The unwinding rate of PFEIF4A is ~1 bp s
-1
 based on the 50/19 Partial Duplex substrate 
(substrate 23, Table 2.3). However, this is assuming that the rate of translocation of 
PFEIF4A on ssDNA is the same as its dsDNA unwinding rate. If this were the case then 
the rate, in terms of base pairs per second (bp s
-1
), would have been the same for all of the 
Partial Duplex substrates of different single-stranded overhang length. Instead the rate of 
unwinding the 25/19 Partial Duplex substrate (substrate 29, Table 2.3) is ~2.5 bp s
-1
. This 
could be due to a mechanical difference in the translocation of PFEIF4A along ssDNA 
compared to the unwinding of dsDNA. Alternatively, it may be that as the single-stranded 
overhang length decreased, so its rigidity increased (Chen et al. 2012), presenting a more 
consistent topology for a chance encounter with PFEIF4A. 
 
4.3.2 PFDH60 
In silico techniques reveal a stark difference in sequence with related human proteins, 
potentially leading to a greater chance of discrimination when considering exploiting 
PFDH60 as an anti-malarial drug target. 
Unlike PFEIF4A, PFDH60 showed no discrimination between substrates during the 
Substrate Specificity Screen. Furthermore, all of the substrates were unwound at a 10:1 
PFDH60 to substrate molar ratio (1 µM to 100 nM). 
Unfortunately further experiments could not be performed, initially due to PFDH60s 
storage issues then due to time restraints. However, based on the experimentation that was 
performed, PFDH60 can be identified as a SF2β helicase, due its ability to unwind blunt-
ended dsDNA using an active helicase mechanism (Singleton et al. 2007). 
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CHAPTER FIVE: STRUCTURAL CHARACTERISATION 
 
5.1 Introduction 
Several structural-based studies (Korolev et al. 1997; Velankar et al. 1999) have elucidated 
helicase structure-function mechanisms. When combined with biochemical data, this has 
lead to proposed models for duplex unwinding (Soultanas et al. 2000; Soultanas et al. 
2001). Furthermore, the identification of interactions between specific residues and the 
substrate has  been a driving force behind mutagenic studies on the conserved helicase 
motifs (Pause et al. 1992; Korolev et al. 1998; Mahdi et al. 2003; Tanner et al. 2003), 
many of which have lead to observations of both increased (Dutta et al. 2011) and 
decreased (Garcίa-Gόmez et al. 2011) activities. 
The relatively recent field of structural-guided drug design also highlights the potential 
application of solved protein target structures which can be used to elucidate sequential 
and topological features for drug design and inhibition. Several crystal structures exist with 
the incorporation of bound inhibitors to clinically important proteins. These include 
Human Immunodeficiency Virus (HIV) 1 protease (Blum et al. 2011), dihydropteroate 
synthase from the gram-negative bacterium Burkholderia cenocepacia (Morgan et al. 
2011), and trypanothione reductase (TRYR) from the Trypanosoma brucei parasite 
(Patterson et al. 2011). High resolution Nuclear Magnet Resonance (NMR) data has also 
been used to perform in silico ligand and structural-based drug design (Hajduk et al. 2005). 
A study performed by Chen et al. (2009) expanded on the original Hepatitis C virus (HCV) 
helicase domain crystal structure (Yao et al. 1997), by crystallising an inhibitor bound 
protein which lead to the design of more potent inhibitors that suppress HCV replication. 
Studies highlighting the usefulness of known structures for in silico screening have been 
published (Kaczor et al. 2010), which in turn has lead to in silico based methodologies 
being devised such as Active Site Pressurisation (ASP) (Withers et al. 2008). 
This chapter will describe preliminary structural work on PFEIF4A and PFDH60 which 
can be used to provide a firm basis for future structural experimentation. 
 
147 
5.2 PFEIF4A 
At present only a structural comparison between the theoretical N- and C-core domains of 
PFEIF4A with human EIF4A3 has been published by the Tuteja group (Pradhan et al. 
2007). 
 
5.2.1 In silico Analysis 
The FASTA protein sequence of PFEIF4A (Appendix 7) was analysed using the Protein 
Homology/Analogy Recognition Engine (PHYRE) server version 2 (Kelley et al. 2009). 
This compares the sequence of interest with up to one-thousand protein sequences with 
known structures, with a priority for proteins with the lowest e-values based on their 
sequence alignment to PFEIF4A to generate a theoretical structure. The resulting Protein 
Database (PDB) file can then be visualised and annotated using a molecular imaging 
program (Figure 5.1). 
The resulting structure predicted for PFEIF4A showed two domains. These resembled the 
N- and C-core domains and showed the core helicase motifs lining the cleft between the 
two. It also showed a high level of superimposition with the human EIF4A isoform 1 
structure. 
 
5.2.2 Nuclear Magnetic Resonance (NMR) Spectroscopy 
All NMR experiments were kindly performed by Dr Chris Read (University of 
Portsmouth, Hampshire, UK). NMR spectroscopy was employed to evaluate the proteins’ 
suitability for more in depth structural studies. 1D NMR spectra showed multiple peaks 
suggesting some degree of tertiary structure; this was followed by multiple 2D 
Heteronuclear Single Quantum Coherence (HSQC) experiments (Bodenhausen et al. 1980) 
(Figure 5.2) on 
15
N-labelled full-length His6-T-PFEIF4A and its two subdomains. The 
subdomains were prepared by size exclusion chromatography of the degradation products 
from full-length His6-T-PFEIF4A as described under the storage conditions in chapter 
three. 
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Figure 5.1 Structural Prediction of PFEIF4A. Rendered using PyMol v0.99; render A 
shows the standard PHYRE2 server predicted structure of PFEIF4A orientated with the N-
core domain at the bottom (red) and the C-core domain at the top (blue). Render B shows 
the intensive PHYRE2 server predicted structure with its N-core domain (red) orientated to 
match that of the standard structure prediction. Its C-core domain (blue) is not only 
orientated around its N-core differently, it is also structured dramatically differently. 
Render C shows the standard structure predicted in blue overlaid with Human EIF4A1 
(PDB code; 2ZU6) shown in red. Some manipulation of the non-structured linker region 
was required to overlay both domains. Due to the high level of superimposition between the 
homologous domains, the standard structure prediction was used to annotate the core 
helicase motifs (D). The motif colour scheme of render D follows that of Figure 4.1; Q 
motif is in pink, motif I, Ia, and Ib are in red, bright green, and dark green respectively, the 
GG doublet in pale green, motif II in bright blue, motif III in yellow, motif IV in purple, 
motif V in pale blue, and motif VI in orange. 
A B 
C D 
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The initial spectra obtained from the 1D NMR showed multiple well defined peaks 
corresponding to chemical shifts associated with a folded protein. However, 2D NMR on 
the full-length protein and the N- and C-terminal domains also gave poorly resolved 
spectra. Due to the time associated collecting the NMR data and the priority focus of this 
study, no further NMR experiments were carried out. 
 
 
 
    
Figure 5.2 PFEIF4A NMR Experiments. Panel A shows the 2D spectrum from a HSQC 
experiment on a 
15
N-labelled full-length His6-T-PFEIF4A, while panels B and C show the 
spectra of its N- and C-terminal domains. After personal communication with Dr Chris 
Read, the pH was reduced in an attempt to increase resolution. However, resolution was 
decreased and the poorly defined peaks at frequencies 5.5 to 9 parts-per-million (ppm), on 
the 1D spectrum of the N-terminus (panel D) suggest a partially unfolded state. 
A B 
C D 
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5.2.3 Analytical Ultracentrifugation (AUC) 
Sedimentation AUC was performed on a 0.6 mg mL
-1
 sample of His6-T-PFEIF4A, 
correlating to 1 Absorbance Unit (AU) at 280 nm, based on PFEIF4As molar extinction 
coefficient of 29715 M
-1
 cm
-1
 calculated with ProtParam (Wilkins et al. 1999), for 100 
scans with 3 minute intervals at 45500 × g at 20 °C, based on the anticipated molecular 
weight (Chervenka 1970). The data collected was analysed using SEDFIT (Schuck 2000) 
to give some insight into His6-T-PFEIF4As size and shape (Figure 5.3). 
Based on the sedimentation coefficient (s = 3.25) and the molecular weight (Mr = 48853) 
obtained from the AUC run, a frictional coefficient ratio (f/f0) of 1.45 and a diffusion 
coefficient of 6.116 × 10
-07 
cm
2
 s
-1
 were calculated. His6-T-PFEIF4As hydrodynamic 
radius (Rh) and rotational radius (R0) were calculated as 3.50 and of 2.42 nm respectively. 
Based on the frictional coefficient ratio, axial ratios of 6.12 for an oblate ellipsoid model 
and 5.63 for a prolate ellipsoid model were also calculated. 
 
5.2.4 Small Angle X-ray Scattering (SAXS) 
Raw SAXS data was kindly collected by Dr Anastasia Callaghan (University of 
Portsmouth, Hampshire, UK). Scattering patterns were taken from successive 90 second 
exposure times. These were used to check for radiation-induced damage or aggregation of 
the protein and were performed on a range of His6-T-PFEIF4A concentrations from 1 to 10 
mg mL
-1
. The data was normalized for experimental noise, including that from the 
intensity of the incident beam and any scatter observed when analysing the blank solvent. 
Using the PRIMUS program (Konarev et al. 2003) from the ATSAS software suite 
(Konarev et al. 2006), the sample data was first normalised against the blank buffer data, 
then translated into a Guinier approximation to elucidate information on His6-T-
PFEIF4As’ radius of gyration (Rg), which was obtained from the slope of the Guinier plot. 
The same normalised data was then transformed to a Kratky plot, where a bell-shaped 
curve indicates a globular macromolecules folded state based on Porod’s law (Putnam et 
al. 2007). Using the GNOM program (Svergun 1992), also from the ATSAS software, 
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Figure 5.3 AUC Data Analysis of PFEIF4A at 45500 × g. Panel A shows the residuals plot taken from between the proximal and distal menisci of the raw 
data with the radius of the ultracentrifugation cell along the x-axis and absorbance along the y-axis, together with residuals for the fit in panel B. Panel C shows 
the continuous c(M) distribution obtained from the analysis of the data from A and B, estimating the molar mass of PFEIF4A. Panel D shows the continuous 
c(s) distribution also calculated from panels A and B, estimating PFEIF4As sedimentation coefficient. Both traces are annotated with their peak values. 
A 
 
 
 
 
 
 
B 
C 
 
 
 
 
 
 
D 
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pair-distribution functions, P(r), were generated (Figure 5.4) which could subsequently be 
used to estimate the particle maximum dimension (Dmax) and calculate the real-space Rg 
value. 
 
The P(r) data was used to generate multiple low resolution reconstructions using the 
DAMMIF program (Svergun 1999; Franke et al. 2009) under its default parameters. Then, 
using the DAMAVER program (Svergun 1999), ten ab initio reconstructions were aligned, 
averaged and filtered for areas of low density (Figure 5.5). Increasing the number of 
aligned reconstructions did not significantly alter the averaged model. Finally, the 
DAMAVER model was overlaid by the PHYRE2 structure described in Figure 5.1 using 
the SUPCOMB program (Kozin et al. 2001) (Figure 5.6). This showed that the 
DAMAVER model could comfortably accommodate the PHYRE2 structure. 
 
 
Figure 5.4 Pair-Distribution Functions of PFEIF4A. The trace of the P(r) plot was 
generated using the Guinier region shown in the inset panel. The slightly bilobal shape 
lends some suggestion to a two domain structure. The radius in angstroms (Å) is shown on 
the x-axis. The x intercept indicates PFEIF4As largest dimension (Dmax) is approximately 
88 Å (8.8 nm). 
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Figure 5.5 Ab Initio Reconstructions and Averaged SAXS Model of PFEIF4A. The 10 ab initio reconstructions obtained from the DAMMIF software 
(Franke et al. 2009) are shown in blue. Each model has been presented to illustrate their resemblance to each other, albeit arbitrary. These models were 
averaged and filtered for areas of low density using the DAMAVER software (Svergun 1999) and the resulting model is shown in green. Again, its 
orientation serves only for its comparison to the ab initio models. 
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Figure 5.6 Superimposition of SAXS Generated Model with PHYRE2 Server Model of PFEIF4A.  Panel A shows the SUPCOMB (Kozin et al. 2001) 
derived superimposition of the PHYRE2 server-generated PFEIF4A model (blue) over a surface render of the SAXS model (green) generated by 
DAMAVER (Svergun 1999). The fit is clearly poor, with the PHYRE2 server model appearing to have been overlaid at the y-axis median, giving a 
normalised spatial discrepancy (NSD) of 3.16. However, manual overlay (B) of the PHYRE2 server model does illustrate the potential for a more 
convincing fit. The large protuberance shown at the top of the DAMAVER model, possibly conferred by the addition amino acids sequence associated with 
the intact His6-tag of the SAXS sample; might be responsible for skewing the superimposition of the PHYRE2 server model, hence the poor fit. In both 
panels A and B, the right-most images are the orthogonal view of the images to their left following a 90° rotation around their y-axis. 
A B 
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5.2.5 Dynamic Light Scattering (DLS) 
Based on the observation in chapter four that helicase activity was dramatically reduced at 
incubation temperatures of 40 to 45 °C, DLS experiments were employed to observe any 
temperature-induced structural changes of His6-T-PFEIF4A. A 100 µL sample was 
prepared at 0.6 mg mL
-1
, correlating to 1 AU based on PFEIF4As molar extinction 
coefficient. The values for Rh and scatter intensity were monitored during 10 minute 
incubations at various temperatures between 20 and 65 °C. Due to the temperature effects 
on viscosity, each measurement was corrected for background fluctuations by scanning a 
blank buffer sample at each of the respective temperatures. 
 
As the temperature increased, both Rh and scattering intensity increased sharply at 43 °C 
(Figure 5.7). Furthermore, a sample incubated at 65 °C then subsequently cooled to 30 °C 
did not give the same Rh or scatter intensity as at 30 °C, suggesting an irreversible 
secondary or tertiary structural change. 
 
Figure 5.7 Effect of Temperature on PFEIF4As Structure. The graph shows the change 
in hydrodynamic radius (Rh), shown as white circles with a solid line of best fit, and the 
intensity of scattering, shown as black circles with a wide-spaced dashed line of best fit, of 
PFEIF4A with increasing temperature. The inset graph shows the magnified portion of the 
Rh between 35 and 45 °C, highlighting the onset of increasing Rh at 43 °C. 
156 
 
5.3 PFDH60 
Other than the identification of the core helicase motifs of PFDH60 from basic 
bioinformatic techniques (Pradhan et al. 2005), no structural characterisation has been 
performed on PFDH60. 
 
5.3.1 In silico Analysis 
The FASTA protein sequence of PFDH60 (Appendix 9) was analysed using the PHYRE2 
server (Kelley et al. 2009) generating a theoretical structure which was then annotated 
(Figure 5.8). 
The standard structure prediction omitted the first 278 and the last 6 amino acid residues, 
as well as those between 363 and 431, whereas the intensive structure prediction included 
every residue. However those omitted from the standard prediction contributed to large 
amounts of unstructured regions within the intensive structure. In spite of this, both 
structures predicted for PFDH60 showed two domains. These resembled the N- and C-core 
domains and the core helicase motifs were shown lining the cleft between the two. 
 
5.3 Discussion 
The work described in this chapter provides preliminary insight into PFEIF4A and 
PFDH60 structures. Coupling the structures with information elucidated from the rest of 
this study supports a more in depth understanding of their activities, and ultimately their 
suitability as novel anti-malarial drug targets. 
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5.3.1 PFEIF4A 
The structural comparison performed by the Tuteja group was on the human EIF4A3 
(Pradhan et al. 2007). However, work presented in this works has already identified that 
PFEIF4A shares the highest identity with EIF4A1 (Table 4.1), justifying its use for a 
comparison in Figure 5.1. Furthermore, unlike the comparison made here, the Tuteja group 
 
Figure 5.8 Structural Prediction of PFDH60. Rendered using PyMol v0.99; render A 
shows the standard PHYRE2 server predicted structure of PFDH60 orientated with the N-
core domain at the bottom (red) and the C-core domain at the top (blue). Render B shows 
the intensive PHYRE2 server predicted structure orientated to match that of the standard 
structure prediction. Unlike the standard predicted structure it has a large amount of 
unstructured regions in its N-core domain (red). For clarity, the standard structure 
prediction was used to annotate the core helicase motifs (C). The motif colour scheme of 
render C follows that of Figure 4.1; Q motif is in pink, motif I, Ia, and Ib are in red, bright 
green, and dark green respectively, the GG doublet in pale green, motif II in bright blue, 
motif III in yellow, motif IV in purple, motif V in pale blue, and motif VI in orange. 
A B 
C  
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did not use the full-length protein. A further comparison exists on the International Centre 
for Genetic Engineering and Biotechnology (ICGEN) bioinformatics website on 
comparative modelling of P. falciparum annotated proteins (Gowthaman et al. 2005). 
However, this model only predicts one domain and it is based on the yeast EIF4A 
orthologue (1FUU). 
The NMR HSQC experiments did not yield high resolution data for either the full-length or 
the subdomains of His6-T-PFEIF4A. This is possibly due to His6-T-PFEIF4A being in the 
upper-range of the generally accepted size limitation of NMR (Yu 1999). Under the advice 
of Dr Chris Read, changing the chemical environment by lowering pH did nothing to 
increase the resolution. Instead it decreased, likely due to the denaturation of the protein. 
However the data was enough to show different chemical environments suggesting the 
protein exhibited secondary and tertiary structure. 
The relative molecular weight (Mr) obtained from the AUC run is approximately 1.1 kDa 
smaller than that predicted using ProtParam. Other than any error incurred by either the 
prediction or AUC run, this discrepancy could also be partly due to a loss of the His6-tag (6 
× 155.15 Da). This would correlate with the weaker western blot detection of intact His6-T-
PFEIF4A with anti-His antibody over-time (as described in 3.2.8). The Rh obtained from 
the AUC is the theoretical radius of a sphere with the same diffusion rate of His6-T-
PFEIF4A (Schuck 2000; Schuck 2010), and was determined to be 3.50 nm. However, the 
experimentally determined R0 was 2.42 nm. The R0 is the distance from the centre of His6-
T-PFEIF4A to the average extremity of the molecule. Therefore if a molecule’s surface has 
a number of large protuberances, these are cancelled out when averaging against the more 
concave surfaces, giving a smaller measured radius than predicted from the Rh. 
This suggests that the overall shape of the His6-T-PFEIF4A molecule is irregular, which is 
substantiated by observations made on the axial ratios. If either axial ratio equals 1 then 
that dimension is perfectly circular. If it is greater than 1 then that dimension is more 
ellipsoid. If both the oblate and prolate axial ratios equal 1, the molecule is spherical. 
However, if one is greater than 1 it would be ‘cylindrical’. Both the oblate and prolate axial 
ratios of His6-T-PFEIF4A are greater than 1, 6.12 and 5.63 respectively, indicating an 
irregular shape. Additionally, a f/f0 over 1.2 also indicates a more globular shape (Schuck 
2005). It should be noted however, that the presence of the relatively unstructured His6-tag 
may impart a significant hydrodynamic friction, and that the true molecular shape may 
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exhibit a lower geometric asymmetry. Additionally, using the Hydropro program (Ortega 
et al. 2011) to analyse the PHYRE2 structure, gave an S value of 3.57 compared to the 
experimentally determined S value of 3.25 from the AUC run. This offers some credibility 
to the predicted PHYRE2 structure of PFEIF4A. 
The normalised spatial discrepancy (NSD) value of 3.16 obtained from the SUPCOMB 
superimposition of the His6-T-PFEIF4A PHYRE2 structure over the DAMAVER model 
indicates an unacceptable fit. The superimposition of identical objects would give an NSD 
of 0. Superimposed objects that are symmetrically different would give an NSD of greater 
than 0 and a fit is considered acceptable with NSDs equal to or less than 1. Anything over 
an NSD of 1.5 would require attention to obtain a better fit. The unacceptable NSD for 
His6-T-PFEIF4A is likely due to the presence of the His-tag moiety in the DAMAVER 
model which is not present in the PHYRE2 structure. Furthermore, taking into account that 
SAXS is a liquid state structural technique, the data generated is affected by the detection 
of multiple consistent conformational states of any dynamic regions within the protein, that 
when averaged can create a model illustrating the protein at its less compact and therefore 
largest condition. Despite this, other parameters obtained from the analysis of the SAXS 
data couples with those elucidated by alternative means. 
For example, the I(0) values obtained from His6-T-PFEIF4A and BSA control samples of 
comparable stoichiometry can be used to estimate the Mr as describe below. 
          
             
           r 
The I(0) values obtained from the Guinier plots of a 6.35 mg mL
-1
 sample of His6-T-
PFEIF4A (I(0) = 2.5192 ± 0.0498) and a 6.29 mg mL
-1
 BSA reference (I(0) = 3.6355 ± 
0.046, Mr = 66.5kDa), estimates His6-T-PFEIF4A Mr to be ~46 kDa ± 1.5. This value is 
similar to the Mr that was obtained by sedimentation AUC (~48 kDa) suggesting the SAXS 
data itself is accurate. 
The data obtained from the DLS experiments revealed a sharp incline in Rh and scattering 
intensity with increasing temperature at all concentrations. This is due to protein structure 
being stabilised by hydrogen bonds, hydrophobic interactions, and Van der Waal forces, 
each of which contributes a small degree of stability to the overall structure. These 
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stabilising forces can be disrupted by the addition of free energy, such as an increase in 
temperature, potentially denaturing the protein into a less ordered or unfolded state. This 
results in a less compact structure which effectively increases the average Rh of the sample. 
In addition, the hydrophobic residues once buried within the interior of the folded structure 
are now exposed to the solvent. Due to the entropically unfavourable state, the 
hydrophobic residues from one denatured protein may associate with those of another. This 
effectively increases the molecular weight of the sample protein which in turn increases the 
scattering intensity. The temperature at which half the maximal unfolding of a protein 
occurs is defined as the melting point (Tm), placing the Tm of PFEIF4A at approximately 
52.5 °C. 
Although these structural studies have elucidated limited information on both helicases, 
structural studies have emerged as an effective way to guide drug and inhibitor design. 
Therefore, this may provide a basis for future work due to the increased incorporation of 
such studies in clinical approaches. 
 
5.3.2 PFDH60 
Due to the issues associated with storage of PFDH60, no experimental analysis could be 
performed. However, the PHYRE2 server predicted model showed large amounts of 
unstructured regions. This may explain why PFDH60 loses activity in a relatively short 
amount of time. 
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CHAPTER SIX: INHIBITOR CHARACTERISATION 
 
6.1 Introduction 
With over one million deaths annually (Greenwood et al. 2005), malaria poses a huge 
threat to some of the world’s most vulnerable people and its long-term control and 
eradication is presently unforeseeable (Tuteja 2007). The present strategy in combating 
malaria, promoted by the World Health Organisation (WHO), involves a combination of 
vector control strategies and parasitic interventions (WHO 2008; WHO 2009; WHO 2010). 
For many countries, treatment consists of either chloroquine or sulphadoxine-
pyrimethamine, or a combination of the two, however wide-spread resistance has long 
been identified (EANMAT 2003; Plowe et al. 2004). This led to a search for novel ways to 
combat the disease and, following the completion of the P. falciparum genome (Gardner et 
al. 2002), a surge in bioinformatics inspired numerous novel approaches in combating the 
disease. 
Many of the emerged strategies have involved the targeting of the parasite’s proteins, such 
as those implicated during gametocytogenesis (Baker 2010; Kuehn et al. 2010) and 
epigenetic modification (Salcedo-Amaya et al. 2010). As previously discussed, helicases 
have been suggested as effective anti-malarial drug-targets (Tuteja 2007) due to their 
involvement in essential cellular processes. The Plasmodium proteome is an attractive 
target as only approximately 40 % of its genome has been annotated, offering considerable 
potential for the discovery of new anti-malarial drug-targets (Birkholtz et al. 2008). 
Previous studies have shown that Plasmodium falciparum growth was successfully 
inhibited with PFEIF4A antibodies, and dsRNA in RNA interference experiments 
(Pradhan et al. 2007). Experiments into the effects of DNA binding compounds on 
PFEIF4A unwinding and ATPase activities have also been performed (Pradhan et al. 
2008). These showed that out of a variety of well-known DNA binding compounds, 
actinomycin, 4’,6-diamidino-2- phenylindole (DAPI), daunorubicin, ethidium bromide, 
netropsin and noglamycin had inhibitory affects. These observations supported the 
suggestion that PFEIF4A would make a viable anti-malarial drug target (Tuteja 2007). 
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This chapter will describe the effect of a novel DNA binding drug on helicase and 
translocase proteins, as well as exploring the potential of DNA aptamers in identifying 
critical binding sites for the development of novel drugs. 
 
6.2 GWL-78 
The work discussed in this section was performed alongside Mr Irfaan Dawood as part of 
collaboration with Prof. David Thurston (King’s College London, London, UK) who 
kindly provided a DNA-interactive C8-bis-pyrrole pyrrolobenzodiazepine (PBD) conjugate 
called GWL-78. 
 
GWL-78 reversibly binds through its C11-position at the C2-NH2 of guanine bases in the 
minor groove, with a preference for 5’-XGX(W)z motifs (X is any base, but commonly a 
purine, W is an A or T, and z is 3 ± 1) (Wells et al. 2006; Rahman et al. 2011) (Figure 6.1). 
Furthermore, it has been shown to inhibit the binding of Nuclear Factor Y (NF-Y) to its 
 
Figure 6.1 Structure and Binding of GWL-78 to DNA Adapted from Rahman et al.  
(2011). Schematic A shows the structure of the C8-bis-pyrrole PDB conjugate while B 
details the theorised mechanism of covalent binding of the PDB moiety (magenta) through 
its C11 to the C2-NH2 of a guanine in the DNA minor groove. The energy minimised 
molecular model in C shows the C8-bis-pyrrole side chain oriented to the 5’-end of a DNA 
duplex. 
A 
B 
C 
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target CCAAT box sequence within the human DNA topoisomerase IIα promoter (Kotecha 
et al. 2008). 
The collaboration was established in order to further characterise the effects of GWL-78 on 
alternative biological systems. 
 
6.2.1 GWL-78 Interaction with DNA 
GWL-78 was provided in powdered form and, under the direction of Mr Irfaan Dawood, 
suspended in 50 % v/v methanol to the desired molar concentration and used to prepare the 
drug-DNA adducts (2.5.5) at a 4:1 molar ratio (Figure 6.2). When visualised on an SDS 
PAGE gel using a Fujifilm FLA-5000 phosphoimager with a blue laser (473 nm) at 550 V 
and a green filter (532 nm), the drug-DNA adduct gave an incomplete shift when 
compared to the DNA only control. Furthermore, the partial shift was not eliminated when 
the samples were run on a native PAGE gel, implying that the shift was not induced by 
SDS, and a DNA-methanol incubation following the adduct preparation protocol failed to 
produce any shift, eliminating methanol as a potential affecter. 
 
     1         2 
 
Figure 6.2 GWL-78 Incubated with the Fork 1 Substrate. The 15 % SDS PAGE gel 
shows the effect of GWL-78 binding on the Fork 1 substrate (substrate 10, Figure 2.5). 
Lane 1 shows the Fork 1 substrate prior to incubation with GWL-78, highlighted by the 
black arrow, while lane 2 shows the Fork 1 substrate after incubation GWL-78 at a 4:1 drug 
to DNA ratio; the resulting band shift is highlighted by the red arrow. 
► 
◄ 
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It was thought likely to be the result of unsaturated binding of GWL-78 to the DNA 
substrate. Therefore, electrophoretic mobility shift assay (EMSA) experiments were 
performed by titrating GWL-78 to the Fork 1 substrate from a 0 to a 32:1 molar ratio 
(Figure 6.3). 
 
This showed a total shift, indicating that GWL-78 binding to the DNA substrate was 
saturated at 12:1 drug to substrate ratio, and a Kd of 0.1694 ± 0.0214 µM. Curiously the 
observed change was a suprashift rather than a supershift, which is typically anticipated 
when studying DNA binding interactions (Fried et al. 1981; Garner et al. 1981). However, 
the downward shift may have been the result of a more compact shape being induced. This 
led to the theory that the free ssDNA ends of the Fork 1 substrate may have been being 
structured by GWL-78. To test the theory, a complimentary DNA strand to the X12-4 
oligonucleotide was used to create a dsDNA 50mer equivalent of the Fork 1 substrate and 
run alongside the drug-DNA adduct. 
 
Figure 6.3 Drug-DNA Adduct of GWL-78 with the Fork 1 Substrate. The graph shows 
the percentage band shift by GWL-78 binding to the Fork 1 substrate (substrate 10, Figure 
2.5) at increasing drug to DNA molar ratios. The lowest concentration showing a 100 % 
shift of the 100 nM Fork 1 substrate is 1.2 µM GWL-78, with a corresponding Kd of 0.1694 
± 0.0214 µM. Data is fit to a single site ligand binding curve. 
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Based on the theory detailed above, the dsDNA 50mer showed an even more compact 
shape than that of the Fork 1 substrate drug-DNA adduct. If the shift was indeed due to a 
more compact shape being induced by GWL-78, the drug-DNA adduct would have to have 
been more compact than the Fork 1 substrate, but less compact than the dsDNA 50mer. 
This led to the idea that maybe GWL-78 was stabilising the free ssDNA ends of the Fork 1 
substrate by opportunistically binding when they formed weak interactions between one 
another, supported by the observed requirement for a large excess of GWL-78 to DNA. 
This would result in a more bubble-like substrate, similar to that described for the Fork 2 
substrate (Table 4.2). The drug-DNA adduct of the Fork 1 substrate was run alongside the 
Fork 2 substrate and the dsDNA 50mer (Figure 6.4). 
 
Based on these observations, it seemed that GWL-78 was ‘clamping’ the two free ssDNA 
ends together, therefore drug-DNA adducts were created for substrates containing one or 
two free ssDNA ends in different configurations (Figure 6.5). This suggested that the 
GWL-78 was clamping the free ssDNA ends within the 3’ Flap and Fork 1 substrates.
1      2      3      4 
 
Figure 6.4 Comparison of the Apparent Size Difference Resulting from GWL-78 
Adduct Formation. The 15 % SDS PAGE gel shows the Fork 1 substrate (substrate 10, 
Figure 2.5) and its GWL-78 adduct, the Fork 2 Substrate (substrate 11, Figure 2.5) and the 
complimentary dsDNA 50mer (substrate 36, Figure 2.5). Lane 1 shows the Fork 1 substrate 
prior to incubation with GWL-78, lane 2 shows the Fork 1 substrate after incubation with 
GWL-78 at a 16:1 drug to DNA ratio, lane 3 shows the Fork 2 substrate, and lane 4 shows 
the full complement Fork 1 dsDNA 50mer. 
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Figure 6.5 Effect of GWL-78 on Substrates of Various Topologies with Free ssDNA Ends. The 15 % SDS PAGE gels show the substrate incubated at 
varying molar ratios of DNA to GWL-78. Each gel lane is numbered 1 to 5; lane 1 shows the substrate without being incubated with GWL-78, while lanes 2 to 
5 contain the substrate after being incubated with GWL-78 at 2, 4, 8, and 16:1 GWL-78 to DNA molar ratios respectively. Above each gel is a representative 
diagram of the substrate relating to that gel, substrates 2, 3, 7, 10, and 11 respectively (Figure 2.5). The solid black triangle identifies the corresponding band 
for each of the primary substrates being screened against, while any red triangles highlight any shift associated with incubation of GWL-78. 
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Moreover, in the case of the 3 Strand Junction and 50/19 Partial Duplex substrates, it was 
capable of clamping the ssDNA end of one molecule to the ssDNA end of another. 
A final experiment was performed to observe the ssDNA clamping potential of GWL-78, 
where it was incubated with the constituent strands of the Fork 1 substrate to observe 
whether it could stimulate annealing. This was performed by incubating the constituent 
oligonucleotides of the Fork 1 substrate in annealing buffer. However, instead of heating 
and cooling slowly, as described under the substrate annealing section of chapter two, the 
mixture was used directly for drug adduct preparation with increasing molar ratios of 
GWL-78 (Figure 6.6). Although GWL-78 did not support the total annealing of the ssDNA 
molecules, there was a reproducible correlation between the amount of GWL-78 and the 
amount of dsDNA formed. 
 
 
Figure 6.6 DNA Annealing by GWL-78. The graph shows the percentage of Fork 1 
substrate (substrate 10, Figure 2.5) formed at increasing drug to DNA molar ratios. The 
leftmost set of data shows the amount of dsDNA formed when the Fork 1 constituent 
oligonucleotides are incubated without the presence of GWL-78. The second, third and 
fourth sets of data show the amount of dsDNA formed in the presence of GWL-78 at 4, 8, 
and 16:1 GWL-78 to DNA molar ratios. Finally, the rightmost set of data shows the amount 
of dsDNA formed under the standard substrate annealing conditions. 
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6.2.2 The Effect of GWL-78 on EcoRI24I Translocase Activity 
Before carrying out experiments determining the effect of GWL-78 on the helicase 
activities of PFEIF4A or PFDH60, experiments on the type IC restriction modification 
(RM) enzyme EcoR124I were performed. EcoR124I is made up of a combination of three 
subunits; HsdR, HsdM, and HsdS. These subunits form complexes referred to as methylase 
(Mtase), R1 and R2. The Mtase is made up from two HsdM and one HsdS, abbreviated as 
M2S1. The R1 complex consists of one HsdR with the Mtase (R1M2S1) and the R2 
complex consists of two HsdR subunits with the Mtase (R2M2S1). Only the R2 complex is 
restriction-proficient, however it is also less stable than the R1 and the Mtase complexes 
(Janscak et al. 1998). 
 
 
Figure 6.7 Effect of GWL-78 on EcoR124I Cleavage. The graph shows the percentage of 
pCFD30 cleaved by the EcoR124I R2 complex in the presence of increasing concentrations 
of GWL-78. The white circles represent the percentage of PCFD30 at the given time-
points, and the solid line represents their line of best fit. The black circles represent the 
percentage of the 4:1 GWL-78 pCFD30 adduct at the given time-points, and the wide-
spaced dashed line represents their line of best fit. The white squares represent the 
percentage of the 8:1 GWL-78 pCFD30 adduct at the given time-points, and the wide-
spaced dotted line represents their line of best fit. Finally, the black squares represent the 
percentage of the 16:1 GWL-78 pCFD30 adduct at the given time-points, and the close-
spaced dashed line represents their line of best fit. Data is fit to a cooperative ligand 
binding curve. 
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While EcoR124I was chosen as it is a relatively well understood enzyme, it had been 
extensively studied locally, and therefore clones and purification strategies were readily 
available from Dr James Youell (University of Portsmouth, Hampshire, UK). 
90 second time-course experiments with 10 second time-points were carried out under the 
conditions described under the EcoR124I cleavage assay (2.3.8), and in the presence of 
pCFD30 GWL-78 adduct, at molar ratios of 4, 8, and 16:1 drug to DNA (Figure 6.7). 
Repeating the experiment without prior incubation of GWL-78 with pCFD30 at the same 
molar ratios had no notable effect on the rate of cleavage. 
These experiments showed that EcoR124I was slower to cleave the available pCFD30 
substrate, possibly due to GWL-78 slowing translocation which became more noticeable as 
the concentration of GWL-78 increased. 
 
6.2.3 The Effect of GWL-78 on PFEIF4A Helicase Activity 
Experiments were performed to see the effects of GWL-78 on the helicase activity of 
PFEIF4A. Based on the observations described in 6.2.1, GWL-78 Fork 1 adducts were 
created by incubating GWL-78 with the Fork 1 substrate at a 16:1 molar ratio. This was 
used in helicase 30 minute time-course experiments, with 20 μL 5 minute time-points. 
Each time-point reaction was carried out as described for the helicase assay with a 50:1 
helicase to substrate ratio (5:0.1 µM), at 37 °C and stopped with 5 µL of 5 × termination 
buffer (Figure 6.8). 
These experiments showed no discernible difference between PFEIF4A unwinding of the 
Fork 1 substrate and the GWL-78 Fork 1 adduct. The same experiment was carried out 
using the BOXTO helicase assay due to its increased resolution of the intermediate 
unwinding states (Figure 6.9). 
These experiments suggest that although GWL-78 does not totally inhibit unwinding, it 
does slow down the initial rate of PFEIF4A helicase activity on the Fork 1 substrate by 
approximately 30 %, down from 185.00 ± 8.40 to 133.30 ± 3.95 fmol min
-1
. 
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6.3 Aptamers 
Protein specific targeting by drugs is lengthy as it relies on basic biological knowledge of 
the target protein (Palchaudhuri et al. 2007) and so aptamers have emerged as an 
alternative strategy. The ability to raise specific aptamers against target molecules has led 
to their proposed use in therapeutics and as diagnostic tools. As therapeutics, aptamers 
could be used as inhibitors, similar to pharmaceutically developed drugs. 
As a diagnostic tool, they could be used as biological markers, as their high specificity and 
affinity lends potential as an alternative to monoclonal antibodies (Stoltenburg et al. 2007). 
They have the advantage of being chemically synthesised easily (Tuerk et al. 1990) and 
1  2 3        4         5         6        7 
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Figure 6.8 Effect of GWL-78 on PFEIF4A Helicase Activity. The 15 % SDS PAGE gels 
are examples of the time-course experiments of PFEIF4A unwinding the Fork 1 substrate 
(substrate 10, Figure 2.5) (top) and the GWL-78 Fork 1 adduct (bottom). The lanes in both 
gels are labelled 1 to 7. Lane 1 shows the 0 minute time-point and lanes 2 to 7 show the 5, 
10, 15, 20, 25, and 30 minute time-points. 
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unlike antibody production, do not require a relatively costly host organism, and can be 
made chemically stable as not to trigger an immune response. 
Furthermore, as biosensors they could be further developed to discriminate between 
species, for example P. falciparum proteins within human blood samples, helping to 
develop specific medical treatments. If linked with structural studies, they could also prove 
a quick way to find critical binding sites which could then be used to raise drugs against. 
 
6.3.1 The Effect of HsdR and Mtase Aptamers on EcoRI24I Translocase 
Activity 
5’ Biotinylated aptamers, generated by Dr Daniel Fordham (University of Portsmouth, 
Hampshire, UK) against the HsdR subunit and Mtase complex (Table 6.1), were used as  
 
Figure 6.9 BOXTO Helicase Assay of PFEIF4A Against the GWL-78 Fork 1 Adduct. 
Graph A shows the lines of best fit for the averaged results from triplicate experiments on 
PFEIF4A unwinding activity on the Fork 1 substrate (substrate 10, Figure 2.5), the solid 
line, and the GWL-78 Fork 1 adduct, the wide-spaced dashed line. Data is fit to a single site 
exponential decay curve .The dotted line and the close-spaced dashed line are the lines of 
best fit used to calculate the initial rates of unwinding (first 5 minutes) of the Fork 1 
substrate and the GWL-78 Fork 1 adduct respectively. The error bars have been omitted for 
clarity. Graph B shows the difference between the initial rate of unwinding (fmol min
-1
) by 
PFEIF4A on the Fork 1 substrate and the GWL-78 Fork 1 adduct. 
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Name Sequence 
HBA1 5’-CCAAGCGGGCGCGAGAACAACGTACGGT-3’ 
HBA3 5’-CCGAGCAGAAGGTGCGATGCTTTATGGT-3’ 
HBA8 5’-CCGAGCAGAAGGTGCGATGCTTTATGGT-3’ 
HBA14 5’-CCCGGGCGGACAGACGGGTGTTCGTTGC-3’ 
HBA15 5’-CCCGGGCGGACAGCAGGCTGTTCGTTGC-3’ 
HBA16 5’-CCCGTAGCGTACAGTCCCAGCTTGGGAT-3’ 
HBA20 5’-CCACAACGAGCCGGGATTGCGGATTGCA-3’ 
MBA1 5’-CCTGCTGATTCGTTGGGTGTTGTGTGGT-3’ 
MBA2 5’-CCCGTANCGTACAGTCCCAGCTTGGTAT-3’ 
MBA3 5’-CCCTGAGTCATAGTGTTCACGTGTT-3’ 
MBA4 5’-CCACAACGAGCCGGGATTGCGGATTGCA-3’ 
MBA5 5’-CCCTGAGTCATAGTGTTCACGTGTT-3’ 
MBA6 5’-GGCGAATTGGGCCCCGAGGGGTCGACT-3’ 
MBA7 5’-CCCGTANCGTACAGTCCCAGCTTGGTAT-3’ 
MBA8 5’-GGCGAATTGGGCCCGAGTCGCATGCTCCC-3’ 
MBA9 5’-CCGGTTGGGATGTGNCNCCCCNNATANN-3’ 
 
 
primary probes to dot blot against various concentrations of their respective targets, and 
developed using a monoclonal Anti-Biotin Peroxidise Conjugate (Abcam) (Figure 6.10). 
The dot blots were scrutinised using densitometry (Schneider et al. 2012) and the two 
aptamers with the highest density were used for EcoR124I cleavage assays. In short, 90 
second time-course experiments with 10 second time-points were carried out in the 
presence of 10 µM HBA6, HBA15, MBA6, or MBA8 (Figure 6.11). 
These experiments showed that although the initial binding of the EcoR124I machinery 
was not affected by the presence of any of the aptamers, the subsequent translocation 
leading to cleavage was greatly inhibited in the presence of MBA6 and to a lesser extent 
MBA8. 
Table 6.1 HsdR and Mtase Binding Aptamers. The table shows each aptamer sequence 
with its name as assigned by Dr Daniel Fordham; HsdR binding aptamers (HBAs) and 
Mtase binding aptamers (MBAs). MBAs 2, 7, and 9 all contain non-determined nucleotides 
(N). 
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6.3.2 Generating Aptamers against PFEIF4A 
Successive rounds of SELEX and PCR amplifications were performed on 100 µg His6-T-
tagged PFEIF4A immobilised to a Ni-NTA centrifuge column. PCR amplified SELEX 
products were run on a native PAGE gel and post-stained with 1 mg mL
-1
 ethidium 
bromide in 1× TAE buffer (Figure 6.12). 
Although a clear product band could not be seen after multiple successive SELEX rounds, 
cloning of the products was continued due to similar previous observations which resulted 
in successful cloning. However, the few recombinant colonies that were obtained did not 
yield any aptamer sequences upon sequencing. 
In an attempt to increase the yield of PCR product, 1 µL of a 1000-fold dilution of the final 
round of SELEX was used as the template for PCR amplification. The rationale being that 
 
 
 
 
 
Figure 6.10 HBA and MBA Dot Blots against the EcoR124I HsdR subunit and Mtase 
Complex. Both dot blots have the aptamers blotted across the x-axis and the HsdR (top) or 
Mtase (bottom) blotted in decreasing concentration down the y-axis. 
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having a more dilute template DNA sample, as opposed to a whole SELEX round product, 
would increase the likelihood of a cooperative encounter between the PCR machinery. The 
PCR product was run on a native PAGE gel (Figure 6.13). This product was then cloned 
using the pGEM-T Easy Vector system (Promega). Recombinant colonies were grown for 
DNA extraction and sequence quality purification using centrifuge columns (Machery-
Nagel). The extracted DNA was then sequenced and their shapes predicted using the mfold 
and RNAfold web servers (Zuker 2003; Gruber et al. 2008) (Table 6.2). Although 
RNAfold is primarily designed for predicting RNA folding, observations made by Chen et 
al. (2012) have shown that short ssDNA is more flexible than short ssRNA. Therefore 
using RNAfold is valid in proposing an alternative shape to that of mfold. Many of the 
 
Figure 6.11 The Effect of HsdR and Mtase Aptamers on EcoR124I Cleavage. The graph 
shows the percentage of pCFD30 cleaved by the EcoR124I R2 complex in the presence of 
HsdR and Mtase aptamers. The white circles represent the percentage of PCFD30 at the 
given time-points for the control experiment, and the solid line represents their line of best 
fit. The black circles represent the percentage of pCFD30 at the given time-points in the 
presence of HBA6, and the wide-spaced dashed line represents their line of best fit. The 
white squares represent the percentage of pCFD30 at the given time-points in the presence 
of HBA15, and the wide-spaced dotted line represents their line of best fit. The black 
squares represent the percentage of the pCFD30 at the given time-points in the presence of 
MBA6, and the close-spaced dashed line represents their line of best fit. Finally, the white 
triangles represent the percentage of pCFD30 at the given time-points in the presence of 
MBA8, and the close-spaced dotted line represents their line of best fit. Data is fit to a 
cooperative ligand binding curve. 
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  1     2  
 
Figure 6.13 PCR Amplification of Diluted Eighth SELEX Round against PFEIF4A. 
The 15 % native PAGE gel shows the HyperLadder V marker (Bioline) in lane 1. Lane 2 
shows the denatured PCR (59 nt) product obtained from the 1000-fold dilution of the eighth 
round of SELEX against PFEIF4A, with a band corresponding in size to approximately 25 
bp. 
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Figure 6.12 Successive Round of SELEX to PFEIF4A. The 15 % native PAGE gel shows 
the HyperLadder V marker (Bioline) in lane 1. Lane 2 shows the pre-screened library, 
while lanes 3 to 11 show the PCR amplified products from the first to the eighth round of 
SELEX respectively. The pre-screened library shows a faint band corresponding in size to 
approximately 25 bp (red), which is expected for the single-stranded 59 nt random library 
pool. Lane 3 shows numerous bands corresponding in size to approximately 50 bp (green), 
with the most predominant band slightly higher (~60 bp). Again, this is expected for the 
PCR amplified product as the dsDNA product (2 × 59 nt) was not denatured prior to 
loading. The dsDNA bands become fainter with each subsequent round of SELEX. 
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Name Sequence 
4ABA1 5’-CCCACAGACATCAGGACGCTACATGGGGT-3’ 
4ABA2 5’-GGGCCAGGTGGTGTGGTGTTGCTGGGT-3’ 
4ABA3 5’-CCCACAGACATTAGGACCCTACGTGTGGT-3’ 
4ABA4 5’-CCCACAGACATTAGGACGCTACATGGGGT-3' 
 
4ABA1 4ABA2 
mfold RNAfold mfold RNAfold 
  
 
 
4ABA3 4ABA4 
mfold RNAfold mfold RNAfold 
    
 
 
sequences returned were multiple copies of the same sequence. 4ABA1 itself was a 
quadruplicate; this is likely due to the use of a relatively small number of template DNA 
molecules, resulting in the yield of large amounts of comparatively few aptamer sequences. 
Initial dot blots performed as described for the EcoR124I aptamers could not be detected. 
As a result, dot blots were performed using alternative probing approaches, including pre-
Table 6.2 PFEIF4A Binding Aptamers. The top table shows each aptamer sequence with 
its name; PFEIF4A binding aptamer (4ABA). The bottom table shows the predicted shapes 
of each of the aptamers based on the mfold (Zuker 2003) and the RNAfold web servers 
(Gruber et al. 2008). 
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incubating each aptamer with PFEIF4A at room temperature for 15 minutes prior to being 
immobilised (Figure 6.14). These experiments suggested that none of the aptamers could 
bind immobilised His6-T-PFEIF4A and be detected above that of the immobilised aptamer 
alone. 
 
6.4 Discussion 
Due to the threat posed to some of the world’s most vulnerable people and the lack of a 
long-term solution, compounded by wide-spread resistance to vector control strategies and 
parasitic interventions (EANMAT 2003; Plowe et al. 2004), the pursuit of effective anti-
malarial strategies remains a constant focus for the WHO (WHO 2008; WHO 2009; WHO 
2010). 
This chapter has described two strategies in targeting the PFEIF4A helicases as proposed 
by Tuteja (2007). They are the effect of the novel DNA-interactive PDB conjugate GWL-
78, and raising aptamers to specifically target PFEIF4A. 
 
 
 
 
Figure 6.14 4ABA Dot Blots against the PFEIF4A. The aptamers 4ABA1 to 4 are blotted 
across the x-axis. The y-axis is labelled A to D. Row A is 2.5 µg of immobilised PFEIF4A 
only and row B is 2.5 µg of PFEIF4A pre-incubated with 1 µL of 100 µM aptamers for 15 
minutes at room temperature prior to the mixture being immobilised. Row C is 1 µL of 100 
µM immobilised aptamers only, and row D is 2.5 µg of immobilised PFEIF4A detected 
with each aptamer based on the standard dot blotting method. 
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6.4.1 GWL-78 
Previous studies identified that GWL-78 binds dsDNA (Wells et al. 2006; Rahman et al. 
2011). This work has presented the hypothesis that it is also capable of binding single-
stranded DNA regions to one another. To explore this further, computational models of the 
Fork 1 substrate with and without GWL-78 were rendered using the Assisted Model 
Building with Energy Refinement (AMBER) package by Mr Irfaan Dawood (Figure 6.15). 
This model supports the theory that GWL-78 was ‘clamping’ the free ssDNA ends creating 
a more compact molecule. 
 
In addition, the experiments performed in this chapter show that although GWL-78 does 
not inhibit either activity totally, it does have an effect on both EcoR124I translocase and 
PFEIF4A helicase activities. 
 
 
Figure 6.15 AMBER Generated Models of the Fork 1 Substrate and its GWL-78 
Adduct. Schematic A shows the structure of the Fork 1 substrate (substrate 10, Figure 2.5) 
with the phophodiester backbone shown in black and the bases shown as stick models. 
Schematic B shows the Fork 1 substrate with six GWL-78 molecules (magenta) bound as 
described by Rahman et al. (2011). Note the forked regions of the substrate (rightmost) are 
seemingly ‘clamped’ into a duplex by the bound GWL-78. 
A 
B 
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6.4.2 Aptamers 
Since being identified approximately twenty years ago (Ellington et al. 1990; Tuerk et al. 
1990), there have been many studies recognising the potential of aptamers. This has led to 
the emergence of two distinct aptamer technologies, therapeutic and diagnostic. 
Therapeutic aptamers are generally used as inhibitors, and at least one commercially 
available therapeutic aptamer, Macugen (OSI Pharmaceuticals), has been approved in the 
United States of America (U.S.A.) (Doggrell 2005). Likewise, NeoVentures Biotechnology 
Inc. now offers a commercial aptamer-based diagnostic platform, which target molecules 
in a similar way to antibody technologies (Jayasena 1999). The approved use and success 
of these aptamer technologies is encouraging for their continued and expanding use for a 
wide range of applications and treatments of severe conditions and diseases. 
The experiments using HsdR and Mtase binding aptamers showed potential for both 
diagnostic and therapeutic applications. All the aptamers seemed to show specific binding 
to the HsdR subunit. Due to time restraints only two aptamers for each target were used for 
further preliminary experiments. Neither HBA6 nor 15 had an effect on EcoR124I 
cleavage. However, MBA6 and 8 both showed inhibitory effects on EcoR124I cleavage. It 
may be that the aptamers interrupted the formation of the EcoR124I complex. Further gel 
shift experiments using the EMSA assay as detailed in chapter two could have been 
performed to test this theory. 
SELEX performed against PFEIF4A only produced four aptamers. None of these showed 
significant detection of immobilised PFEIF4A. Time permitting, alternative techniques 
could have been explored, as the immobilisation of PFEIF4A to the nitrocellulose 
membrane may have affected its structure, distorting the potential aptamer binding sites. 
Therefore, a solution based detection strategy may have been more suitable. This could 
have been done by immobilising the His6-T-PFEIF4A to a Ni-lined well and washing the 
bound PFEIF4A with the aptamers, followed by washing with the 2° HRP conjugated 
probe prior to detection. 
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CHAPTER SEVEN: CONCLUSIONS 
 
7.1 Background 
Helicases are a subclass of translocases that are capable of unwinding the nucleic acid 
duplexes. As a consequence they are vital to all living organisms, playing key roles in all 
cellular processes, such as DNA repair and replication (Cobb et al. 2002), transcription 
(Ciampi 2006), translation (Rogers et al. 1999), recombination (Singleton et al. 2004), 
RNA maturation and splicing (Staley et al. 1998), RNA degradation (Py et al. 1996), 
ribosome biogenesis (Venema et al. 1995), nuclear export processes (Kanai et al. 2004), 
and mitochondrial genome replication (Korhonen et al. 2003). 
Plasmodium falciparum is responsible for over 90 % of worldwide cases of malaria in 
humans, with the highest reported complications and mortality rates when compared to all 
other human malaria-causing Plasmodium (WHO 2009; WHO 2010). Interest in the 
control of malaria has become increasingly focused on the worsening situation in sub-
Saharan Africa and its contributory factors (Greenwood et al. 2002) such as climate 
instability and global warming (Hay et al. 2002; Tanser et al. 2003), healthcare breakdown 
due to war and civil-unrest (Bloland et al. 2002), interaction with and increased 
susceptibility to malaria due to HIV infection (Whitworth et al. 2000; French et al. 2001; 
Mount et al. 2004; Kublin et al. 2005), and the increased rate of travel between non-
endemic and endemic areas. However, drug-resistant parasites and insecticide-resistant 
Anopheles gambiae mosquitoes are thought to be the likely main cause (Snow et al. 2001; 
Korenromp et al. 2003). 
 
7.2 Observations made in this Study 
The P. falciparum genome has been fully sequenced (Gardner et al. 2002), and several 
studies exploring the exploitation of the parasites’ proteins as anti-malarial targets have 
been performed. The helicases described within this study, PFEIF4A and PFDH60, were 
first proposed as potential drug-targets by  Dr Renu Tuteja (Malaria Group, International 
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Centre for Genetic Engineering and Biotechnology, New Deli, India) (Tuteja 2007). The 
work described here was aimed at expanding the understanding of PFEIF4A and PFDH60 
through biochemical and structural analyses, and the high-throughput generation and 
effects of novel inhibitors. It should be noted that the PFDH60 protein discussed within 
this study is the full-length gene product (87 kDa). It is referred to as its 60 kDa namesake 
for the benefit of continuity regarding previous studies (Pradhan et al. 2005; Pradhan et al. 
2006; Pradhan et al. 2007), however the work described in this study is entirely novel. 
This was performed firstly by optimising the growth and purification conditions as the 
original strategies (Pradhan et al. 2005; Pradhan et al. 2007) proved inadequate for the 
yields required for full biochemical and structural analysis. Initial biochemistry reported 
PFEIF4A helicase and ATPase activities on a limited range of substrates (Pradhan et al. 
2008). This study has expanded to use numerous substrates with diverse topologies. It has 
identified an absolute requirement for a single-stranded overhang and a 3’-5’ polarity bias 
by PFEIF4A. It has detailed the effects of different DNA topologies on its ATPase activity, 
its preference for dsDNA, and DNA:RNA and RNA:DNA hybrid duplexes over dsRNA. It 
has also explored the effects of different divalent metal ions, its optimum temperature for 
unwinding activity, and its NTP usage. Dynamic Light Scattering (DLS) experiments have 
expanded on the observations made while examining the optimum working temperature of 
PFEIF4A to show that it becomes structurally unstable with temperature increases above 
its 37 °C optimum and that its unwinding activity is susceptible to inhibition by DNA 
binding compounds. 
These observations have led to two questions. Firstly, is the effect of temperature 
significant? Secondly, can PFEIF4A and PFDH60 be exploited as anti-malarial targets? 
 
7.2.1 Is the Effect of Temperature Significant? 
Both proteins were liable to degradation and loss of activity during prolonged storage and 
incubation at increasing temperatures. PFDH60 was the less stable of the two proteins, 
displaying a total loss of activity within one week regardless of storage buffer or 
temperature. PFEIF4A was stable during storage at -20 °C in 10 % glycerol, but degraded 
at higher temperatures (4 °C) or without glycerol after a single freeze-thaw. 
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This observation is not surprising as unwinding activity is tightly regulated by the cell 
which invests substantial effort in maintaining more stable dsDNA over less stable ssDNA. 
The fact that PFDH60 degrades over a short space of time and that its expression within 
the parasite is limited mainly to the schizont life stage (Pradhan et al. 2005), suggests it is 
required for a specific role during the massive growth phase observed prior to the release 
of thousands of merozoites back into the bloodstream. Therefore, it is only required to be 
expressed for a short period of time before being recycled through the cells protein 
degradation process. Its susceptibility to degradation is also supported by the PHYRE2 
server predicted structure of PFDH60 showing large unstructured regions, which are 
potentially vulnerable to degradation by proteolytic enzymes. 
As described earlier, storage of PFEIF4A was more successful than that of PFDH60. Based 
on its expression throughout the parasitic life cycle (Pradhan et al. 2007), its similarity 
with human EIF4A1, and the identification of potential binding partners (Tuteja et al. 
2009), it is suggested that PFEIF4A may contribute to the orthologous P. falciparum EIF4 
complex. If so, like the human EIF4 complex it would serve as the main regulatory 
element of protein expression (Conroy et al. 1990; Yoder-Hill et al. 1993), and so would 
be required to be ubiquitously expressed throughout the cells life-span. 
Ironically Julius Wagner-Jauregg received the 1927 Nobel Prize in medicine for 
inoculating neurosyphilis patients with malaria to induce a fever to treat the Treponema 
pallidum infection. However, temperature has long been acknowledged to affect the 
growth and development of P. falciparum (Kwiatkowski 1989). Curiously, inhibition of 
parasite growth has been reported at temperatures as low as 40 °C, despite febrile 
temperatures associated with malarial infection often exceeding this. Furthermore, 
mimicking febrile temperatures in combination with the administration of common anti-
malarial drugs shows marked inhibition of field isolated parasites (Long et al. 2001; 
Aunpad et al. 2009). These observations may lend credibility to the traditional 
hydrotherapy strategies for the treatment of malaria infections performed by African and 
Malaysian tribes (Jennings 2006). Then, 3 to 4 hours before the onset of each fever 
associated with the release and re-infection of red blood cells (RBCs) by the parasite, the 
sufferer is wrapped in a blanket and placed into the sun to raise their body temperature and 
induce sweating, at which point they are submerged into cold water. The sufferer is kept 
bound and cool in between the process being repeated during the course of the infection. 
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The dramatic decrease in unwinding activity by PFEIF4A at temperatures greater than 37 
°C coupled with its decreasing structural integrity around the same temperature, based on 
the observations made during the DLS experimentation, may help to provide a molecular 
link to these observations. This could prove an interesting direction for research towards an 
effective combination treatment against malaria. 
 
7.2.2 Can PFEIF4A and PFDH60 be exploited as Anti-Malarial Targets? 
PFEIF4A has been shown to share a high degree of identity to the human EIF4A1 (66.7 %) 
and its helicase and ATPase activities are affected by various DNA-binding compounds 
(actinomycin, 4’,6-diamidino-2- phenylindole (DAPI), daunorubicin, ethidium bromide, 
netropsin and noglamycin) (Pradhan et al. 2008). This study has also shown that the 
unwinding activity of PFEIF4A is affected by the novel DNA-interactive PDB conjugate 
GWL-78. Previous studies have shown that parasite growth was inhibited by anti-PFEIF4A 
antibodies, and with PFEIF4A dsDNA in RNA interference experiments (Pradhan et al. 
2007). 
Although PFEIF4A is relatively similar in sequence and potential structure to its human 
orthologue EIF4A1, the biochemical analysis undertaken during this study has elucidated 
substantial differences between the two proteins’ activities. Drugs that target the protein 
directly could take advantage of the two protein NTP usages. Both proteins have an 
optimal unwinding activity in the presence of ATP. However, human EIF4A1 can only 
utilise dATP as an alternative hydrolysis source (Du et al. 2002). The Tuteja group 
(Pradhan et al. 2008) observed that PFEIF4A utilised dATP, dCTP, and UTP, whereas this 
study has also observed significant unwinding in the presence of dGTP. Another distinct 
difference is between the nucleic acid substrates each protein acts upon. Human EIF4A has 
only been observed to unwind dsRNA, as well as RNA:DNA and DNA:RNA hybrid 
substrates (Rogers et al. 2001; Rogers et al. 2002). Although previous studies have shown 
PFEIF4A to unwind simple short RNA substrates (Pradhan et al. 2007; Pradhan et al. 
2008), this study has shown that PFEIF4A is incapable of unwinding a dsRNA forked 
substrate despite being capable of unwinding dsDNA, and DNA:RNA and RNA:DNA 
hybrid forked substrates. Furthermore, human EIF4A is capable of unwinding blunt-ended 
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substrates (Rogers et al. 2001; Rogers et al. 2002), whereas PFEIF4A has an absolute 
requirement for a single-stranded overhang to support unwinding. 
If the differences between human EIF4A1 and  PFEIF4A are directly related to their 
structures, for example the size of the ATP binding pocket, then specific drugs that bind to 
PFEIF4A but not human EIF4A1 binding sites could be used to inhibit the unwinding or 
ATPase activities (Spencer et al. 2011) without affecting the parasite hosts’ EIF4A 
proteins. 
This study has identified that PFDH60 has very little identity to any human proteins. 
Previous studies have identified that PFDH60 unwinding and ATPase activities are 
affected by various DNA-binding compounds (actinomycin D, daunorubicin, ethidium 
bromide, netropsin, and nogalamycin) and that parasitic growth is affected by anti-
PFDH60 antibodies, and PFDH60 dsRNA (Pradhan et al. 2006). These observations 
support that firstly it is an effective target, but also one with potentially minimal side 
effects to the host system. Its schizont limited expression may also help to specifically 
target PFDH60, as treatments that target the parasitised red blood cell (pRBC) could be 
directly injected into the bloodstream. 
 
7.3 Future Work 
Due to time restraints and unforeseen complications while undertaking this study, the 
pursuit of some lines of experiments had to be neglected or cut short. If time permitted, 
investigation into the biochemical and structural characterisation of PFDH60 would have 
been performed to the same extent as PFEIF4A. Further experimentation into dsRNA 
unwinding would have been explored to see if PFEIF4A could unwind RNA duplexes of 
sufficiently low thermostability to expand on observations made in this study in support of 
those made by Pradhan et al (Pradhan et al. 2007; Pradhan et al. 2008). 
The BOXTO based unwinding assay and luciferase ATPase assay would have would have 
made high-throughput analysis of both PFEIF4A and PFDH60 helicase activities relatively 
easier. Work had been started on developing a high-throughput SPR binding analysis 
method. This involved attaching an array of thiolated DNA substrates to a high index gold 
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prism (Horiba) using the Genetix QArray2 micro-array printer. This could be visualised 
using the Horiba SPRi-Lab+ system, which converts the resonance into an image (Figure 
7.1). Unfortunately, PFEIF4A non-specifically bound to the gold surface despite 
passivation with bovine serum albumin (BSA). Concern over the amount of time it could 
take to explore more effective means of passivation, and other experiments requiring 
attention, resulted in the technique being abandoned. 
 
The prevalence of single molecule experiments being published has greatly increased in 
recent years. There were 979 articles published in 2002, available through the PubMed 
website when searching for ‘single molecule’ in all fields. The number of articles 
published in 2011 was 2529, and there were already 2043 new publications in 2012 at the 
beginning of September. Due to the increased interest and the robust data generated from 
 
Figure 7.1 SPRi-Lab+ DNA Array. Panel A shows the high index glass prism and panel A 
shows the DNA substrates arrayed on its surface under a 1000 × magnification optical 
microscope. Panel C shows the image created using the SPRi-Lab+ system from the 
resonance profiles obtained using the arrayed prism. The 6 × 6 grid of dots correspond to 
three copies of the 12 Özsoy substrates; substrates 1 to 12 as described in Table 2.3, 
incorporating thiolated oligonucleotides 1, 4, 9, and 11 (Appendix 1). 
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single molecule studies, a collaboration was established with Prof. David Bensimon (Ecole 
Normale Superieure (ENS), Paris, France) to study PFEIF4A and PFDH60 using a 
magnetic tweezers system (PicoTwist). When PFEIF4A was first purified, but before the 
biochemistry was performed, experiments using the basic hairpin substrate were performed 
(Manosas et al. 2010). However, no data was generated. After performing the biochemistry 
described in this study and discovering that although PFEIF4A could unwind hairpin 
containing substrates, it also had an absolute requirement for a free single-stranded 
overhang in order to unwind a DNA duplex, a new substrate was designed (Figure 7.2). 
Unfortunately, the opportunity to perform any experiments with the novel substrate 
tailored to the specific requirements of PFEIF4A was not available due to the time 
restraints of this study. 
 
The relative ease to generate and characterise aptamers has already been described in this 
study, and limited experimentation on aptamers targeting PFEIF4A has been undertaken. 
The effect of aptamers on cleavage by EcoR124I has also been reported on. This should 
provide good proof of concept for the promise of aptamer targeting and inhibition of both 
 
   
Figure 7.2 Substrates for use in the Magnetic Tweezers Single Molecule System. Panel 
A shows the typical hairpin substrate used by the Bensimon Group, adapted from Manosas 
et al (2010). Panel B shows the substrate specifically designed to observe PFEIF4A 
unwinding using the magnetic tweezers system, adapted from Firman et al (2012). 
Construction of the substrate involves the PCR amplification and gel purification of a 
digoxigenin and a biotin, incorporating fragments for surface and bead attachment 
respectively. The branched substrate is gel purified after annealing of its two component 
strands (Invitrogen). Each end fragment has either a BamHI or EcoRI restriction site for 
ligation to the annealed branch substrate. The final substrate is then gel purified. 
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PFEIF4A and PFDH60, and should not be disregarded when considering future 
investigation into novel anti-malarial therapeutics and diagnostic platforms. 
Another area of interest in determining the suitability of PFEIF4A as an anti-malarial 
target was its direct comparison with human EIF4A, and a clone was kindly provided by 
Dr Christian Wasmer of Prof. Gerhard Wagners’ laboratory (Harvard Medical School, 
Boston, Massachusetts, USA). Furthermore, human EIF4A activity has been shown to be 
greatly influenced by other EIF4 proteins (Imataka et al. 1997; Rogers et al. 2001; Oberer 
et al. 2005; Rozovsky et al. 2008; Marintchev et al. 2009; Özeş et al. 2011), and more 
recently potential P. falciparum EIF4 orthologues have been identified (Tuteja 2009; 
Tuteja et al. 2009; Tuteja et al. 2010). Therefore, PFEIF4E, PFEIF4G, P. falciparum 
poly-A binding protein (PFPABP), and P. falciparum single-stranded binding protein 
(PFSSB) genes were synthesised by GENEART (Regensburg, Bavaria, Germany) and 
cloned into the pET-28a(+) expression vector. Despite preliminary expression analysis and 
purification of PFEIF4E and PFEIF4G, a thorough comparison could not be performed due 
to time restraints. However, particular interest was placed in comparing the inhibition of 
the P. falciparum and human proteins with established compounds as well as inhibitor 
molecules already shown to affect human EIF4A, such as hippuristanol (Lindqvist et al. 
2008), or cytotoxins such as BPSL1549 (Cruz-Migoni et al. 2011). A particularly 
interesting outcome would be the identification of compounds that could distinguish 
between PFEIF4A and human EIF4A. 
 
7.4 Summary 
The increase of drug-resistant parasites and insecticide-resistant A. gambiae mosquitoes 
has resulted in the call for new approaches to combat malaria. One proposed strategy 
focuses on the targeting of Plasmodium helicases due to their necessity in all cellular 
processes, and therefore the organisms’ survival and infection of their host. 
PFEIF4A has emerged as a target of particular interest due to its similarity to human 
EIF4A. Although further investigation is required to fully appreciate its potential as an 
anti-malarial target, this study has furthered the understanding of its biochemistry, with 
particular interest in its absolute requirements for specific substrate topologies, and the 
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influence temperature has on its unwinding activity. This study has also expanded on the 
susceptibility of PFEIF4A to inhibition from DNA binding compounds, as well as 
providing preliminary information on its structure. 
Significant in vivo studies as well as biochemical and biophysical experimentations have 
been performed to understand the underlying activities of PFEIF4A as an integral protein 
to the life processes of P. falciparum. However, studies into PFEIF4A as part of the P. 
falciparum EIF4 complex and novel inhibitors that distinguish it from human proteins are 
now required. Furthermore, structural studies into how the complex forms and where 
interaction by small molecules takes place would be of interest for the pursuit of 
developing more effective anti-malarial solutions in the future. 
i 
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APPENDICES 
Appendix 1: Oligonucleotides 
Number Name Sequence 
1 X12-1 5’-GACGCTGCCGAATTCTGGCTTGCTAGGACATCTTTGCCCACGTTGACCCG-3’ 
2 X12-2 5’-CGGGTCAACGTGGGCAAAGATGTCCTAGCAATGTAATCGTCTATGACGTC-3’ 
3 X12-3 5’-GACGTCATAGACGATTACATTGCTAGGACATGCTGTCTAGAGACTATCGC-3’ 
4 X12-4 5’-GCGATAGTCTCTAGACAGCATGTCCTAGCAAGCCAGAATTCGGCAGCGTC-3’ 
5 BUB4 5’-CGGGTCAACGTGGGCAAAGATAGAATAGCAAGCCAGAATTCGGCAGCGTC-3’ 
6 BUB12 5’-CGGGTCAACGTGGGCAAAGTCTATGCTTAGCGCCAGAATTCGGCAGCGTC-3’ 
7 3’ Flap A 5’-GCTGTCTAGAGACTATCGC-3’ 
8 5’ Flap A 5’-CGGGTCAACGTGGGCAAAG-3’ 
9 BF18 5’-GCCTCGCTGCCGTCGCCA-3’ 
10 BF36 5’-TGGCGACGGCAGCGAGGCTTTTTTTTTTTTTTTTTT-3’ 
11 JS-80 5’-CCAAAAGCACCACACCCCACGCAAAAACAAGTTTTTGCTGATTTTTCTTTATAAATAGAGTGTTATGAAAAATTAGTTTC-3’ 
12 JS-80nic 5’-GAAACTAATTTTTCATAACACTCTATTTATAAAGAAAAATCAGCAAAAACTTGTTTTTGCGTGGGGTGTGGTGCTTTTGG-3’ 
13 5’ Hairpin A 5’-GATCCGACCGGCTACTCTAATAGCCGGTTGGACGCACATACTGTGTGCATATG-3’ 
   
xxvi 
   
14 3’ Flap B 5’-CATATGCACACAGTATGTGCGTCCAG-3’ 
15 5’ Hairpin B 5’-GATCCGATCGGCCATTAGAGTGGCCGATTGGACGCACATACTGTGTGCATATG-3’ 
16 Deleted Loop 5’-GATCCGATCGGCCAGTGGCCGATTGGACGCACATACTGTGTGCATATG-3’ 
17 3’ Blunt 5’-CATATGCACACAGTATGTGCGTCCA-3’ 
18 5’ Hairpin C 5’-ACCGGCTACTCTAATAGCCGGTTGGACGCACATACTGTGTGCATATG-3’ 
19 3’ Hairpin A 5’-GATCCATATGCACACAGTATGTGCGTCCAACCGGCTATTAGAGTAGCCGGTTTGATCC-3’ 
20 5’ Flap B 5’-GTGGACGCACATACTGTGTGCATATGGATC-3’ 
21 5’ Blunt 5’-TGGACGCACATACTGTGTGCATATGGATC-3’ 
22 3’ Hairpin B 5’-GATCCATATGCACACAGTATGTGCGTCCAACCGGCTATTAGAGTAGCCGGT-3’ 
23 Rev 3’ Flap A 5’-CGCTATCAGAGATCTGTCG-3’ 
24 Rev X12-4 5’-CTGCGACGGCTTAAGACCGAACGATCCTGTACGACAGATCTCTGATAGCG-3’ 
25 26 Overhang 5’-GCGATAGTCTCTAGACAGCATGTCCTAGCAAGCCAGAATTCGGCA-3’ 
26 21 Overhang 5’-GCGATAGTCTCTAGACAGCATGTCCTAGCAAGCCAGAATT-3’ 
27 16 Overhang 5’-GCGATAGTCTCTAGACAGCATGTCCTAGCAAGCCA-3’ 
28 11 Overhang 5’-GCGATAGTCTCTAGACAGCATGTCCTAGCA-3’ 
29 6 Overhang 5’-GCGATAGTCTCTAGACAGCATGTCC-3’ 
30 1 Overhang 5’-GCGATAGTCTCTAGACAGCA-3’ 
xxvii 
31 RNA X12-4 5’-GCGAUAGUCUCUAGACAGCAUGUCCUAGCAAGCCAGAAUUCGGCAGCGUC-3’ 
32 RNA X12-1 5’-GACGCUGCCGAAUUCUGGCUUGCUAGGACAUCUUUGCCCACGUUGACCCG-3’ 
33 Duplex A 5’-AAGAAAAGAAAGAAGAAAGAAACCGTGCAGAATTCGAGGTCGACGGATCCGG-3’ 
34 Duplex B 5’-CCGGATCCGTCGACCTCGAATTCTGCACGGTTTCTTTCTTCTTTCTTTTCTT-3’ 
35 Duplex C 5’-CCGTGCAGAATTCGAGGTCGACGGATCCGGAAGAAAAGAAAGAAGAAAGAAA-3’ 
36 Duplex D 5’-TTTCTTTCTTCTTTCTTTTCTTCCGGATCCGTCGACCTCGAATTCTGCACGG-3’ 
37 TFO 5’-TTCTTTTCTTTCTTCTTTCTTT-3’ 
38 X12-4 Comp. 5’-GACGCTGCCGAATTCTGGCTTGCTAGGACATGCTGTCTAGAGACTATCGC-3’ 
  
xxviii 
Appendix 2: PFH45 Sequences 
Unspliced Native DNA (PlasmoDB gene ID: PF14_0655) 
ATGAGTACTA AAGAAGAGAC TTTTAATAAT GAAAACGACA TTGAAGGAAA TACAGAAGAG 
ATTGTTGATA CATTCGACGC TCTTGGATTA AATGAAAAAC TTTTAAGGGG TATATATTCT 
TATGGTTTTG AAAAGCCATC AGCAATTCAA CAAAGAGGTA TTAAACCTAT TTTGAATGGT 
TACGATACTA TTGGTCAAGC TCAATCTGGT ACAGGAAAAA CAGCTACTTT CGTTATTTCC 
TCATTGCAGT TAATTAATTA CGATTATGTT GCATGTCAAG CTTTAATTTT AGCCCCCACT 
CGTGAGTTAG CTCAACAAAT TCAAAAGGTA ATAATGAATA AAATGAAATA TAGAAGGTTA 
TATATGTAAA TAGATAAATA TATATATATA TATATATATA TATATGTATA TACATATTTA 
TGTATGATTT ATGATTTGTT AATTTTTAGG TTGTTTTGGC TTTGGGAGAT TATTTAAAAG 
TCAAGTGCCA TGCTTGTGTC GGAGGTACCG TTGTAAGAGA AGATATTGAT AAACTTAAAC 
AAGGAGTACA TATGGTTGTT GGTACCCCAG GTAGAGTTTA TGATATGATT GATAAGAGAC 
ATTTAGGTGT TGATAGATTA AAGTTATTTA TATTAGATGA AGCAGATGAA ATGTTATCAA 
GAGGATTTAA AGCTCAAATA TATGAAGTTT TTAAGAAATT AGTACCAGAT ATTCAAGTTG 
CTTTATTTTC TGCTACAATG CCACAAGAAA TATTAGAATT AACTACTAGG TTTATGAGAG 
ACCCCAAAAC TATTTTAGTT AAAAAAGATG AATTGACACT TGAAGGTATT AGGCAGTTCT 
ATGTTGCTGT AGAAAAGGAA GAATGGAAAT TAGATACCTT ATGTGATTTA TATGAAACAT 
TAACCATTAC ACAATCTATA ATATATTGTA ACACTAGGAA AAAGGTTGAT ATATTAACTC 
AAGAAATGCA CAATCGTCTT TTCACTGTAT CATGTATGCA CGGAGATATG GACCAAAAAG 
ACAGAGATTT AATTATGAGA GAATTCAGAT CTGGATCAAC AAGAGTTTTA GTAACAACAG 
ATTTGTTAGC AAGAGGTATT GATGTACAAC AAGTTTCATT AGTTATCAAT TATGATTTAC 
CAGCTTCACC AGATACATAT ATTCACAGGT AATATATGGA AAATGAATAT ATATAAATAT 
AAATATATAT ATATATATAT ATAAATATAT GTGTATTTTA TTTTTATTTT TTTCTCTTTA 
GAATTGGTCG TTCTGGAAGA TTTGGTCGTA AGGGAGTTGC TATCAACTTT GTTACCAACG 
ATGATAAGGA AAAAGATAAG TTAAAGAAAA TCGAATCCTA CTATAGTACT CAAATAGAAG 
AAATGCCCTT AGAAGTAATA AAAATAAAAT ATATATATAT ATATGTGTAT CACTTTATAT 
GTATCTATTG TTTTATAATA ATATATATTT CATTTTAATA TATATATATG TATATATTTT 
TTTTTTTTTT TTTTTTTTTT TTCTTTTGTA GGTTGCTGAC TATTTATAA 
 
Spliced Native DNA (PlasmoDB gene ID: PF14_0655) 
ATGAGTACTA AAGAAGAGAC TTTTAATAAT GAAAACGACA TTGAAGGAAA TACAGAAGAG 
ATTGTTGATA CATTCGACGC TCTTGGATTA AATGAAAAAC TTTTAAGGGG TATATATTCT 
TATGGTTTTG AAAAGCCATC AGCAATTCAA CAAAGAGGTA TTAAACCTAT TTTGAATGGT 
TACGATACTA TTGGTCAAGC TCAATCTGGT ACAGGAAAAA CAGCTACTTT CGTTATTTCC 
TCATTGCAGT TAATTAATTA CGATTATGTT GCATGTCAAG CTTTAATTTT AGCCCCCACT 
CGTGAGTTAG CTCAACAAAT TCAAAAGGTT GTTTTGGCTT TGGGAGATTA TTTAAAAGTC 
xxix 
AAGTGCCATG CTTGTGTCGG AGGTACCGTT GTAAGAGAAG ATATTGATAA ACTTAAACAA 
GGAGTACATA TGGTTGTTGG TACCCCAGGT AGAGTTTATG ATATGATTGA TAAGAGACAT 
TTAGGTGTTG ATAGATTAAA GTTATTTATA TTAGATGAAG CAGATGAAAT GTTATCAAGA 
GGATTTAAAG CTCAAATATA TGAAGTTTTT AAGAAATTAG TACCAGATAT TCAAGTTGCT 
TTATTTTCTG CTACAATGCC ACAAGAAATA TTAGAATTAA CTACTAGGTT TATGAGAGAC 
CCCAAAACTA TTTTAGTTAA AAAAGATGAA TTGACACTTG AAGGTATTAG GCAGTTCTAT 
GTTGCTGTAG AAAAGGAAGA ATGGAAATTA GATACCTTAT GTGATTTATA TGAAACATTA 
ACCATTACAC AATCTATAAT ATATTGTAAC ACTAGGAAAA AGGTTGATAT ATTAACTCAA 
GAAATGCACA ATCGTCTTTT CACTGTATCA TGTATGCACG GAGATATGGA CCAAAAAGAC 
AGAGATTTAA TTATGAGAGA ATTCAGATCT GGATCAACAA GAGTTTTAGT AACAACAGAT 
TTGTTAGCAA GAGGTATTGA TGTACAACAA GTTTCATTAG TTATCAATTA TGATTTACCA 
GCTTCACCAG ATACATATAT TCACAGAATT GGTCGTTCTG GAAGATTTGG TCGTAAGGGA 
GTTGCTATCA ACTTTGTTAC CAACGATGAT AAGGAAAAAG ATAAGTTAAA GAAAATCGAA 
TCCTACTATA GTACTCAAAT AGAAGAAATG CCCTTAGAAG TTGCTGACTA TTTATAA 
 
Spliced Codon-Optimised DNA 
ATGAGCACCA AAGAAGAAAC CTTTAATAAC GAAAATGATA TTGAAGGCAA  ACCGAAGAA 
ATTGTGGATA CCTTTGATGC ACTGGGCCTG AATGAAAAAC TGCTGCGTGG TATTTATAGC 
TATGGCTTTG AAAAACCGAG CGCAATTCAG CAGCGTGGTA TTAAACCGAT TCTGAATGGC 
TATGATACCA TTGGTCAGGC ACAGAGCGGC ACCGGTAAAA CCGCAACCTT TGTTATTAGC 
AGCCTGCAGC TGATTAATTA TGATTATGTT GCATGCCAGG CCCTGATTCT GGCACCGACC 
CGTGAACTGG CACAGCAGAT TCAGAAAGTT GTTCTGGCAC TGGGTGATTA TCTGAAAGTT 
AAATGTCATG CATGTGTTGG TGGCACCGTT GTTCGTGAAG ATATTGATAA ACTGAAACAG 
GGTGTGCATA TGGTTGTTGG TACACCGGGT CGTGTTTATG ATATGATTGA TAAACGTCAT 
CTGGGTGTGG ATCGTCTGAA ACTGTTTATT CTGGATGAAG CAGATGAAAT GCTGAGCCGT 
GGTTTTAAAG CCCAGATTTA TGAAGTGTTT AAAAAACTGG TGCCGGATAT TCAGGTTGCA 
CTGTTTAGCG CAACCATGCC GCAAGAAATT CTGGAACTGA CCACCCGTTT TATGCGTGAT 
CCGAAAACCA TTCTGGTGAA AAAAGATGAA CTGACCCTGG AAGGTATTCG TCAGTTTTAT 
GTTGCCGTGG AAAAAGAAGA ATGGAAACTG GATACCCTGT GCGATCTGTA TGAAACCCTG 
ACCATTACCC AGAGCATTAT TTATTGCAAT ACCCGCAAAA AAGTGGATAT TCTGACCCAA 
GAAATGCATA ATCGTCTGTT TACCGTTAGC TGTATGCATG GTGATATGGA TCAGAAAGAT 
CGCGATCTGA TTATGCGTGA ATTTCGTAGC GGTAGCACCC GTGTTCTGGT TACCACCGAT 
CTGCTGGCAC GTGGTATTGA TGTTCAGCAG GTTAGCCTGG TTATTAATTA TGATCTGCCG 
GCAAGTCCGG ATACCTATAT TCATCGTATT GGTCGTAGCG GTCGTTTTGG TCGTAAAGGT 
GTTGCCATTA ATTTTGTGAC CAATGATGAT AAAGAAAAAG ACAAACTGAA AAAAATCGAA 
AGCTATTATA GCACCCAGAT TGAAGAAATG CCGCTGGAAG TTGCAGATTA TCTGTAA 
  
xxx 
Appendix 3: PFH45 Codon Optimisation Table 
Amino 
Acid 
3 Letter 
Code 
E. coli Codon Usage for PFH45 
Expression 
P. falciparum Codon Usage for PFH45 
Expression 
Number 
Frequency 
(‰) 
Fraction Number 
Frequency 
(‰) 
Fraction 
Ala GCG 0 0 0 0 0 0 
Ala GCA 15 37.59 0.79 4 10.03 0.21 
Ala GCT 0 0 0 14 35.09 0.74 
Ala GCC 4 10.03 0.21 1 2.51 0.05 
Cys TGT 3 7.52 0.5 5 12.53 0.83 
Cys TGC 3 7.52 0.5 1 2.51 0.17 
Asp GAT 30 75.19 0.97 25 62.66 0.81 
Asp GAC 1 2.51 0.03 6 15.04 0.19 
Glu GAG 0 0 0 3 7.52 0.11 
Glu GAA 28 70.18 1 25 62.66 0.89 
Phe TTT 14 35.09 1 9 22.56 0.64 
Phe TTC 0 0 0 5 12.53 0.36 
Gly GGG 0 0 0 0 0 0 
Gly GGA 0 0 0 11 27.57 0.44 
Gly GGT 19 47.62 0.76 14 35.09 0.56 
Gly GGC 6 15.04 0.24 0 0 0 
His CAT 6 15.04 1 3 7.52 0.5 
His CAC 0 0 0 3 7.52 0.5 
Ile ATA 0 0 0 8 20.05 0.26 
Ile ATT 30 75.19 0.97 20 50.13 0.65 
Ile ATC 1 2.51 0.03 3 7.52 0.1 
Lys AAG 0 0 0 12 30.08 0.41 
Lys AAA 29 72.68 1 17 42.61 0.59 
Leu TTG 0 0 0 6 15.04 0.15 
Leu TTA 0 0 0 30 75.19 0.73 
Leu CTG 41 102.76 1 0 0 0 
Leu CTA 0 0 0 0 0 0 
Leu CTT 0 0 0 5 12.53 0.12 
Leu CTC 0 0 0 0 0 0 
Met ATG 11 27.57 1 11 27.57 1 
Asn AAT 11 27.57 0.92 8 20.05 0.67 
Asn AAC 1 2.51 0.08 4 10.03 0.33 
Pro CCG 10 25.06 1 0 0 0 
Pro CCA 0 0 0 6 15.04 0.6 
Pro CCT 0 0 0 1 2.51 0.1 
Pro CCC 0 0 0 3 7.52 0.3 
Gln CAG 18 45.11 0.9 2 5.01 0.1 
Gln CAA 2 5.01 0.1 18 45.11 0.9 
Arg AGG 0 0 0 4 10.03 0.18 
Arg AGA 0 0 0 14 35.09 0.64 
xxxi 
Arg CGG 0 0 0 0 0 0 
Arg CGA 0 0 0 0 0 0 
Arg CGT 20 50.13 0.91 4 10.03 0.18 
Arg CGC 2 5.01 0.09 0 0 0 
Ser AGT 1 2.51 0.06 2 5.01 0.12 
Ser AGC 16 40.1 0.94 0 0 0 
Ser TCG 0 0 0 0 0 0 
Ser TCA 0 0 0 7 17.54 0.41 
Ser TCT 0 0 0 6 15.04 0.35 
Ser TCC 0 0 0 2 5.01 0.12 
Thr ACG 0 0 0 0 0 0 
Thr ACA 1 2.51 0.03 12 30.08 0.41 
Thr ACT 0 0 0 12 30.08 0.41 
Thr ACC 28 70.18 0.97 5 12.53 0.17 
Val GTG 9 22.56 0.3 0 0 0 
Val GTA 0 0 0 7 17.54 0.23 
Val GTT 21 52.63 0.7 21 52.63 0.7 
Val GTC 0 0 0 2 5.01 0.07 
Trp TGG 1 2.51 1 1 2.51 1 
Tyr TAT 16 40.1 1 13 32.58 0.81 
Tyr TAC 0 0 0 3 7.52 0.19 
End TGA 0 0 0 0 0 0 
End TAG 0 0 0 0 0 0 
End TAA 1 2.51 1 1 2.51 1 
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Appendix 4: PFDH60 Sequences 
Native DNA (PlasmoDB gene ID: PFL1310c) 
ATGAGAAGAA ATTTACTGAA GTTAACCTCT ATAAATTGTA AGAAGAATGA CTATGTTTCC 
CTTTCTAACA ATTTTTTTTT AATAAAAAAT AGGTCATATA AATATATAAC CGTAAGAAAC 
AAAATAGGAA GAAATGTATT TAATGAGAAG GATAATTGTG CCATATTGAA TCGAGGACAA 
ACACATGTCG TAGGTATCAA GAAAAATATA TGTACCGAAA ATAAAGTTAA ACAACAGGAT 
GGAGAGTTTT ATATGAATCA AAGAGTTCCA GATGATATGG ATAATGATAT GGATAATAAT 
GTGGATAATG ATATGGATAA CAATGTGGAT AATCATGTGG ATAATCATGT GGATAATCAT 
GTGGATAATC ATGTGGATAA TCATATGGAT AATCATATAA ATAATCATAC ACATAAAAAT 
GTGCATGATG ACACATCATA TGATAATAAT TCTTTCGATA GATACCAAAG AAAAAGAGAC 
GAAATAGGTG AAAACGGTTT TGTTCAAAAT AGAAGATATG AAAATTATGA AAAACGTAAA 
CAATCAAAAA CAAATTATTC ATATGATAAT GATTATAATC AGGGTTCAAG AAATAAAAGA 
AATATGTCAT ATCCTGATAG ATATGAAGAA TTAGGAAGTC ATTTAAAGGA CATCGAATGG 
GATAATGTGA AATATAAAAT GGAAAGGCAA AATCTATACA ACAACAATTA TAATAAGTGT 
AATGATCAGA ATAATAATCA GAATAGTAAT GATAATTTAA ATAATGAGCA AACAAATTGT 
TTAAGTAAAG AGGATATACA AAACGAATTA AAGAAAAATA ATATTTATAT TAACAAGGAT 
GGAATAATAC ATAATATCAT TAATAAATTC TCAGATGTAT GTTTTCATGA ATCCATATTA 
AATTATCTAA ATAATAAATT TAGTGAACCT ACAGCTATTC AAAAAATCAC ATGGCCTATT 
GCTTTATCAG GAAAAGATCT TATAGGTGTA GCAGAAACGG GAAGTGGAAA AACGTTAGCT 
TTTGTTTTGC CGTGTTTTAT GCATATACTT AAGCATAAAG AAATTATACA AAATAATAAT 
AATAATAAAC AAACAAATCA AAACAATAAT TTACAGCAAG AACAGGAAGG GAAAACAAAT 
AATCATCATA TAATAAATAA TTATAATGAA AATAATGACA ACAATGAAAA TAATCACAAC 
AACAACAACA ATAATAATAA TAATAATAAT AATAGTTATG ATTATGATTA TGATATAAAT 
TCCTCTGAAC GGGCAAGTGA TACTTATGGA CTCATTTTAT TACCCACGAG AGAATTGTGC 
TTACAAGTTT TAGATGAAAT CAAATCCTTC GAAAAAAACC TACCAATTAA AAGTGTTGCT 
GTTTATGGTG GAGTACCGAA ATATTATCAA ATAAATAATT TAAAAAAAGG TGCTGATATT 
ATTGTTGCTA CCCCAGGAAG ACTTTTAGAC TTTTTAGAAA ATGGTAACAT CAACCTTTTA 
AAATGTATTT ATGTTGTTAT TGATGAAGCT GATCGTTTAC TTGATATGGG ATTCGAAAAA 
CAATTAAGAA AAATTATGAC CCAAGTTAAT AAAAATAAAC AATTGCTATT CTTAACTGCT 
ACATGGCCTG AACAAGTCAG GAAACTTGCA TATGATTTTT GTTCCTATGA TCCAGTAAAA 
ATTCAAATAG GAAAAAATGA ATTGACAGCA AATAAAAATA TTGAGCAAAA TGTTATTATA 
AGTTCTTCTA TTGATATGAA GAAAAAATTA TTAGATTGGT TAAAAGAAAA TTATGAAAAT 
AATAAAATAT TAATATTTTG TGATACCAAA AGAAATTGTG ATAATTTATG TAAAGAATTA 
AGATATCATC AGTATAATGC TTTATCAATT CATGGGGATA AGCAGCAAAG AGAAAGAGAT 
CGAATATTGA ATAATTACAA AACAGATCGA TGTAATATAT TAGTAGCAAC CGATGTAGCT 
TCAAGAGGAT TAGATATTAA AAATATTTCT GTTGTCATTA ATTATGATAT ACCTAATACT 
ATAGAAGATT ATATACATAG AATAGGAAGA ACAGGAAGAG CTGGGAAAAA AGGGAAATCA 
ATCTTGTTCT TTTCGTATGA TTATTATATG CCACAAAAAT TAAAGTTTGC AAAAGAGTTA 
xxxiii 
ATTAAATTGT TAAATAAAAC AAATCAAACT GTTCCACCAC AGTTAAAAGA AATAGCTTAT 
TCAAGATGA 
 
Codon-Optimised DNA 
ATGCGTCGTA ATCTGCTGAA ACTGACCAGC ATTAATTGCA AAAAAAATGA CTACGTGAGC 
CTGAGCAACA ACTTTTTTCT GATTAAAAAT CGCAGCTATA AATATATTAC CGTGCGCAAT 
AAAATTGGTC GCAACGTGTT TAACGAAAAA GATAATTGCG CCATTCTGAA TCGTGGTCAG 
ACCCATGTTG TGGGCATTAA AAAAAACATC TGCACCGAAA ATAAAGTGAA ACAGCAGGAT 
GGCGAGTTCT ATATGAATCA GCGTGTTCCG GATGATATGG ATAATGATAT GGACAACAAC 
GTGGATAACG ACATGGATAA TAACGTTGAC AACCATGTGG ATAACCATGT TGATAATCAC 
GTGGACAATC ACGTCGATAA TCATATGGAT AACCATATCA ACAATCATAC CCATAAAAAC 
GTGCACGATG ATACCAGCTA TGATAACAAT AGCTTCGATC GTTATCAGCG CAAACGTGAT 
GAAATTGGTG AAAATGGCTT TGTTCAGAAC CGTCGCTATG AAAATTATGA GAAACGCAAA 
CAGAGCAAAA CCAACTATAG CTATGATAAT GACTACAATC AGGGCAGCCG CAATAAACGT 
AATATGAGCT ATCCGGATCG CTATGAAGAA CTGGGTAGCC ATCTGAAAGA TATTGAATGG 
GACAATGTGA AATATAAAAT GGAACGCCAG AATCTGTATA ACAATAATTA CAACAAATGC 
AATGACCAGA ATAATAATCA GAATAGCAAT GATAATCTGA ATAATGAACA GACCAATTGC 
CTGAGCAAAG AAGATATTCA GAACGAACTG AAAAAAAACA ACATCTATAT TAACAAAGAT 
GGCATCATCC ACAATATCAT TAATAAATTT AGCGACGTGT GCTTTCACGA AAGCATTCTG 
AATTATCTGA ATAACAAATT CAGCGAACCG ACCGCCATTC AGAAAATTAC CTGGCCGATT 
GCACTGAGCG GTAAAGATCT GATTGGTGTT GCAGAAACCG GTAGCGGTAA AACCCTGGCA 
TTTGTTCTGC CGTGTTTTAT GCATATTCTG AAACATAAAG AAATCATTCA GAACAACAAT 
AATAACAAAC AGACCAATCA GAACAATAAT CTGCAGCAAG AACAAGAAGG CAAAACCAAC 
AACCATCACA TCATCAACAA TTACAATGAA AATAACGACA ACAACGAAAA TAATCATAAC 
AACAACAACA ACAATAACAA TAACAACAAT AATAGCTATG ACTATGACTA TGATATTAAT 
AGCAGCGAAC GTGCAAGCGA TACCTATGGT CTGATTCTGC TGCCGACCCG TGAACTGTGT 
CTGCAGGTTC TGGATGAAAT CAAAAGCTTT GAAAAAAATC TGCCGATCAA AAGCGTTGCA 
GTTTATGGTG GTGTGCCGAA ATATTATCAG ATTAATAATC TGAAAAAAGG TGCCGATATT 
ATTGTTGCAA CACCGGGTCG TCTGCTGGAT TTTCTGGAAA ATGGCAATAT CAACCTGCTG 
AAATGCATCT ATGTGGTTAT TGATGAAGCA GATCGCCTGC TGGATATGGG TTTTGAAAAA 
CAGCTGCGCA AAATTATGAC CCAGGTGAAT AAAAACAAAC AGCTGCTGTT TCTGACCGCA 
ACCTGGCCTG AACAGGTTCG TAAACTGGCA TATGATTTCT GTAGCTATGA CCCGGTGAAA 
ATTCAGATTG GCAAAAATGA ACTGACCGCC AACAAAAACA TCGAACAGAA TGTGATTATT 
AGCAGCAGCA TTGATATGAA AAAAAAACTG CTGGATTGGC TGAAAGAAAA TTACGAGAAT 
AATAAAATTC TGATTTTTTG CGATACCAAA CGCAACTGTG ACAATCTGTG TAAAGAACTG 
CGCTATCATC AGTATAATGC CCTGAGCATT CATGGTGATA AACAGCAGCG TGAACGTGAT 
CGTATTCTGA ATAACTATAA AACCGACCGC TGCAATATTC TGGTTGCAAC CGATGTTGCA 
AGCCGTGGTC TGGATATCAA AAATATTAGC GTGGTGATTA ATTATGATAT TCCGAACACC 
xxxiv 
ATTGAAGATT ACATCCATCG TATTGGTCGT ACCGGTCGTG CAGGTAAAAA AGGTAAAAGC 
ATCCTGTTCT TTAGCTATGA TTACTACATG CCGCAGAAAC TGAAATTTGC CAAAGAACTG 
ATTAAACTGC  TGAATAAAAC CAATCAGACC GTTCCGCCTC AGCTGAAAGA AATTGCATAT 
AGCCGCTAA 
  
xxxv 
Appendix 5: PFDH60 Codon Optimisation Table 
Amino 
Acid 
3 Letter 
Code 
E. coli Codon Usage for PFDH60 
Expression 
P. falciparum Codon Usage for PFDH60 
Expression 
Number 
Frequency 
(‰) 
Fraction Number 
Frequency 
(‰) 
Fraction 
Ala GCG 0 0 0 0 0 0 
Ala GCA 13 17.5 0.68 6 8.08 0.32 
Ala GCT 0 0 0 12 16.15 0.63 
Ala GCC 6 8.08 0.32 1 1.35 0.05 
Cys TGT 5 6.73 0.36 13 17.5 0.93 
Cys TGC 9 12.11 0.64 1 1.35 0.07 
Asp GAT 43 57.87 0.74 52 69.99 0.9 
Asp GAC 15 20.19 0.26 6 8.08 0.1 
Glu GAG 3 4.04 0.08 6 8.08 0.15 
Glu GAA 36 48.45 0.92 33 44.41 0.85 
Phe TTT 15 20.19 0.75 14 18.84 0.7 
Phe TTC 5 6.73 0.25 6 8.08 0.3 
Gly GGG 0 0 0 4 5.38 0.14 
Gly GGA 0 0 0 16 21.53 0.57 
Gly GGT 20 26.92 0.71 8 10.77 0.29 
Gly GGC 8 10.77 0.29 0 0 0 
His CAT 15 20.19 0.71 20 26.92 0.95 
His CAC 6 8.08 0.29 1 1.35 0.05 
Ile ATA 0 0 0 30 40.38 0.51 
Ile ATT 42 56.53 0.71 22 29.61 0.37 
Ile ATC 17 22.88 0.29 7 9.42 0.12 
Lys AAG 0 0 0 13 17.5 0.19 
Lys AAA 68 91.52 1 55 74.02 0.81 
Leu TTG 0 0 0 8 10.77 0.14 
Leu TTA 0 0 0 36 48.45 0.63 
Leu CTG 57 76.72 1 1 1.35 0.02 
Leu CTA 0 0 0 4 5.38 0.07 
Leu CTT 0 0 0 7 9.42 0.12 
Leu CTC 0 0 0 1 1.35 0.02 
Met ATG 13 17.5 1 13 17.5 1 
Asn AAT 74 99.6 0.6 106 142.66 0.86 
Asn AAC 49 65.95 0.4 17 22.88 0.14 
Pro CCG 13 17.5 0.87 2 2.69 0.13 
Pro CCA 0 0 0 7 9.42 0.47 
Pro CCT 2 2.69 0.13 5 6.73 0.33 
Pro CCC 0 0 0 1 1.35 0.07 
Gln CAG 32 43.07 0.94 9 12.11 0.26 
Gln CAA 2 2.69 0.06 25 33.65 0.74 
Arg AGG 0 0 0 3 4.04 0.09 
Arg AGA 0 0 0 25 33.65 0.74 
xxxvi 
Arg CGG 0 0 0 1 1.35 0.03 
Arg CGA 0 0 0 3 4.04 0.09 
Arg CGT 19 25.57 0.56 2 2.69 0.06 
Arg CGC 15 20.19 0.44 0 0 0 
Ser AGT 0 0 0 9 12.11 0.26 
Ser AGC 34 45.76 1 0 0 0 
Ser TCG 0 0 0 1 1.35 0.03 
Ser TCA 0 0 0 12 16.15 0.35 
Ser TCT 0 0 0 7 9.42 0.21 
Ser TCC 0 0 0 5 6.73 0.15 
Thr ACG 0 0 0 3 4.04 0.11 
Thr ACA 1 1.35 0.04 14 18.84 0.5 
Thr ACT 0 0 0 4 5.38 0.14 
Thr ACC 27 36.34 0.96 7 9.42 0.25 
Val GTG 18 24.23 0.51 8 10.77 0.23 
Val GTA 0 0 0 9 12.11 0.26 
Val GTT 16 21.53 0.46 15 20.19 0.43 
Val GTC 1 1.35 0.03 3 4.04 0.09 
Trp TGG 4 5.38 1 4 5.38 1 
Tyr TAT 31 41.72 0.79 36 48.45 0.92 
Tyr TAC 8 10.77 0.21 3 4.04 0.08 
End TGA 0 0 0 1 1.35 1 
End TAG 0 0 0 0 0 0 
End TAA 1 1.35 1 0 0 0 
 
  
xxxvii 
Appendix 6: BLAST Alignment of PFH45 against EIF4A1 
ALIGN calculates a global alignment of two sequences version 2.2u 
Please cite: Myers and Miller, CABIOS (1989) 4:11-17 
PFH45 398 bp  398 aa vs. 
EIF4A1 406 bp 406 aa 
using matrix file: BLOSUM50, gap open/ext: -14/-4 
66.7% identity in 408 aa overlap; Global score: 1786 
 
                        10        20        30        40        50  
PFH45  ---------MSTKEETFNNENDIEGNTEEIVDTFDALGLNEKLLRGIYSYGFEKPSAIQQ 
                 ..  . .. :. ::.: .::::.:: ..:.:.::::::.::::::::::: 
EIF4A1 MSASQDSRSRDNGPDGMEPEGVIESNWNEIVDSFDDMNLSESLLRGIYAYGFEKPSAIQQ 
               10        20        30        40        50        60 
 
              60        70        80        90       100       110  
PFH45  RGIKPILNGYDTIGQAQSGTGKTATFVISSLQLINYDYVACQALILAPTRELAQQIQKVV 
       :.: : ..:::.:.::::::::::::.:: :: :. :  : :::.::::::::::::::: 
EIF4A1 RAILPCIKGYDVIAQAQSGTGKTATFAISILQQIELDLKATQALVLAPTRELAQQIQKVV 
               70        80        90       100       110       120 
 
             120       130        140       150       160       170 
PFH45  LALGDYLKVKCHACVGGTVVREDIDKLK-QGVHMVVGTPGRVYDMIDKRHLGVDRLKLFI 
       .:::::. ..::::.::: :: ...::. .. :..:::::::.::...:.:.   .:.:. 
EIF4A1 MALGDYMGASCHACIGGTNVRAEVQKLQMEAPHIIVGTPGRVFDMLNRRYLSPKYIKMFV 
              130       140       150       160       170       180 
 
              180       190       200       210       220       230 
PFH45  LDEADEMLSRGFKAQIYEVFKKLVPDIQVALFSATMPQEILELTTRFMRDPKTILVKKDE 
       ::::::::::::: :::..:.::  . ::.:.:::::...::.: .:::::  :::::.: 
EIF4A1 LDEADEMLSRGFKDQIYDIFQKLNSNTQVVLLSATMPSDVLEVTKKFMRDPIRILVKKEE 
              190       200       210       220       230       240 
 
              240       250       260       270       280       290 
PFH45  LTLEGIRQFYVAVEKEEWKLDTLCDLYETLTITQSIIYCNTRKKVDILTQEMHNRLFTVS 
       ::::::::::. ::.:::::::::::::::::::..:. :::.::: ::..:: : :::: 
EIF4A1 LTLEGIRQFYINVEREEWKLDTLCDLYETLTITQAVIFINTRRKVDWLTEKMHARDFTVS 
              250       260       270       280       290       300 
 
              300       310       320       330       340       350 
PFH45  CMHGDMDQKDRDLIMREFRSGSTRVLVTTDLLARGIDVQQVSLVINYDLPASPDTYIHRI 
        ::::::::.::.:::::::::.:::.:::::::::::::::::::::::.. ..::::: 
EIF4A1 AMHGDMDQKERDVIMREFRSGSSRVLITTDLLARGIDVQQVSLVINYDLPTNRENYIHRI 
              310       320       330       340       350       360 
 
              360       370       380       390         
PFH45  GRSGRFGRKGVAINFVTNDDKEKDKLKKIESYYSTQIEEMPLEVADYL 
       ::.:::::::::::.::..::.   :. ::..:.:.::::::.::: . 
EIF4A1 GRGGRFGRKGVAINMVTEEDKRT--LRDIETFYNTSIEEMPLNVADLI 
              370       380         390       400 
  
xxxviii 
Appendix 7: FASTA Amino Acid Sequences of PFEIF4A and Human 
EIF4A Isoforms 1, 2, and 3 
PFEIF4A 
MSTKEETFNNENDIEGNTEEIVDTFDALGLNEKLLRGIYSYGFEKPSAIQQRGIKPILNGYDTIGQAQSGTGK
TATFVISSLQLINYDYVACQALILAPTRELAQQIQKVVLALGDYLKVKCHACVGGTVVREDIDKLKQGVHMVV
GTPGRVYDMIDKRHLGVDRLKLFILDEADEMLSRGFKAQIYEVFKKLVPDIQVALFSATMPQEILELTTRFMR
DPKTILVKKDELTLEGIRQFYVAVEKEEWKLDTLCDLYETLTITQSIIYCNTRKKVDILTQEMHNRLFTVSCM
HGDMDQKDRDLIMREFRSGSTRVLVTTDLLARGIDVQQVSLVINYDLPASPDTYIHRIGRSGRFGRKGVAINF
VTNDDKEKDKLKKIESYYSTQIEEMPLEVADYL 
 
EIF4A1 (NCBI accession number: AAV38684.1) 
MSASQDSRSRDNGPDGMEPEGVIESNWNEIVDSFDDMNLSESLLRGIYAYGFEKPSAIQQRAILPCIKGYDVI
AQAQSGTGKTATFAISILQQIELDLKATQALVLAPTRELAQQIQKVVMALGDYMGASCHACIGGTNVRAEVQK
LQMEAPHIIVGTPGRVFDMLNRRYLSPKYIKMFVLDEADEMLSRGFKDQIYDIFQKLNSNTQVVLLSATMPSD
VLEVTKKFMRDPIRILVKKEELTLEGIRQFYINVEREEWKLDTLCDLYETLTITQAVIFINTRRKVDWLTEKM
HARDFTVSAMHGDMDQKERDVIMREFRSGSSRVLITTDLLARGIDVQQVSLVINYDLPTNRENYIHRIGRGGR
FGRKGVAINMVTEEDKRTLRDIETFYNTSIEEMPLNVADLI 
 
EIF4A2 (NCBI accession number: AAP88862.1) 
MSGGSADYNREHGGPEGMDPDGVIESNWNEIVDNFDDMNLKESLLRGIYAYGFEKPSAIQQRAIIPCIKGYDV
IAQAQSGTGKTATFAISILQQLEIEFKETQALVLAPTRELAQQIQKVILALGDYMGATCHACIGGTNVRNEMQ
KLQAEAPHIVVGTPGRVFDMLNRRYLSPKWIKMFVLDEADEMLSRGFKDQIYEIFQKLNTSIQVVLLSATMPT
DVLEVTKKFMRDPIRILVKKEELTLEGIKQFYINVEREEWKLDTLCDLYETLTITQAVIFLNTRRKVDWLTEK
MHARDFTVSALHGDMDQKERDVIMREFRSGSSRVLITTDLLARGIDVQQVSLVINYDLPTNRENYIHRIGRGG
RFGRKGVAINFVTEEDKRILRDIETFYNTTVEEMPMNVADLI 
 
EIF4A3 (NCBI accession number: AAH11151.1) 
MATTATMATSGSARKRLLKEEDMTKVEFETSEEVDVTPTFDTMGLREDLLRGIYAYGFEKPSAIQQRAIKQII
KGRDVIAQSQSGTGKTATFSISVLQCLDIQVRETQALILAPTRELAVQIQKGLLALGDYMNVQCHACIGGTNV
xxxix 
GEDIRKLDYGQHVVAGTPGRVFDMIRRRSLRTRAIKMLVLDEADEMLNKGFKEQIYDVYRYLPPATQVVLISA
TLPHEILEMTNKFMTDPIRILVKRDELTLEGIKQFFVAVEREEWKFDTLCDLYDTLTITQAVIFCNTKRKVDW
LTEKMREANFTVSSMHGDMPQKERESIMKEFRSGASRVLISTDVWARGLDVPQVSLIINYDLPNNRELYIHRI
GRSGRYGRKGVAINFVKNDDIRILRDIEQYYSTQIDEMPMNVADLI 
  
xl 
Appendix 8: Clustal Alignment of PFEIF4A with Human EIF4A 
Isoforms 1, 2, and 3 
EIF4A1 --MSASQDSRSRDNG-PDGMEPEGVIESNWNEIVDS---FDDMNLSESLLRGIYAYGFEK 54 
EIF4A2 --MSGGSADYNREHGGPEGMDPDGVIESNWNEIVDN---FDDMNLKESLLRGIYAYGFEK 55 
PFEIF4A --MSTKEETFNNEND----------IEGNTEEIVDT---FDALGLNEKLLRGIYSYGFEK 45 
EIF4A3 MATTATMATSGSARKRLLKEEDMTKVEFETSEEVDVTPTFDTMGLREDLLRGIYAYGFEK 60 
    :      .  .           :* : .* **    ** :.* *.******:***** 
 
EIF4A1 PSAIQQRAILPCIKGYDVIAQAQSGTGKTATFAISILQQIELDLKATQALVLAPTRELAQ 114 
EIF4A2 PSAIQQRAIIPCIKGYDVIAQAQSGTGKTATFAISILQQLEIEFKETQALVLAPTRELAQ 115 
PFEIF4A PSAIQQRGIKPILNGYDTIGQAQSGTGKTATFVISSLQLINYDYVACQALILAPTRELAQ 105 
EIF4A3 PSAIQQRAIKQIIKGRDVIAQSQSGTGKTATFSISVLQCLDIQVRETQALILAPTRELAV 120 
 *******.*   ::* *.*.*:********** ** ** :: :    ***:********  
 
EIF4A1 QIQKVVMALGDYMGASCHACIGGTNVRAEVQKLQMEAPHIIVGTPGRVFDMLNRRYLSPK 174 
EIF4A2 QIQKVILALGDYMGATCHACIGGTNVRNEMQKLQAEAPHIVVGTPGRVFDMLNRRYLSPK 175 
PFEIF4A QIQKVVLALGDYLKVKCHACVGGTVVREDIDKLKQGV-HMVVGTPGRVYDMIDKRHLGVD 164 
EIF4A3 QIQKGLLALGDYMNVQCHACIGGTNVGEDIRKLDYGQ-HVVAGTPGRVFDMIRRRSLRTR 179 
 **** ::*****: . ****:*** *  :: **.    *::.******:**: :* *    
 
EIF4A1 YIKMFVLDEADEMLSRGFKDQIYDIFQKLNSNTQVVLLSATMPSDVLEVTKKFMRDPIRI 234 
EIF4A2 WIKMFVLDEADEMLSRGFKDQIYEIFQKLNTSIQVVLLSATMPTDVLEVTKKFMRDPIRI 235 
PFEIF4A RLKLFILDEADEMLSRGFKAQIYEVFKKLVPDIQVALFSATMPQEILELTTRFMRDPKTI 224 
EIF4A3 AIKMLVLDEADEMLNKGFKEQIYDVYRYLPPATQVVLISATLPHEILEMTNKFMTDPIRI 239 
  :*:::********.:*** ***:::: * .  **.*:***:* ::**:*.:** **  * 
 
EIF4A1 LVKKEELTLEGIRQFYINVEREEWKLDTLCDLYETLTITQAVIFINTRRKVDWLTEKMHA 294 
EIF4A2 LVKKEELTLEGIKQFYINVEREEWKLDTLCDLYETLTITQAVIFLNTRRKVDWLTEKMHA 295 
PFEIF4A LVKKDELTLEGIRQFYVAVEKEEWKLDTLCDLYETLTITQSIIYCNTRKKVDILTQEMHN 284 
EIF4A3 LVKRDELTLEGIKQFFVAVEREEWKFDTLCDLYDTLTITQAVIFCNTKRKVDWLTEKMRE 299 
 ***::*******:**:: **:****:*******:******::*: **::*** **::*:  
 
EIF4A1 RDFTVSAMHGDMDQKERDVIMREFRSGSSRVLITTDLLARGIDVQQVSLVINYDLPTNRE 354 
EIF4A2 RDFTVSALHGDMDQKERDVIMREFRSGSSRVLITTDLLARGIDVQQVSLVINYDLPTNRE 355 
PFEIF4A RLFTVSCMHGDMDQKDRDLIMREFRSGSTRVLVTTDLLARGIDVQQVSLVINYDLPASPD 344 
EIF4A3 ANFTVSSMHGDMPQKERESIMKEFRSGASRVLISTDVWARGLDVPQVSLIINYDLPNNRE 359 
   ****.:**** **:*: **:*****::***::**: ***:** ****:****** . : 
 
EIF4A1 NYIHRIGRGGRFGRKGVAINMVTEEDKRTLRDIETFYNTSIEEMPLNVADLI 406 
EIF4A2 NYIHRIGRGGRFGRKGVAINFVTEEDKRILRDIETFYNTTVEEMPMNVADLI 407 
PFEIF4A TYIHRIGRSGRFGRKGVAINFVTNDDKEKDK--------------------- 375 
EIF4A3 LYIHRIGRSGRYGRKGVAINFVKNDDIRILRDIEQYYSTQIDEMPMNVADLI 411 
  *******.**:********:*.::* .  : 
  
xli 
Appendix 9: FASTA Amino Acid Sequences of PFDH60 
MRRNLLKLTSINCKKNDYVSLSNNFFLIKNRSYKYITVRNKIGRNVFNEKDNCAILNRGQTHVVGIKKNICTE
NKVKQQDGEFYMNQRVPDDMDNDMDNNVDNDMDNNVDNHVDNHVDNHVDNHVDNHMDNHINNHTHKNVHDDTS
YDNNSFDRYQRKRDEIGENGFVQNRRYENYEKRKQSKTNYSYDNDYNQGSRNKRNMSYPDRYEELGSHLKDIE
WDNVKYKMERQNLYNNNYNKCNDQNNNQNSNDNLNNEQTNCLSKEDIQNELKKNNIYINKDGIIHNIINKFSD
VCFHESILNYLNNKFSEPTAIQKITWPIALSGKDLIGVAETGSGKTLAFVLPCFMHILKHKEIIQNNNNNKQT
NQNNNLQQEQEGKTNNHHIINNYNENNDNNENNHNNNNNNNNNNNNSYDYDYDINSSERASDTYGLILLPTRE
LCLQVLDEIKSFEKNLPIKSVAVYGGVPKYYQINNLKKGADIIVATPGRLLDFLENGNINLLKCIYVVIDEAD
RLLDMGFEKQLRKIMTQVNKNKQLLFLTATWPEQVRKLAYDFCSYDPVKIQIGKNELTANKNIEQNVIISSSI
DMKKKLLDWLKENYENNKILIFCDTKRNCDNLCKELRYHQYNALSIHGDKQQRERDRILNNYKTDRCNILVAT
DVASRGLDIKNISVVINYDIPNTIEDYIHRIGRTGRAGKKGKSILFFSYDYYMPQKLKFAKELIKLLNKTNQT
VPPQLKEIAYSR 
  
xlii 
Appendix 10: FASTA Amino Acid Sequences of PFDH60 
ALIGN calculates a global alignment of two sequences version 2.2u 
Please cite: Myers and Miller, CABIOS (1989) 4:11-17 
PFDH60     742 bp 742 aa vs. 
ATP-DEPENDENT RNA HELICASE 707 bp 707 aa 
using matrix file: BLOSUM50, gap open/ext: -14/-4 
30.8% identity in 775 aa overlap; Global score: 822 
 
               10        20        30         40        50          
PFDH60 MRRNLLKLTSINCKKNDYVSLSNNFFLIKNRSYKYI-TVRNKIGRNVFNEKD--NCAILN 
       :   .   . ..     ..:   ..:. .. . . .  . ... ::. .  .  :   .  
ATP-DE MFVFFTPGNVLDLALMLFLSQLLSIFITHSMALNPLHRLSSSLPRNLTHSLNITNSLTIP 
               10        20        30        40        50        60 
 
        60            70        80         90       100       110   
PFDH60 RGQTHVVGIKK----NICTENKVKQQDGEFYMN-QRVPDDMDNDMDNNVDNDMDNNVDNH 
       :. :: . : .    .:    ..   .  :    .:: . . . . :  . :  ..:    
ATP-DE RNLTHSLTIPSLTIPTITIPRSITIPSFTFISPVNRVTSRVKTGLGNFGNYDNISTVTAP 
               70        80        90       100       110       120 
 
             120         130       140       150       160          
PFDH60 VD-NHVDNHVDNH--VDNHMDNHINNHTHKNVHDDTSYDNNSFDRYQRKRDEIGEN---- 
        . ... :   :.  : :.         ... . . .  :..::         : .     
ATP-DE YQVGYTPNLSPNYTTVPNYSPYTTPYTGYSTGYGSGTGYNTGFDTNTGYSTGYGSGNTGY 
              130       140       150       160       170       180 
 
           170            180        190       200         210      
PFDH60 --GFVQNRRYEN-----YEKRKQSKTN-YSYDNDYNQGSRNKR--NMSYPDRYEELGSHL 
         :. ..  :..     : ::.  .   :.: : ::   ...:  : . :        .  
ATP-DE STGYGSGTGYNTGYGTGYVKRQGYRPRPYNYANRYNTFRQTRRFYNTNTPLGSPPPHYYP 
              190       200       210       220       230       240 
 
         220          230       240        250       260            
PFDH60 KDIEWD---NVKYKMERQNLYNNNYNKCN-DQNNNQNSNDNLNNEQTNCLSK--EDIQNE 
        ..  :   . ..       :.   .. . :...  . . .. . . .  :.  :.:.   
ATP-DE GQFTLDFGVHSRFGDAVGRGYDIPVSSIDWDKEELVEIKKDFYDLSYEADSRPGEEIERI 
              250       260       270       280       290       300 
 
     270       280       290       300        310       320         
PFDH60 LKKNNIYINKDGIIHNIINKFSDVCFHESILNYLN-NKFSEPTAIQKITWPIALSGKDLI 
       :: .:: :. .  . . .. :... :...: : .. ..:.::: :::. :   :.:.:.: 
ATP-DE LKAHNIIIEGEHPLPKPVTTFDEAVFNQQIQNIIKESNFTEPTPIQKVGWTSCLTGRDII 
              310       320       330       340       350       360 
 
      330       340       350       360       370       380         
PFDH60 GVAETGSGKTLAFVLPCFMHILKHKEIIQNNNNNKQTNQNNNLQQEQEGKTNNHHIINNY 
       ::..:::::::.:.:: ..:.: .  .                                  
ATP-DE GVSQTGSGKTLTFLLPGLLHLLAQPPV--------------------------------- 
              370       380                                         
 
      390       400       410       420       430       440         
PFDH60 NENNDNNENNHNNNNNNNNNNNNSYDYDYDINSSERASDTYGLILLPTRELCLQVLDEIK 
                                           ..    ::: ::::::::. .: . 
ATP-DE -----------------------------------GTGGPIMLILSPTRELCLQIAEEAR 
                                          390       400       410   
 
      450       460       470       480       490       500         
xliii 
PFDH60 SFEKNLPIKSVAVYGGVPKYYQINNLKKGADIIVATPGRLLDFLENGNINLLKCIYVVID 
        . . : .. : .:::. :. :. .:..::.:.::::::::.:: ::.:.: .  : :.: 
ATP-DE PYSRLLNLRLVPIYGGASKFAQVRELQNGAEIMVATPGRLLEFLSNGTIKLNRVSYFVMD 
            420       430       440       450       460       470   
 
      510       520       530       540       550       560         
PFDH60 EADRLLDMGFEKQLRKIMTQVNKNKQLLFLTATWPEQVRKLAYDFCSYDPVKIQIGKNEL 
       ::::.:::::: :.:::. :.  ..: :...:::: ....:: .::. . . ::.:  :: 
ATP-DE EADRMLDMGFEPQIRKIVGQIRPDRQTLMFSATWPSEIKRLASEFCKANSIYIQVGDLEL 
            480       490       500       510       520       530   
 
      570       580       590       600       610       620         
PFDH60 TANKNIEQNVIISSSIDMKKKLLDWLKENYENNKILIFCDTKRNCDNLCKELRYHQYNAL 
       ::: ::.::: . .: ... ::.:.:     ..:.::: : :   :.: . :::.....  
ATP-DE TANPNIRQNVEFPNSYEVRDKLFDFLGSIPPEKKVLIFSDLKSFADQLTSALRYRRFKSA 
            540       550       560       570       580       590   
 
      630       640       650       660       670       680         
PFDH60 SIHGDKQQRERDRILNNYKTDRCNILVATDVASRGLDIKNISVVINYDIPNTIEDYIHRI 
       :.::.: : .:.:::: ...   :.:::::::.::::::.:. ::: :.:... :::::: 
ATP-DE SLHGNKTQAQRERILNMFRSGDVNVLVATDVAARGLDIKDIDYVINLDVPKSLLDYIHRI 
            600       610       620       630       640       650   
 
      690       700       710       720       730       740    
PFDH60 GRTGRAGKKGKSILFFSYDYYMPQKLKFAKELIKLLNKTNQTVPPQLKEIAYSR- 
       :::::...::.:.:.:  :   : :.:::..: :::.:.::::: :: .:: .   
ATP-DE GRTGRGNSKGESLLYFPIDTLTPAKVKFAQDLSKLLSKVNQTVPSQLTQIANNNL 
            660       670       680       690       700         
  
xliv 
Appendix 11: FASTA Amino Acid Sequences of DHX16 
MATPAGLERWVQDELHSVLGLSERHVAQFLIGTAQRCTSAEEFVQRLRDTDTLDLSGPARDFALRLWNKVPRK
AVVEKPARAAEREARALLEKNRSYRLLEDSEESSEETVSRAGSSLQKKRKKRKHLRKKREEEEEEEASEKGKK
KTGGSKQQTEKPESEDEWERTERERLQDLEERDAFAERVRQRDKDRTRNVLERSDKKAYEEAQKRLKMAEEDR
KAMVPELRKKSRREYLAKREREKLEDLEAELADEEFLFGDVELSRHERQELKYKRRVRDLAREYRAAGEQEKL
EATNRYHMPKETRGQPARAVDLVEEESGAPGEEQRRWEEARLGAASLKFGARDAASQEPKYQLVLEEEETIEF
VRATQLQGDEEPSAPPTSTQAQQKESIQAVRRSLPVFPFREELLAAIANHQVLIIEGETGSGKTTQIPQYLFE
EGYTNKGMKIACTQPRRVAAMSVAARVAREMGVKLGNEVGYSIRFEDCTSERTVLRYMTDGMLLREFLSEPDL
ASYSVVMVDEAHERTLHTDILFGLIKDVARFRPELKVLVASATMDTARFSTFFDDAPVFRIPGRRFPVDIFYT
KAPEADYLEACVVSVLQIHVTQPPGDILVFLTGQEEIEAACEMLQDRCRRLGSKIRELLVLPIYANLPSDMQA
RIFQPTPPGARKVVVATNIAETSLTIEGIIYVLDPGFCKQKSYNPRTGMESLTVTPCSKASANQRAGRAGRVA
AGKCFRLYTAWAYQHELEETTVPEIQRTSLGNVVLLLKSLGIHDLMHFDFLDPPPYETLLLALEQLYALGALN
HLGELTTSGRKMAELPVDPMLSKMILASEKYSCSEEILTVAAMLSVNNSIFYRPKDKVVHADNARVNFFLPGG
DHLVLLNVYTQWAESGYSSQWCYENFVQFRSMRRARDVREQLEGLLERVEVGLSSCQGDYIRVRKAITAGYFY
HTARLTRSGYRTVKQQQTVFIHPNSSLFEQQPRWLLYHELVLTTKEFMRQVLEIESSWLLEVAPHYYKAKELE
DPHAKKMPKKIGKTREELG 
